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Abstract 
 
 
Background 
Hyperglycaemia is common in acute stroke and is associated with a poor 
outcome.  Underlying  aetiology  and  mechanism  of  action  is  poorly 
understood. Management remains uncertain.  
 
Methods 
We undertook a randomised placebo controlled trial to assess the effect of 
GKI  (Glucose-Potassium-Insulin)  versus  placebo  on  lesion  volume 
progression and cerebral lactate levels using magnetic resonance imaging 
(MRI) and spectroscopy (MRS). 
 
An  observational  study  of  the  capillary  blood  glucose  within  48  hours  of 
stroke onset was performed to define the temporal profile of glucose, with a 
subset  followed  prospectively  to  determine  the  prevalence  of  abnormal 
glucose metabolism in patients with stress hyperglycaemia.  
 
The  association  between  insular  cortex  involvement  and  hyperglycaemia 
was determined by analysing MRI data sets from two randomised trials. 
 
Stroke  unit  practice  for  the  management  of  glucose  was  assessed  in  a 
review of the stroke unit trialists’ collaboration data set. 
   6 
Results 
•  GKI  infusion  failed  to  attenuate  infarct  growth  in  patients  with 
moderate hyperglycaemia within 24 hours of acute ischaemic stroke.  
A trend towards attenuation of increased lactate concentration was 
evident in the GKI treatment arm.  Exploratory analyses raised the 
possibility that GKI may be harmful in patients with persistent arterial 
occlusion.  
•  Over  the  48hour  monitoring  period  75%  of  patients  developed 
Hyperglycaemia.  Stroke  severity  was  not  predictive  of  admission 
hyperglycaemia  whereas  glycosylated  haemoglobin  was  (OR  2.97; 
95%CI 1.84-4.78; p<0.001). 50% of patients screened were found to 
have abnormal glucose metabolism at follow-up.   
•  Insular  cortex  involvment  on  MRI  was  not  predictive  of  admission 
hyperglycaemia. 
•  Testing for blood glucose concentration in stroke units was infrequent.  
Of the minority of units that had a protocol in place, the threshold for 
intervention with insulin was >10mmol/l.   
 
Conclusion 
We found no evidence that GKI infusion attenuated infarct growth in patients 
with  mild  hyperglycaemia  following  acute  ischaemic  stroke.  In  post-hoc 
analysis the possibility that GKI infusion may be harmful in patients with total 
occlusion  suggests  an  effect  dependent  on  recanalisation  status.  A  non-  7 
significant trend towards attenuation of increased lactate concentration was 
evident.    Stroke  severity  was  not  found  to  be  a  predictor  of  post  stroke 
hyperglycaemia.  Underlying  dysglycaemia  was  common  in  non-diabetic 
patients  manifesting  hyperglycaemia  within  48hours  of  stroke  ictus. 
Screening of high risk patients with oral glucose tolerance testing is justified 
and provides a potential opportunity for secondary prevention. Insular cortex 
involvement did not independently predict hyperglycaemia in acute stroke. 
Current management of hyperglycaemia is guided by consensus guidelines 
with little evidence base. Stroke unit practice varies with little change across 
stroke units over the years.    8 
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EMBASE  a bibliographic database 
eNOS  nitric oxide synthetase 
EPI  echo planar imaging 
EPIC-Norfolk  European Prospective Investigation of Cancer : a large multi-centre study looking   16 
at the connection between diet and cancer 
EPITHET  Echoplanar Imaging Thrombolytic Evaluation Trial 
Europid  Caucasian 
EUSI  European Stroke Initiative 
FBG  fasting blood glucose 
FFA  free fatty acid  
FLAIR  fluid attenuated inversion recovery  
GAIN  Glycine Antagonist in Neuroprotection  
GAMI  Glucose tolerance in Patients with Acute Myocardial Infarction 
GIST UK  United Kingdom Glucose Insulin in Stroke Trial 
GKI regime 
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with potassium supplementation  
GLcNac  O-linked N-acetylglucosamine  
Glx  glutamate plus glutamine  
GRASP  Glucose Regulation in Acute Stroke Patients Trial  
HAEC  human aortic endothelial cells  
HbA1C  Glycosylated Haemoglobin, Type A1C 
HR  hazard ratio 
HS  haemorrhagic stroke 
IC-  without insular cortex involvement 
IC+  with insular cortex involvement 
ICU  intensive care unit  
IDF  International Diabetes Federation  
IFG  Impaired Fasting Glucose  
IGF  insulin like growth factor  
IGT  Impaired Glucose Tolerance  
IIT  Intensive insulin therapy  
IMAGES  Intravenous magnesium efficacy in stroke 
IQR   interquartile range 
IS  Ischaemic Stroke 
IV  intravenous 
LAC  lactate 
LACS  lacunar syndrome 
LCR  lactate creatine ratio 
LUB-INT  International trial of Lubeluzole 
MAST-E  Multicentre Acute Stroke Trial 
MCAO  middle cerebral artery occlusion  
MCP-1  pro-inflammatory chemokine  
MeSH 
Medical Subject Headings The National Library of Medicine's controlled 
vocabulary thesaurus 
MI  myocardial infarction  
mI  myo-Inositol  
MMP-9  matrix metalloproteinase 9  
modified rankin scale  a measure of functional ability 
MR  magnetic resonance 
MRA  Magnetic Resonance Angiography 
MRI  Magnetic Resonance Imaging 
MRS  magnetic resonance spectroscopy  
MTT  Mean Transit Time  
NAA  N-acetylaspartate  
NADH  nicotinamide adenine dinucleotide    17 
NADPH  nicotinamide adenine dinucleotide phosphate-oxidase 
NBM  nil by mouth  
NBO  Normobaric oxygen  
NEMESIS  North East Melbourne Epidemiological and Stroke Incidence Study 
NEX  number of excitations  
NFκB   cardinal pro-inflammatory transcription factor 
NICE-SUGAR 
Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose 
Algorithm Regulation 
NIHSS  National Institute of Health Stroke Scale  
NINDS  National Institute of Neurological Disorders and Stroke  
NMDA  N-methyl-D-aspartate 
NO   nitric oxide  
NOMASS  North Manhattan Stroke Study 
NXY059  disufenton sodium, a benzene sulfonate with antioxidant and vascular effects 
OCSP  Oxfordshire Community Stroke Project 
OGTT  oral glucose tolerance test  
OVID  a bibliographic database 
OXVASC  Oxford Vascular Study 
PACS  Partial Anterior Circulation Syndrome 
PAI-1  plasminogen activator inhibitor-1 
PCr  Phosphocreatine 
PET  positron emission tomography 
PICH  primary intracerebral haemorrhage 
PIDS  Peri-infarct depolarisations  
POCS  Posterior Circulation Syndrome 
PROACT II  PROlyse for Acute Cerebral Thromboembolism 
PROBE  Proton Brain Exam 
PSH  post stroke hyperglycaemia 
PWI  Perfusion Weighted Imaging 
reteplase  a thrombolytic drug 
ROS   reactive oxygen species 
r-proUK  recombinant pro-urokinase  
rtPA  recombinant tissue –Plasminogen Activator 
SAA  serum amyloid A  
SAH  subarachnoid haemorrhage 
SAINT  Stroke-Acute Ischaemic NXY Treatment 
SCMU  stroke care monitoring unit  
SELESTIAL 
Spectroscopic Evaluation of Lesion Evolution in Stroke: Trial of Insulin for Acute 
Lactic acidosis 
SEM   standard error of the mean 
SIS ward  a semi-intensive stroke ward 
SITSMOST  Safe Implementation of Thrombolysis in Stroke: Monitoring Study 
SPSS  a statistical software package 
STOP-NIDDM  Study to prevent Non Insulin Dependent Diabetes Mellitus trial  
stroke ictus  moment of stroke onset 
SU  stroke unit  
SVS  Single Voxel Spectroscopy  
TACS  Total Anterior Circulating Syndrome 
TCA   tricarboxylic acid  
TCD  Transcranial Doppler  
TE  echo time    18 
TGF-β  transforming growth factor 
THIS  Treatment of Hyperglycaemia in Ischaemic Stroke trial  
TIA  transient ischaemic attack 
TMS  tetramethylsilane 
TOAST  Trial of ORG 10172 in Acute Stroke Treatment 
TOF  Time of Flight  
VEGF  vascular endothelial growth factor 
VISEP  Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis  
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Web of Knowledge  a citation and journal database 
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Chapter 1: Introduction   25 
1.1 Introduction 
 
Stroke  is  the  third  commonest  cause  of  death  and  the  leading  cause  of 
disability in the United Kingdom. Recent national audit office figures estimate 
that  in  England  there  are  110,000  strokes  and  a  further  20,000  transient 
ischaemic attacks each year
1. In Scotland, there are an estimated 15,000 
strokes annually
2. Stroke is predominantly a condition affecting older people 
with 75% of strokes occurring in those greater than 65 years of age
3.  The 
estimated increase in the numbers of older people in society suggests that 
the cost of stroke will continue to rise. Stroke care directly costs the NHS 
£2.8 billion per year with an additional estimated indirect costs of £1.8 billion 
for lost productivity and £2.4 billion incurred through informal care by family 
and friends
4.  
 
A  stroke  is  characterised  by  rapidly  developing  clinical  signs  of  focal  (or 
occasionally global) disturbance of cerebral function, lasting for more than 24 
hours  or  leading  to  death  with  no  apparent  cause  other  than  of  vascular 
origin  (World  Health  Organisation  definition  1976).
5    Stroke  can  be 
subdivided  into  ischaemic  stroke,  accounting  for  85%  of  all  strokes  and  
haemorrhagic stroke which accounts for the remaining 15%.
5  Haemorrhagic 
strokes are then subdivided into primary intracerebral haemorrhages (PICH, 
10%) or subarachnoid haemorrhages (SAH, 5%). About 10% of all people 
with acute ischaemic stroke will die within 30 days of stroke onset. Of those 
who  survive,  about  50%  will  experience  some  level  of  disability  after  six   26 
months.
6  In  contrast  35%  to  52%  of  patients  with  primary  intracerebral 
haemorrhage will die within one month of symptom onset and only 20% are 
functionally independent at 6months.
7,8  
 
Methodological factors within different populations have made comparison of 
stroke incidence difficult. Criteria have now been proposed for accurate case 
ascertainment.
9  The crude annual incidence per 1000 population for any 
stroke as measured in the OXVASC (Oxford Vascular) study was 1.87 (95% 
Confidence Intervals 1.67-2.08) and 1.45 (95% CI 1.28 – 1.63) for first ever 
stroke.
10      
 
 
1.2 Ischaemic Stroke 
 
Ischaemic  strokes  are  mainly  due  to  cardioembolism,  extracranial  or 
intracranial atherosclerosis or non-atherosclerotic cerebral vasculopathies. It 
is  estimated  that  cardiac  embolism  accounts  for  12  to  35%  of  ischaemic 
strokes.
11  The  most  common  cardiac  source  in  western  societies  is  non-
rheumatic atrial fibrillation, the prevalence of which increases with age. It is 
estimated that 30% of patients with stroke aged >80 years of age have atrial 
fibrillation  compared  to  5%  of  patients  <60years.
12  A  presumed 
atherosclerotic mechanism is found in nearly 50% of patients with ischaemic 
stroke.  Atherosclerosis  primarily  affecting  the  extracranial  or  intracranial 
vessels  is  responsible  for  25%  of  all  ischaemic  strokes.  About  20%  of 
ischaemic strokes are due to lacunar infarcts. The mechanism underlying   27 
lacunar ischaemic stroke is poorly understood but is thought to arise from a 
pathologically  diffuse  vascular  abnormality,  involving  endothelial  damage 
and blood brain barrier permeability.
13 Only a small proportion is now felt to 
be as a result of artery-to-artery or cardiogenic emboli or intracranial large 
artery  stenoses.  Risk  factors  for  atherosclerosis  include  hypertension, 
smoking, dyslipidaemia and diabetes.
5  
 
1.3 Haemorrhagic Stroke 
 
Off the 15% of strokes that are non-ischaemic in origin, 10% will be due to 
primary  intracerebral  haemorrhage  (PICH)  and  5%  subarachnoid 
haemorrhage  (SAH).  The  main  risk  factor  for  PICH  is  hypertension.  In  a 
population based study the overall incidence of PICH was 12-15 cases per 
100,000 people per year.
14 PICH is most common in men, in elderly people 
and  in  Asian  and  African  Americans.
15  Common  underlying  mechanisms 
include  hypertension,  ruptured  arteriovenous  malformations  (AVM)  or 
intracranial aneurysm, iatrogenic bleeds, cerebral amyloid angiopathy and 
the abuse of sympathomimetic drugs (cocaine, amphetamines).
16  
 
In a comparison of data from two epidemiological stroke studies in the same 
area 20 years apart (Oxford Community Stroke Project (OCSP) 1981-84 and 
1986) and (OXVASC 2002-06), there was found to be no difference in the 
overall number of cases of PICH in the two studies. Interestingly, when the 
groups were further divided by age, there was a significant reduction in the   28 
incidence of PICH in patients aged under 75 (rate ratio 0.53, 95% CI 0.29-
0.95; p=0.03) but the number of cases of in patients ≥75 tended to increase. 
(2.0,  95%  CI  0.8-4.6;  p=0.09).  The  incidence  of  PICH  associated  with 
premorbid  hypertension  fell  (0.37,  95%  CI  0.20-0.69;  p=0.002)  but  the 
incidence associated with antithrombotic use increased (7.4, 95% CI 1.7-32; 
p=0.007). In patients above the age of 75, the proportion of cases who were 
non-hypertensive with lobar bleeds and presumed to have amyloid related 
haemorrhages increased (4.0, 95% CI 1-17; p=0.003).
17  
   
1.4 Stroke Management 
 
The managment of stroke patients has seen significant changes over the last 
decade, with the development and implementation of dedicated stroke units.  
When the outcomes of patients admitted to stroke units were compared to 
those receiving conventional treatment  as part of randomised trials, stroke 
units  were  found  to  reduce  patient  mortality  and  both  dependency  and 
disability amongst stroke survivors.
18   The definition of stroke unit includes 
models  of  care  at  different  ends  of  the  spectrum.  This  varies  from  acute 
physiological  monitoring
19  with  high  nurse  staffing  levels  to  the  more 
historical  rehabilitation  wards
20  that  admit  patients  following  an  in-patient 
delay. In a systematic review involving almost 5,000 patients from 23 clinical 
trials,  stroke  patients  managed  in  stroke  units  were  less  likely  to  die 
(Absolute Risk Reduction (ARR) 3%), require institutional care (2% absolute 
reduction)  or  have  long  term  dependency  (5%  absolute  reduction).
21  An   29 
additional  advance  in  stroke  care  has  been  the  recent  licensing  of 
thrombolysis for acute ischaemic stroke within three hours of stroke onset.
22 
Stroke is now recognized as an acute emergency with the emphasis on early 
recognition,  hospital  presentation  and  rapid  imaging.    The  changes 
necessary  to  advance  the  management  of  stroke  patients  have  been 
highlighted in the recently published national stroke strategy for England.   
 
1.5 Acute Stroke Treatments 
 
(a) Thrombolysis 
The licensing of intravenous alteplase for the treatment of acute ischemic 
stroke in appropriately selected patients within three hours of stroke onset 
has  seen  a  greater  emphasis  on  early  presentation,  prompt  assessment, 
access  to  imaging,  interpretation  of  imaging  and  treatment.  Intravenous 
alteplase  (recombinant  tissue  –Plasminogen  Activator,  rt-PA)  within  three 
hours of onset improves the chances of neurological recovery and functional 
independence after ischaemic stroke, with a number needed to treat of only 
8  for  one  additional  person  to  make  a  full  or  nearly  full  recovery  in  the 
National  Institute  of  Neurological  Disorders  and  Stroke  (NINDS)  trial.
23 
Although there was an increase in haemorrhage rates at 6.4% in the rt-Pa 
group versus 0.6% in the placebo group, there was no significant difference 
in mortality between the rt-PA group (17%) and the placebo group (21%; 
p=0.30) at three months. 
A further pooled analysis of stroke thrombolysis trials has shown that the   30 
odds of a good outcome are greater the earlier treatment is provided, with an 
additional apparent benefit up to 4.5 hours.
24 Attempts to extend the time 
window using brain imaging techniques have shown differing results. The 
recent randomized placebo controlled Desmetoplase In Acute Stroke (DIAS) 
II study showing no benefit over placebo when desmetoplase, a novel new 
thrombolytic  agent  was  administered  up  to  9hours  following  ictus,
25.  The 
pooled  multi-centre  observational  analysis  of  core  CT  and  MRI  based 
prospective thrombolysis data involving 1,210 patients treated with alteplase, 
demonstrated  that  the  use  of  MRI  for  patient  selection  beyond  3hours 
predicted  a  favourable  outcome  (OR:  1.467;  95%  CI:  1.017  to  2.117, 
p=0.040)
26. A more detailed description of MRI in acute stroke is given in 
chapter three. 
 
Despite initial slow acceptance of rt-Pa, there has been a gradual increase in 
its use. Alteplase was provisionally licensed in the United Kingdom in April 
2003 within three hours of stroke onset for patients aged eighty or younger. 
There were two restrictions imposed with the licensing; (a) all patients were 
recorded with the Safe Implementation of Thrombolysis in Stroke: Monitoring 
Study  (SITS-MOST)  online  database
22  and  (b)  Boehringer-Ingelheim  the 
drug manufacturers performed a further study, aimed at extending the time 
window to 4.5hours (ECASS III: European Cooperative Acute Stroke Study 
3).  The  recent  publication  of  the  SITS-MOST  study  including  more  than 
6,000 patients reported that the use of thrombolysis was feasible in centres   31 
of varying experience and more importantly in centres not actively involved 
in  research.
22  Outcomes from  the  study  were  similar  to the  NINDS  study 
population  and  reassuringly  haemorrhage  rates  were  similar  for  both 
treatment groups when similar definitions were applied.   
 
Despite increased acceptance of the drug and confirmation of its efficacy 
and feasibility, widespread uptake remains poor. Stumbling blocks include 
early  presentation  and  access  to  both  imaging  and  interpretation.  In  the 
United Kingdom initial concerns that few patients would be eligible due to the 
short time window were contradicted by a prospective study, which identified 
that over one third of patients were present in hospital within three hours of 
onset.
27 In the National Audit Office report “Reducing brain damage: faster 
access to stroke care”, less than 1% of stroke patients in England received 
thrombolysis  annually.
28  Although  attempts  have  been  made  to  increase 
early hospital presentation and provide greater access to thrombolysis, there 
appears to be an upper limit of patients eligible for thrombolytic treatment. 
Even in the most active thrombolysis centres, almost 80% of patients with 
stroke would still either not be eligible or ultimately not receive intravenous 
alteplase.
29  
 
(b) Neuroprotective agents 
Multiple  neuroprotective  agents;  NMDA  antagonists,  calcium  channel 
blockers  and  antioxidants  have  been  studied  in  clinical  trials.
30  Despite   32 
positive  results  from  pre-clinical  models  no  drug  has  yet  been  proven 
efficacious  in  the  treatment  of  acute  stroke.    In  the  recent  randomised 
placebo controlled SAINT I trial (Stroke-Acute Ischaemic NXY Treatment), 
involving 1,722 patients within six hours of acute ischaemic stroke, NXY-059 
(a nitrone spin trap molecule with free radical sink properties) significantly 
improved the overall distribution of scores on the modified rankin scale at 
day  90.
31  However  a  subsequent  SAINT  II  study  involving  3,400  patients 
failed  to  confirm  the  initial  trial  results.
32  The  earlier  IMAGES  trial 
(Intravenous  Magnesium  Efficacy  in  Stroke)  which  randomised  2,589 
patients to magnesium or placebo within 12 hours of ictus found no overall 
benefit  for  magnesium  over  placebo.
33  The  lack  of  clinical  evidence 
supporting the role of neuroprotective agents and the limited eligibility for 
widespread use of thrombolysis emphasises the importance of stroke unit 
care.  
 
1.6 Key components of Stroke Unit Care 
 
Whereas restrictions are imposed on the number of patients eligible for and 
thus receiving thrombolysis, all stroke patients irrespective of severity, time 
to presentation and aetiology can benefit from stroke unit admission. The 
key components of good stroke unit care remain poorly understood but it is 
suggested  that  patient  outcomes  are  improved  by  minimizing  preventable 
complications of stroke and enhancing independence in functional abilities. 
In  a  report  compiled  by  the  stroke  unit  trialists’  collaboration,  consistent   33 
approaches  in  stroke  unit  services  that  resulted  in  a  beneficial  outcome 
included  a)  assessment  procedures  (medical,  nursing  and  therapy 
assessments),  b)  early  management  policies  (e.g.  early  mobilization, 
avoidance of urinary catheterization, treatment of hypoxia, hyperglycaemia 
and suspected infection) and c) ongoing rehabilitation policies (co-ordinated 
multi-disciplinary care, early assessment for discharge).
34  
 
Despite the proven benefit, recent figures taken from the national sentinel 
stroke audit estimate that as many as 38% of stroke patients in the United 
Kingdom  are  still  not  managed  in  stroke  units  during  the  period  of  their 
hospital stay.
35 In addition, it has been shown that only 15% of patients are 
admitted to the stroke unit on the same day as their stroke.
35 Set standards 
defined  by  the  sentinel  stroke  audit  and  the  recently  published  stroke 
strategy  should  ensure  optimal  and  continued  improvements  in  patient 
management.  Recognition  of  stroke  as  a  medical  emergency  with  rapid 
hospital admission will allow many patients ineligible for lytic treatment to 
benefit  from  stroke  unit  care.  Optimisation  of  care  within  the  hyper-acute 
phase of stroke through manipulation of physiological parameters is currently 
receiving  significant  interest.    It  is  generally  accepted  that  correction  of 
dehydration, hypoxia and use of anti-pyretics are beneficial in the light of 
deficiencies  in  clinical  randomized  trials.  In  a  case  controlled  study 
comparing patients with normal physiological values (peak calculated serum 
osmolarity <300mOsm/kg; peak temperature ≤37.5°C; peak blood glucose   34 
≤10.0mmol/l; minimum oxygen saturation ≥93%) during the first three days of 
stroke  admission  to  those  with  at  least  one  abnormality,  patients  with 
physiological  homeostasis  had  improved  outcomes  across  a  range  of 
measurements.
36  When  the  stroke  unit  trialists  collaboration  data  was 
examined in relation to stroke unit interventions versus conventional care, 
stroke unit practice was associated with statistically significant increases in 
the reported use of oxygen (OR 2.39; 95% Confidence Intervals CI; 1.39 to 
4.66),  measures  to  prevent  aspiration  (2.42;  95%  CI  1.36  to  4.36)  and 
paracetamol use (2.80; 95% CI 1.14 to 4.83).
37  Understanding of the role of 
physiological  homeostasis  in  the  management  of  acute  stroke  appears 
important in influencing stroke outcome. In a pilot study, patients randomised 
to a stroke care monitoring unit (SCMU) with continuous oxygen saturations, 
body  temperature  and  cardiac  rhythm  monitoring,  had  a  lower  mortality 
(3.7%) compared to patients managed in a non-monitored stroke unit (SU) 
(25.9%)  despite  standardized  protocols  (OR  0.11;  95%  CI  0.02  to  0.96) 
(p=0.05).
19 When monitoring was examined in a larger cohort of 206 patients 
admitted  to  either  a  monitored  semi-intensive  care  stroke  unit  (SU)  or  a 
standard cerebrovascular unit (CU) that did not have access to continuous 
monitoring, a good outcome was observed at discharge in 114 SU patients 
(85%) and 78 CU patients (58%), (OR 2.63; 95% CI, 1.4 to 4.8; p<0.02).
38   
 
1.7 Pathophysiology 
 
The  pathophysiology  of  acute  ischaemic  stroke  encompasses  two  main   35 
processes:  (1)  Altered  cerebral  metabolism  and  its  effect  on  cellular 
metabolism and ultimate cell death and (2) Reduction in cerebral blood flow 
through the action of vascular, haematological and cardiac events.  
 
Cerebral Metabolism 
The  human  brain  has  a  high  metabolic  demand  and  uses  glucose  as  its 
primary  substrate  for  metabolism.  Glucose  is  metabolised  by  aerobic 
glycolysis in the cellular cytoplasm and generates two moles of pyruvate, two 
moles of nicotinamide adenine dinucleotide (NADH) and a net of two moles 
of  adenosine  triphosphate  (ATP)  for  every  mole  of  glucose  consumed.  A 
constant supply of ATP is needed to maintain neuronal integrity and to keep 
the major extra-cellular cations Ca++ (calcium ions) and Na+ (sodium ions) 
outside the cells and the intracellular cation K+ (potassium ions) within the 
cells.  The rate of glycolysis is regulated to supply the energy necessary for 
normal  cellular  function  by  the  modulation  of  the  glycolytic  enzyme 
phosphofructokinase-1.  Increased  ATP  use  activates  this  enzyme  by 
increasing  cellular  AMP  (adenosine  monophosphate)  levels  and  in  turn 
increases the rate of glycolytic ATP generation. Pyruvate is metabolized in 
one  of  three  different  ways:  1)  Reversibly  converted  to  lactate  and 
accumulates,  2)  Converted  to  the  amino  acid  alanine,  or  3)  Enters  the 
mitochondrial  matrix  and  is  further  metabolized  by  the  tricarboxylic  acid 
(TCA)  cycle.    In  normal  brain  in  the  presence  of  oxygen,  pyruvate  is 
metabolized with the net formation of 38moles of ATP. In the absence of   36 
oxygen, anaerobic glycolysis occurs resulting in the conversion of pyruvate 
to lactic acid through the action of lactate dehydrogenase. This process is 
less energy efficient with only two molecules of ATP produced along with 
lactic  acid.  Neurones  in  the  brain  require  a  constant  supply  of  ATP  to 
maintain  their  integrity  and  maintain  cellular  homeostasis.  As  the  brain  is 
unable to store energy it requires a constant supply of oxygenated blood 
containing an adequate glucose concentration.
39 
 
The  normal  global  cerebral  blood  flow  (CBF)  in  a  healthy  adult  is  50-
55ml/100g of brain per minute. Critical thresholds for the brain have been 
identified  using  both  experimental  animal  models  and  clinical  studies  in 
patients  during  endarterectomy.  When  CBF  falls  to  15ml/100gm/min, 
spontaneous  and  electrical  activity  ceases.  With  further  falls  in  CBF  the 
water and electrolyte content of ischaemic tissue changes due to failure of 
ATP-dependent cell ionic pumps. The critical threshold for the beginning of 
irreversible cell damage is a CBF of approximately 10ml/100g/min
40. For a 
short period neurones may remain viable and recover function if perfusion is 
restored. If reperfusion does not occur the lack of oxygen results in inhibition 
of  normal  enzymes  and  the  development  of  anaerobic  glycolysis  and 
subsequent loss of ion homeostasis. Knowledge of two different thresholds 
gives  rise  to  the  concept  of  the  ischaemic  penumbra,  a  region  of  tissue 
defined by CBF that lies between the thresholds for loss of electrical function 
and loss of cellular homeostasis.
39 In humans it is uncertain as to how long   37 
the  ischaemic  brain  can  survive  and  still  be  salvaged  by  reperfusion  or 
measures to protect neurones from dying.  
 
1.8 Management of Physiological Parameters (other than glucose) 
 
The  neurons  in  the  ischaemic  penumbra  are  vulnerable  to  any  additional 
insults,  including  any  further  falls  in  perfusion  pressure  caused  by 
hypovolaemia due to either dehydration or iatrogenic manipulation of blood 
pressure. Monitoring of blood pressure and the creation of an appropriate 
environment  through  maintenance  of  physiological  parameters  may  avoid 
conversion of the potentially viable neurons to necrotic tissue. Knowledge of 
the ischaemic penumbra and the potential for stabilizing the physiological 
environment in which the penumbral tissue exists has seen an aggressive 
approach to the maintenance of physiological parameters.  
 
(a)  Oxygen:  Common  abnormalities  contributing  to  hypoxia  in  stroke 
patients  include  aspiration  pneumonia
41  and  Cheyne-stokes 
respiration.
42  Oxygen  is  important  for  aerobic  metabolism  and 
correction of hypoxia may prevent further neurological deterioration
43. 
A quasi-randomised controlled trial found that routine (100%) oxygen 
supplementation for 24 hours after stroke onset had no benefit on 
stroke  survival.
44  Over  correction  of  patients  not  hypoxic  may  be 
detrimental to the ischaemic brain due to the possible promotion of 
free  radical  oxygen  formation  during  reperfusion.
45  Current  AHA 
(American  Heart  Association)  guidelines  recommend  that  hypoxic   38 
patients with stroke should receive supplemental oxygen.
46   
(b)  Hydration: dehydration leads to a rise in haematocrit and a reduction 
in blood pressure, which can then exacerbate the ischaemic cascade 
by  reducing  cerebral  blood  flow.    It  has  been  hypothesised  that 
routine  use  of  saline  infusions  in  the  first  24  hours  may  improve 
cerebral  blood  flow  by  limiting  dips  in  systemic  arterial  blood 
pressure.
47 However moderate haemodilution with venesection and 
dextran was found to have no overall beneficial effect over placebo in 
patients within 48hours of an acute ischaemic stroke.  
(c)  Body  temperature:  A  meta-analysis  suggested  that  a  temperature, 
defined in the range >37ºC to ≥38ºC in the first week post stroke was 
significantly  associated  with  increased  morbidity  and  mortality. 
Mechanisms  for  hyperthermia  induced  brain  damage  include 
neurotransmitter  release,  free  radical  formation  and  impaired 
recovery  of  brain  metabolism.
48  Recommendations  advise 
maintaining normothermia with anti-pyretics and antibiotics.  
(d)  Hypertension: The management of hypertension in the acute setting 
of  stroke  remains  controversial  and  there  remains  no  agreed 
consensus.      Stroke  council  guidelines  advise  management  of 
systolic  blood  pressure  exceeding  220mmHg  or  diastolic  blood 
pressure exceeding 120mmHg, but adherence to these criteria vary 
and  uncertainty  remains.
46  Within  the  normal  physiological  range, 
blood flow to the brain is independent of mean arterial pressure and   39 
cerebral  perfusion  pressure  and  gives  rise  to  the  phenomenon  of 
cerebral  auto-regulation.  In  the  ischaemic  brain  the  ability  to auto-
regulate  is  lost  and  CBF  becomes  passively  dependent  on  blood 
pressure (BP), such that lowering BP in patients with acute stroke 
might further decrease CBF to already ischaemic tissue.
49 In those 
patients  eligible  for  treatment  with  rtPA,  current  AHA  guidelines 
stipulate that blood pressure should be lowered so that the systolic is 
≤185mmHg and diastolic ≤110mmHg before thrombolytic therapy is 
started.
46   
(e)  Post-Stroke Hyperglycaemia: Continued uncertainty in the absence 
of  substantive  clinical  evidence  surrounds  the  appropriate 
management of hyperglycaemia during the acute post ictal phase of 
ischaemic stroke and forms the basis of this thesis.  
   40 
 
1.9 Aims and Objectives of Thesis 
The aims of the research are as follows  
(i)  Perform a review of the current literature relating to the detection 
and management of hyperglycaemia in acute ischaemic stroke. To 
include an assessment of the evidence for glucose as a prognostic 
indicator.  Describe potential mechanistic actions of glucose on the 
ischaemic  brain  and  accompanying  vasculature,  including  a 
description of experimental animal studies.  
(ii)  Review  current  guidelines  for  blood  glucose  management  in 
stroke, the basis for these guidelines and current audited practice. 
The  study  will  include  an  assessment  of  evidence  available  for 
insulin use in both stroke and non-stroke populations. A separate 
study will examine the use of blood glucose lowering protocols in 
stroke units included in the Cochrane systematic review of stroke 
unit management.   
(iii)  The  main  study  within  the  thesis  will  focus  on  a  single-centre 
randomised  placebo  controlled  trial  undertaken  to  examine  the 
effect of insulin in the form of a Glucose-potassium-insulin infusion 
on lesion volume progression and final infarct size using magnetic 
resonance  imaging  (MRI)  surrogate  markers  and  lactate 
concentration measured using magnetic resonance spectroscopy 
(MRS).    41 
(iv)  To explain the methodology of the different magnetic resonance 
imaging  techniques,  separate  chapters  will  focus  on  the  use  of 
MRI and MRS in acute stroke.  
(v)  Examine the temporal profile of glucose within the acute stroke 
phase  and  potential  predictive  factors  for  the  development  of 
hyperglycaemia. 
(vi)  Consenting patients involved in the blood glucose profiling study 
with hyperglycaemia will undergo an oral glucose tolerance test to 
determine  the  true  prevalence  of  abnormal  glucose  metabolism 
and metabolic syndrome.  
(vii)  A  further  chapter  will  determine  the  effect  of  lesion  localisation 
within  the  ischaemic  brain  on  the  development  of  post  stroke 
hyperglycaemia. 
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Chapter 2: Literature Review 
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2.1 Literature Search Methodology 
The main purpose of the literature search was to review articles relating to 
the effect of blood glucose on outcome in patients with acute stroke. The 
search  strategy  was  designed  to  capture  original  articles  examining  the 
effect  of  blood  glucose  on  stroke  outcome  in  clinical  and  experimental 
studies.  The  search  included  studies  documenting  both  clinical  and 
radiological  outcome  measures,  the  use  of  both  blood  glucose  lowering 
interventions and thrombolytic therapy. Additional searches focused on the 
use  of  magnetic  resonance  imaging  surrogate  markers  and  magnetic 
resonance spectroscopy in acute stroke and a specific search on the use of 
insulin  therapy  in  focal  models  of  ischaemia.  Additional  information  was 
obtained  on  the  current  use  of  insulin  in  both  stroke  and  non-stroke 
populations. 
 
Databases searched for the main literature review included OVID (1950 to 
April  2007)  and  Embase  (1980  to April  2007). Terms used  in the  search 
strategy are shown in Table 2.1. Additional information was obtained from 
bibliographies of suitably referenced material. A further search strategy for 
focal  models  of  ischaemia  included  accessing  BIOSIS  and  Web  of 
Knowledge  databases,  along  with  abstract  books  from  relevant  scientific 
meetings. Training in literature searching was undertaken through a course 
run by the library department of the University of Glasgow and reinforced 
through sessions with the lead librarian on the Southern General Hospital 
site.     44 
Databases:  OVID (1950 to April 2007); EMBASE (1980 to April 2007) 
Terms used  MeSH Headings  Keywords 
 - stroke  Cerebrovascular Accident  
Cerebrovascular Disorders 
Carotid Artery Diseases  
Hypoxia-Ischemia, Brain 
Intracranial Arteriovenous Malformations  
Intracranial Embolism and Thrombosis  
Intracranial Hemorrhages  
Vertebral Artery Dissection 
Brain Infarction 
Subarachnoid Hemorrhage 
Intracranial Hemorrhages 
Cerebral Infarction 
Brain Ischemia 
Ischemic Attack, Transient 
Cerebral Hemorrhage 
Parietal Lobe 
Temporal Lobe 
stroke 
cerebrovascular accident   
brain infarct$ 
cerebral infarct$ 
cerebral ischaemia 
subarachnoid h$emhorrage  
subarachnoid h$emorrhage 
intracranial h$emorrhage 
cerebral h$emorrhage 
cerebellar h$emorrhage 
intracranial bleed 
cerebral bleed 
cerebellar bleed 
 
insular cortex 
parietal lobe 
temporal lobe 
-glucose 
control 
Blood Glucose 
Insulin 
Diabetes Mellitus, Type 1 
Diabetes Mellitus, Type 2 
Diabetes Mellitus 
Glucose 
Hypoglycemic Agents 
Hyperglycemia  
Glucose Intolerance 
blood glucose 
blood sugar 
insulin 
diabetes 
glucose 
oral hypoglyc$emic$ 
glyc$emic control 
dextrose 
 
-outcomes  Morbidity 
Hospital Mortality 
Mortality 
Activities of Daily Living 
Quality of Life 
Geriatric Assessment 
Disability Evaluation  
Health Status Indicators 
Severity of Illness Index 
morbidity  
morbidity  
mortality 
disability 
functional dependence 
institutional$ 
infarct size 
infarct volume 
lesion size 
lesion volume 
h$emorrhage progression 
rankin score 
barthel score 
stroke severity 
NIHSS 
NIH stroke scale 
complication$ 
stroke complication 
-additional 
interventions 
Tissue Plasminogen Activator 
Fibrinolytic Agents 
Thrombolytic Therapy 
Neuroprotective Agents 
 
tPA 
tissue plasminogen activator 
thrombolysis 
thromboly$ 
fibrinoly$ 
neuroprotectant agents 
neuroprotective agent$ 
Table 2.1: Search Strategy (main literature review) (The symbol ($) represents unlimited truncation)   45 
2.2 Definition of Post-Stroke Hyperglycaemia 
 
Post-stroke  hyperglycaemia  (PSH)  is  common  and  is  recognised  as  a 
prognostic indicator of poor stroke outcome. A proportion of patients with 
PSH  will  have  underlying  diabetes,  already  established  from  the  clinical 
history or detected at the time of presentation. The remainder of the patients 
with  PSH  are  labelled  as  having  “stress  hyperglycaemia”,  although  a 
proportion  have  underlying  impaired  glucose  tolerance  when  screened  at 
later time points.  
 
Studies examining the influence of blood glucose on stroke outcome have 
certain limitations. There remains no consensus definition for PSH and as 
such blood glucose levels and the timing and nature of the blood glucose 
sample vary among studies (Table 2.2). The definition for hyperglycaemia 
has included both random and fasting blood glucose values greater than 6.1-
8.0mmol/l, at differing time points from stroke ictus. The time elapsed from 
stroke  onset  to  blood  glucose  sampling  in  prospective  trials  has  included 
patients presenting up to 72 hours from stroke onset.
50 In view of this non-
uniformity  in  PSH  definition  prevalence  rates  differ  across  studies.  By 
combining studies from Table 2.2 with documented numbers of patients with 
diabetes  and  stress  hyperglycaemia,  the  overall  prevalence  for  each 
respective  group  (±SD)  was  (1)  Diabetics  17.3%  (±6.0%);  (2)  Stress 
Hyperglycaemia 20.3% (±14.2%) and (3) Normoglycaemia 62.4% (±18.0%). 
The chronological span of the studies cited date from 1976-2002 reflecting   46 
both  clinical  practice  and  access  to  radiological  imaging  in  improving 
diagnostic  classification.  Earlier  studies  based  the  stroke  type  on  clinical 
scores and undoubtedly combined both ischaemic and haemorrhagic strokes 
in the analysis for final outcome.  
 
In  patients  with  primary  intracerebral  haemorrhage  (PICH),  admission 
hyperglycaemia  was  not  found  to  be  associated  with  increased  stroke 
mortality.  Unfortunately  patient  numbers  with  PICH  included  in  the 
systematic review were small. Two larger studies have subsequently been 
published demonstrating that high admission blood glucose increases short-
term mortality in both diabetic and non-diabetic patients with PICH. In non-
diabetic patients admission blood glucose was associated with parameters 
of  stroke  severity:  reduced  consciousness  level,  haematoma  size  and 
intraventricular haemorrhage extension.
51;52    
   
Year  Study lead author 
Country of 
origin 
Number  
Recruited 
Type of strokes 
included 
Definition of Hyperglycaemia 
 (mmol/l) 
Time window 
for recruitment 
 
Diabetics 
Stress 
Hyperglycaemia 
Outcome 
1976  Melamed et al
53d}  Israel  392  IS, HS, SAH  >6.7(fasting)  Not stated  79 (20%)  108 (28%)  Increased hospital mortality 
1983  Pulsinelli et al
54d}  USA  107  IS  Not Specified  <48hours 
35 (33%)  Not defined  Worse neurological outcome and 
increased   mortality in diabetics 
1985  Candelise et al
55d}  Italy  72  IS, HS  >6.1 (Fasting)  <48hours  11 (15%)  23 (32%)  Higher 30day mortality 
1986  Cox et al.
56d}  UK  81  Hemiplegic stroke   ≥8.0 (Random)  Not stated  6 (7.4%)  5 (6.2%)  Increased Mortality 
1988  Adams et al
57d}  USA  65  IS  Not Specified  <48hours 
21 (32.3%)  Not defined  Hyperglycaemia or diabetes did not 
predict stroke outcome 
1988  Power et al
58d}  UK  205  IS,HS  Not defined 
<18hours of 
admission 
11 (5.4%)  Not defined  Hyperglycaemia is a stress response 
1988  Woo et al.
59d}  China  252  IS, HS  Not Specified  <24hours 
31 (12.3%)  Not defined  Admission glucose correlated with 
stroke mortality 
1989  Gray et al.
60d}   UK  200  IS, HS  Not Specified  <72hours  17 (8.5%)  13 (6.5%)  Higher 4 week mortality  
1990  Woo et al.
61d}  China  304  IS, HS  >7.8 (Fasting)  <48hours  76 (25%)  23 (7.6%)  Increased mortality 
1990  Kushner et al
62d}  USA  39  IS  ≥8.6  <12hours  18 (46.2%)  Not defined  Poorer recovery if hyperglycaemia 
1991  Cazzato G et al
63d}  Italy  76  IS  >6.1 (Fasting)  <24hours 
17 (22.4%)  37 (48.7%)  Higher 30 day mortality with stress 
hyperglycaemia 
1991  O’Neill et al.
64d}  UK  23  IS, HS  Not Specified  <24hours  0  Not defined  Increased mortality.  
1992  Toni et al
65d}  Italy  327  IS  >6.7  <12hours 
70 (21.5%)  93 (28.5%)  Higher mortality for diabetics and 
stress hyperglycaemia than 
normoglycaemics 
1992  Kiers et al
66d}.  Australia  176  IS, HS  >7.8 (Fasting)  Not stated 
30 (17%)  10 (5.7%)  Increased  early  mortality  in  stress 
hyperglycaemia 
1992  Murros et al.
67d}  Finland  99  IS, HS  Not Specified  <48hours 
15 (15.2%)  11 (11.1%)  correlation with lesion volume in non-
diabetics 
1993  Van Kooten et al
68d}.  Holland  91  IS, HS  ≥8.0 (Random) or ≥6.7 (fasting)  <24hours 
10 (11%)  17 (18.7%)  Normoglycaemia  associated  with 
better outcome 
1993  Tracey et al
69d}  UK  68  IS, HS  Not Specified  <24hours 
0  Not defined  Lesion  volume  correlated  with 
glucose 
1997  Weir et al
70d}.  UK  750  IS, HS  >8.0 (Random)  Mean 14.4hours  0  Not defined  Poor 3 month outcome 
1999  Scott et al
71d}  UK  303  IS  >6.0mmol/l, >6.9mmol/l  Not stated 
Not defined  Not defined  PSH is common across all stroke 
types 
2001  Wang et al
72d}  Australia  416  IS  ≥ 8.0 (Random)  <24hours  83 (20%)  57 (13.7%)  Increased hospital mortality 
2001  Szczudlik et al
73d}  Poland  262  IS  ≥7.8 on admission, ≥6.4 day 0   <24hours 
65 (24.8%)  95 (36.3%)  Higher 30 day mortality in stress 
hyperglycaemia  
2002  Christensen et al
74d}.  Denmark  445  IS, HS  Not Specified  <12hours 
0  Not defined  Blood glucose increase is related to 
stroke severity 
2003  Passero et al
51d}  Italy  764  HS  ≥ 7.2 (Random)  <24hours  127 (16.6%)  Not defined  Increased 30 day mortality  
2005  Fogelholm et al
75d}  Finland  329  HS  Not specified  89%<24hrs  39 (11.2%)  Not defined  Increased 1 month mortality 
Table 2.2: Definition of Post Stroke Hyperglycaemia, numbers recruited, country of origin, stroke type, time to recruitment and outcomes.  
(Stroke type abbreviations -  IS: Ischaemic Stroke; HS: haemorrhagic stroke; SAH: Sub-arachnoid Haemorrhage)   48 
2.3 Hyperglycaemia and effect on stroke outcome 
 
Despite  the  recognised  association  between  hyperglycaemia  and  poor 
stroke  outcome,  uncertainty  remains  as  to  whether  blood  glucose  has  a 
direct  neurotoxic  effect  on  the  ischaemic  brain  or  if  it  represents  a 
pathophysiological  response  to  increased  stroke  severity  or  unmasking  of 
abnormal glucose metabolism. A number of different hypotheses exist: (1) 
PSH is an epiphenomenon of stroke severity and plays no mechanistic role 
in  poorer  outcome;  (2)  PSH  is  an  unmasking  of  previously  undiagnosed 
diabetes or impaired glucose metabolism with its associated comorbidities 
that is relevant to long term outcome; (3) Hyperglycaemia is associated with 
infarction/injury within specific anatomical areas of the brain independent of 
stroke severity; (4) PSH regardless of the mechanism is harmful and needs 
to be treated and (5) PSH is irrelevant mechanistically in worsening of stroke 
and treatment is unnecessary or indeed harmful.  
 
2.4 Aetiology of Post-Stroke Hyperglycaemia: Dysglycaemia 
 
Stroke is predominantly a disorder of older people. Diabetes is common in 
the elderly population with approximately 20% affected by the age of 75.
76 
Within epidemiological stroke studies the prevalence of recognised diabetes 
varies  from  9.4%  to  33%  (Table  2.3).    This  noted  variation  appears 
dependent on the population studied. In the OCSP and OXVASC studies, 
the  prevalence  of  diabetes  in  a  predominantly  caucasian  population  was 
9.4% - 10.5%.
10 In the NEMESIS study it was slightly higher at 17%.
77  In   49 
contrast 33% of the overall patients recruited to NOMASS had documented 
diabetes.
78 When divided on the basis of ethnicity 18% caucasians and 39% 
carribean/ hispanics were diabetic. In a more recent study documenting the 
proportion of diabetics recruited to acute stroke trials of neuropotectant and 
thrombolytic agents, the figure was almost 20% (Table 2.4).
79   
 
Table  2.3:  Epidemiological  incidence  stroke  studies,  documenting 
numbers  recruited,  year  of  study  and  the  proportion  with  confirmed 
diabetes at presentation 
Epidemiological Study  Year of 
study 
recruitment 
No. 
recruited 
Mean Age 
(±SD) 
Percentage 
Diabetic 
OCSP (Oxfordshire 
Community Stroke 
Project)
10 
 
1981-84  429  72.3(12.7)  45(10.5%) 
OCSP (Oxfordshire 
Community Stroke 
Project)
10 
 
1986  128  70.6(15.3)  12(9.4%) 
OXVASC (Oxford Vascular 
Study)
10 
 
2002-2004  262  73.6(11.9)  25(9.5%) 
NOMASS (North Manhattan 
Stroke Study)
78 
 
1990-1997  980  70.0(12.6)  320(33%) 
NEMESIS (North East 
Melbourne Stroke 
Incidence Study)
77 
 
1997-1998  721  75.8  126(17%) 
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Table  2.4:  Prevalence  of  diabetes  amongst  populations  enrolled  to 
acute stroke trials. Adapted from Table 1: Lees et al Cerebrovasc. Dis 
2005; 20 (suppl 1):9-14 
Trial  Number of Diabetics/ total 
number recruited 
Percentage diabetic (%) 
IMAGES  413/2386  17.3 
GAIN-I  310/1523  20.4 
LUB-INT  405/1785  22.7 
CLASS  292/1198  24.4 
NINDS  85/624  13.6 
ECASS-II  169/800  21.1 
MAST-E  33/310  10.6 
COMBINED  1707/8626  19.8 
 
 
Diabetes prevalence is increasing worldwide. It is estimated that 28-44% of 
adults  aged  45-74  have  diabetes  or  impaired  glucose  tolerance,  with  an 
estimated  5.4  million  Americans  unaware  of  an  underlying  diagnosis  of 
diabetes.
80  Diabetes  is  an  established  risk  factor  for  atherosclerosis. 
Prevalence of carotid artery disease in elderly diabetic patients is 20%.
81 In 
any given stroke population the prevalence of diabetes is said to be of the 
order  of  7-25%,
50;61  with  a  further  6-32%  having  evidence  of  previously 
unrecognised diabetes prior to the acute event.
55;56 Abnormalities in glucose 
metabolism insufficient to fulfil diabetic criteria are also known to increase 
cardiovascular  risk.  In  a  meta-regression  analysis  of  18  studies  involving   51 
88,000 patients, cardiovascular disease increased continuously with glucose 
levels  of  greater than  4.2mmol/l.
82  In  patients  with  known  coronary  artery 
disease  the  relationship  between  fasting  blood  glucose  and  incident 
ischaemic  stroke  was  J-Shaped,  with  stroke  rate  increasing  with  fasting 
glucose levels >5.6mmol/l.
83 The metabolic syndrome characterised by high 
fasting glucose, high blood pressure, low high-density lipoprotein cholesterol, 
high triglycerides and abdominal obesity
84, is associated with an increased 
risk  of  morbidity  and  mortality  from  cardiovascular  disease.
85  In  14,000 
patients  with  coronary  artery  disease  followed  prospectively  for  4.8-8.1 
years, patients with the metabolic syndrome had a 1.49 fold increased odds 
for  ischaemic  stroke  or  transient  ischaemic  attack  (TIA)  (95%CI,  1.20-
1.84).
86  When  patients  recruited  to  the  Norfolk  arm  of  the  prospective 
multicentre European Prospective Investigation into Cancer (EPIC-Norfolk) 
were  examined  for  the  relationship  between  glycosylated  haemoglobin  at 
baseline and incident stroke risk in patients without diabetes and stroke at 
baseline,  a  threshold  relationship  was  found.  A  total  of  10,489  men  and 
women followed for a mean of 8.5years had 164 incident strokes, with stroke 
ascertainment  being  defined  on  the  basis  of  death  certificate  data  and 
hospital  record  linkage.  After  adjustment  for  age,  sex  and  cardiovascular 
factors the relative risk of stroke for participants with HbA1c (5-5.4%), (5.5-
6.9%) and (≥7%) were 0.78 (0.50 to 1,22), 0.83 (0.54 to 1.27) and 2.83 (1.40 
to  5.74)  respectively.
87  Patients  in  the  latter  group  who  undoubtedly  had 
undiagnosed  diabetes  had  a  significantly  increased  risk  of  stroke.  The   52 
methodology of the study did not permit breakdown of strokes into subtypes.  
 
Screening for abnormal glucose metabolism in patients manifesting “stress 
hyperglycaemia”  following  stroke  is  not  routinely  performed.  In  a 
retrospective review of 90 acute stroke patients with no history of diabetes 
and a hyperglycaemia prevalence of 31%, one patient had a management 
plan to screen for diabetes following discharge.
88  
 
A recent study using an oral glucose tolerance test after three months to 
screen  98  TIA/stroke  patients  with  an  initial  fasting  blood  glucose  of 
<7.0mmol/l demonstrated impaired glucose tolerance in 28% and diabetes in 
24%.  The  median  HbA1c  value  in  those  patients  who  were  confirmed 
diabetic was 5.5%
89, a value much lower than has been used previously to 
define patients with preceding hyperglycaemia in stroke trials.  In a study of 
62 patients screened at three months following an acute ischaemic stroke 
with admission blood glucose was ≥6.1mmol/l, 21% had diabetes mellitus 
and 37% had impaired glucose tolerance. A blood glucose ≥6.1mmol/l and 
HbA1c  ≥6.2%  on  admission  had  an  80%  positive  predictive  value  for 
diabetes  at  12  weeks.
90  In  a  recent  study  of  238  consecutively  admitted 
stroke patients screened twice within a two-week period, 16.4% of patients 
were diabetic and 23.9% had impaired glucose tolerance or impaired fasting 
glucose. 19.7% had transient hyperglycaemia on one test and a second test 
within  normal  limits  and  19.7%  had  normal  glucose  metabolism  on  both   53 
tests.
91 The study raises a number of interesting issues (a) all patients were 
eligible  for  screening  and  not  just  patients  with  demonstrated 
hyperglycaemia; (b) fasting blood glucose values during the first week were 
generally higher than values obtained in the second week, favouring a role 
for stress hyperglycaemia in the acute phase of stroke; and (c) patients with 
diabetes  known  and newly  diagnosed had  more  severe  strokes,  a  higher 
rate  of  pneumonia  and  urinary  tract  infection  and  a  worse  outcome  at 
discharge  than  non-diabetic  patients.  If  screening  is  to  be  advocated  for 
acute stroke patients the best time for undertaking the oral glucose tolerance 
test  remains  uncertain.  In  a  recent  study  of  122  patients  with  acute 
myocardial infarction undergoing OGTT prior to hospital discharge (day 4 or 
5), 34% were diagnosed as having type-2 diabetes. When re-screened at 
12months 93% of the patients still had abnormalities in glucose metabolism 
(64%  diabetic  and  29%  impaired  glucose  tolerance).
92  Justification  was 
given to the screening of patients at the time of initial hospital presentation 
with appropriate intervention as opposed to a wait and watch policy.    
 
Abnormal fasting glucose is part of the criteria for the metabolic syndrome In 
a  Greek  population  based  case  control  study  examining  the  association 
between  metabolic  syndrome  and  acute  ischemic/non-embolic  stroke  in 
subjects over  the  age  of  70. The  prevalence  of metabolic  syndrome  was 
higher in stroke patients than in controls (46% versus 15.7%).
93 Recognition 
of the syndrome is important as it confers increased risk for the development   54 
of diabetes mellitus and for cardiovascular morbidity and mortality. In a study 
of patients with established vascular disease in the form of coronary artery 
disease, stroke, peripheral vascular disease or abdominal aortic aneurysm, 
the  presence  of  the  metabolic  syndrome  on  testing  was  associated  with 
advanced vascular damage as measured by carotid intima media thickness, 
ankle  brachial  pressure  indices  and  albuminuria.
94  Thus,  identification  of 
either abnormal glucose metabolism or metabolic syndrome is important for 
the  identification  of  patients  who  may  benefit  from  additional  secondary 
preventative therapy input. 
 
2.5 Temporal Profile of Glucose Post-Stroke 
 
Elevated  admission  or  fasting  blood  glucose  at  variable  time  points  from 
stroke  onset  has  been  used  to  define  post-stroke  hyperglycaemia  (PSH). 
Blood glucose has been shown to increase in the first 12 hours after stroke 
with the increase in blood glucose said to correlate with increased stroke 
severity.
74 In an earlier publication of patients randomised to the placebo arm 
of the Glucose Insulin in Stroke Trial (GIST)-UK, blood glucose fell within the 
first eight hours of the infusion (median time to infusion 13 hours).
95 Using a 
capillary  glucose  monitor  to  measure  interstitial  glucose  over  a  72-hour 
period, blood glucose was noted to decrease from a peak at eight hours 
following stroke, reach its lowest level at 14 hours, plateau and then have a 
further peak at 66-88 hours.
96 Recognition of the temporal profile of blood 
glucose in acute stroke is important for management of PSH. In addition to   55 
stroke severity, time to hospital presentation may be important in predicting 
hyperglycaemia in the acute phase of stroke. Additional factors often poorly 
described in the literature include the possible impact of feeding and fluid 
regimes.  In  determining  the  temporal  profile  it  is  important  to  have  a 
consistent measure of determining blood glucose levels. Confusion remains 
surrounding  the  difference  between  capillary  whole  blood,  venous  whole 
blood and venous plasma in determining glucose levels. Following an OGTT 
in 75 healthy subjects, capillary blood glucose was significantly higher than 
venous blood. This has implications in determining profiles in patients during 
post-prandial monitoring phases.
97    
 
2.6 Stroke Severity and Blood Glucose 
 
Studies examining the interaction between stroke severity, blood glucose, 
counter-regulatory hormones and catecholamines have reported conflicting 
results.  Following  an  acute  physiological  illness,  stress  hyperglycaemia  is 
thought to develop through glucagon, adrenaline and cortisol opposing the 
normal action of insulin.
98 The more severe the stroke the more marked the 
stress  response.  Serum  cortisol  has  been  shown  to  correlate  with  stroke 
severity, blood glucose and temperature and is an independent predictor of 
short-term outcome.
99 However plasma catecholamines associated with both 
stroke severity and hypertension were not found to correlate with glucose 
levels in a stroke population.
68  
In patients randomised to the NINDS rt-Pa trial, blood glucose within three 
hours  of  stroke  onset  was  not  associated  with  stroke  severity  measured   56 
using  the  National  Institute  of  Health  Stroke  Scale  (NIHSS).
100  Patients 
assessed  using  the  Glasgow  outcome  scale  within  24  hours  of  symptom 
onset had an association between hyperglycaemia and stroke outcome but 
not between hyperglycaemia and initial stroke severity.
68 However, patients 
examined with two blood glucose tests within 12 hours of stroke onset had a 
strong  association  between  blood  glucose  and  stroke  severity  measured 
using the Scandinavian stroke scale.
74  
 
2.7 Stroke Location 
 
Another factor potentially relevant to the development of hyperglycaemia is 
stroke location. In a prospective study of 31 patients who underwent acute 
MRI within 24 hours of stroke onset, median admission blood glucose was 
significantly  higher  in  patients  with  insular  cortical  ischaemia  (8.6mmol/l) 
compared  with  those  patients  without  (6.5mmol/l).
101  Insular  cortical 
ischaemia and pre-existing diabetes mellitus predicted glucose level, whilst 
HbA1c did not. There was no correlation between blood glucose and lesion 
volume. The insular cortex has been shown to influence autonomic function 
especially sympathetic activity.
102 Insular damage in experimental stroke has 
been  shown  to  result  in  an  increase  in  the  circulating  levels  of 
catecholamines  suggesting  this  as  a  mechanism  for  the  cardiac 
complications associated with stroke.
103     
 
2.8 Hyperglycaemia and Ischaemic Injury  
 
Hyperglycaemia has been shown in experimental and clinical studies to act   57 
on vascular and haemostatic function, altering local blood flow and platelet 
aggregation and influencing both vessel occlusion and recanalisation. The 
“ischaemic penumbra” is also susceptible to the effects of hyperglycaemia 
through  its  action  on  tissue  cellular  metabolism  and  has  the  potential  to 
influence infarct progression and clinical outcome.  
 
 
Endothelial Abnormalities  
 
Epidemiological studies have consistently shown diabetes to be a major risk 
factor for atherosclerotic vascular disease.
104;105 There is evidence that the 
primary initiating lesion in the pathogenesis of atherosclerosis is endothelial 
cell  dysfunction.
106  Hyperglycaemia  has  a  direct  effect  on  endothelial  cell 
function and is known to induce a variety of biochemical changes. It has 
been  established  that  four  independent  biochemical  abnormalities  are 
involved  -  increased  polyol  pathway  flux  with  increased  consumption  of 
NADPH  (nicotinamide  adenine  dinucleotide  phosphate-oxidase)  and 
depletion of GSH (reduced Glutathione), increased formation of advanced 
glycation  end  products  (AGE),  activation  of  protein  kinase  C  through 
increased flux  of  dihydroxyacetone  phosphate  to  DAG  (Diacylglycerol)  and 
finally  increased  hexosamine  pathway  flux  with  increase  modification  of 
proteins by O-linked N-acetylglucosamine (GLcNac).
107    58 
 
 
 
 
      NADPH     NADP
+    NAD
+    NADH 
 
↑ Glucose           ↑Sorbitol              ↑Fructose 
 
            Polyol Pathway 
↑ Glucose-6-P 
 
 
      GFAT 
↑ Fructose-6-P       ↑Glucosamine-6-P  ↑UDP-GlcNAc     
   
      Gln  Glu 
            Hexosamine pathway 
 
 
         NADH  NAD
+ 
 
↑DHAP     ↑α-Glycerol-P    ↑DAG      ↑PKC 
 
Protein kinase C pathway 
 
↑ Glyceraldehyde-3-P 
 
 
NAD
+ 
  ↓ GADPH           ↑ O2    ↑ Methylglyoxal    ↑AGEs 
 
NADH 
            AGE pathway 
 
1,3-Diphosphoglycerate 
 
 
 
 
The  pathways  are  related  through  the  action  of  mitochondrial  reactive 
oxygen species inhibiting the glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase,  which  diverts  increased  substrate  flux  from  glycolysis  to 
pathways  of  glucose  overutilisation.    It  is  postulated  that  hyperglycaemia 
Figure 2.1: Potential mechanisms by which hyperglycaemia induced mitochondrial 
superoxide overproduction activates four pathways leading to hyperglycaemic damage. 
[Adapted from Brownlee et al 
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triggered  oxidative  stress  induces  overproduction  of  superoxide  which 
results  in  the  activation  of  the  four  pathways  and  endothelial  damage
108. 
Activation  of  protein  kinase  C  results  in  vascular  occlusion,  decreased 
fibrinolysis and blood flow abnormalities by affecting the expression of nitric 
oxide synthetase (eNOS), endothelin-1, vascular endothelial growth factor 
(VEGF), TGF-β (transforming growth factor - β) and plasminogen activator 
inhibitor-1 (PAI-1).
107  
 
PAI-1  binds  rt-Pa  rendering  it  inactive.    In  a  study  of  44  stroke  patients, 
elevated  PAI-1  levels  were  independently  associated  with  failure  to 
recanalise the middle cerebral artery despite receiving thrombolysis within 
three  hours  of  symptom  onset.  Lower  PAI-1  levels  correlated  with  vessel 
recanalisation. 
109 There is evidence that elevated PAI-1 levels contribute to 
hyperglycaemia induced exacerbation of post-ischemia reperfusion injury in 
stroke models.
109 Hyperglycaemia induced ROS (reactive oxygen species) 
also appears to increase the activity of matrix metalloproteinase 9 (MMP-9). 
In tPa treated stroke patients elevated MMP-9 levels has been associated 
with haemorrhagic conversion.
110  
 
Haemostatic abnormalities  
 
Platelet  aggregability  and  adhesiveness  are  increased  in  diabetics.
111 
Interaction  between  endothelium  and  platelets  contributes  to  the 
hypercoaguable  state  of  diabetes.  A  key  factor  in  promoting  the   60 
prothrombotic state seen in diabetics involves the glycation of annexin II, a 
regulatory protein involved in fibrinolysis surveillance. In a hyperglycaemic 
environment,  glycation  of  annexin  II  impairs  the  formation  of  the 
plasminogen/tissue plasminogen activator/annexin II complex with resulting 
decreased fibrinolytic activity.
112   
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2.9 Ischaemic Penumbra  
 
Controversy  continues  regarding  the  potential  mechanism  by  which 
hyperglycaemia causes neuronal injury. Experimental models demonstrate a 
consistent correlation between acidosis, hyperglycaemia and brain injury.
113 
Anaerobic  metabolism  is  less  energy  efficient  and  produces  lactate  and 
unbuffered  hydrogen  ions.  Experimental  models  have  consistently  shown 
that hyperglycaemia prior to ischaemia results in higher levels of lactate than 
euglycaemic controls.
113;114  
 
Hyperglycaemia  may  initially  be  neuroprotective,  with  increased  glucose 
available  for  metabolism  and  ATP  production.  Persisting  anaerobic 
metabolism results in the development of intracellular acidosis. It has been 
shown using both pH-sensitive microelectrodes and 31P nuclear magnetic 
resonance spectroscopy that the brain pH of animals pretreated with glucose 
is  considerably  more  acidotic  than  saline  treated  controls.
115;116  The 
mechanism  by  which  acidosis  exaggerates  neuronal  injury  is  uncertain. 
Astrocytes were previously thought to be the target, with selective neuronal 
necrosis giving way to pan-necrosis through failure of astroglial nutritional 
support and ion homeostasis.
117 This has not been replicated in subsequent 
studies.  The pronounced acidosis seen with hyperglycaemia provides an 
environment in which secondary mechanisms can act.  Acidosis enhances 
free  radical  formation,  activation  of  pH  dependent  endonucleases  and   62 
glutamate release with subsequent alteration of intracellular Ca++ regulation 
and mitochondrial failure. 
113;118-120   
 
There is currently no direct proof that lactate is detrimental to the ischaemic 
brain. The “glucose paradox of cerebral ischemia” questions why glucose, 
the main energy substrate for the brain, causes demise of brain tissue at the 
time of cerebral ischemia.
121 Cellular injury hinges on the role of lactate in 
the brain. Recent in-vitro work using murine hippocampal slices has shown 
that glucose and acidosis are detrimental to cells whereas lactate is not.
122 
Work performed by Schurr et al has continuously questioned the detrimental 
role of lactate and has proposed that the effect of hyperglycaemia is related 
to the effect of corticosterone on the ischaemic brain, thus favouring a stress 
response.
121  Support  for  this  hypothesis  comes  from  an  animal  model 
whereby blockade of corticosterone (the equivalent of human cortisol) with 
metyrapone attenuates the effect of pre-ischaemic hyperglycaemia on post-
ischaemic  outcome.
123  It  is  postulated  that  lactate  is  a  source  of  energy 
during  cerebral  ischaemia.  Using  PET  scanning  it  has  been  shown  that 
lactate may be the preferred energy supply to the brain especially during 
times of stress.
124 “The glucose paradox” remains unanswered.   63 
 
2.10 The Role of MRI in understanding hyperglycaemia in acute stroke 
 
 
Despite controversy surrounding the role of lactate in the ischaemic brain, 
advances in MRI now permit the study of stroke evolution in hyperglycaemic 
patients.    Studies  using  MRI  in  acute  stroke  have  demonstrated  that 
persistent  hyperglycaemia  (blood  glucose  ≥7.0mmol/l)  in  the  72hours 
following acute stroke is associated with increased infarct size and worse 
stroke  outcome.
125  Twenty  patients  recruited  within  24  hours  of  an  acute 
ischemic stroke underwent MRI at three distinct time points: Day 1 (median 
15hours),  Days  3-6  and  Day  90.  Blood  glucose  as  measured  using  a 
continuous glucose monitor was measured for 72hours. In patients with a 
mean  capillary  blood  glucose  ≥7.0mmol/l,  significantly  greater  changes  in 
lesion volume were measured acutely (difference between first and second 
scan) and at final infarct (difference between first and third scan). Clinical 
outcome scores were worse in patients with hyperglycaemia (Table 2.5).    
                       
In  a  prospective  MRI  study  acute  hyperglycaemia  was  associated  with 
reduced penumbra salvage, greater final infarct size and worse functional 
outcome  in  40  patients  who  had  an  acute  perfusion-diffusion  mismatch. 
Using multiple regression analysis, a strong relationship between increasing 
acute blood glucose and reduced penumbral salvage was demonstrated with 
a doubling of blood glucose from 5 to 10mmol/l leading to a 60% reduction in 
Lactate 
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penumbral salvage. A close correlation was also found between acute blood 
glucose and lactate levels in the ischemic brain.
126 Interestingly the time to 
initial  MRI  scan  was  much  shorter  (4.5  hours)  in  those  patients  with  a 
mismatch  than  for  those  patients  in  which  a  diffusion-perfusion  mismatch 
could not be detected (13 hours). These results support experimental animal 
work  in  which  the  detrimental  effect  of  hyperglycaemia  was  seen  in 
ischaemic tissue which has a collateral supply and a penumbra.
127   65 
Reference  Time 
Window 
Number of 
patients 
Study Parameters  Results 
Baird et al
128  <24hrs  25  Correlation between mean 
blood glucose and infarct 
volume change  
Mean blood glucose over 72hours correlated with infarct volume change 
between acute and subacute DWI (r≥0.60, p<0.01), and acute DWI and 
day 90 T2-MRI (r≥0.53, p<0.02) 
 
Parsons et 
al
129 
<24hrs  63  The effect of 
hyperglycaemia on 
patients with and without 
DWI/PWI mismatch 
In 40/63 patients with mismatch, acute hyperglycaemia (≥144mg/dl) 
correlated with reduced salvage of mismatch tissue from infarction and 
greater final infarct size 
In patients with no mismatch acute blood glucose did not independently 
correlate with outcome measures  
 
Ribo et al
130  <6hrs  47  Hyperglycaemia effect on 
DWI lesion growth relative 
to occlusion time.  
DWI lesion volume grew 2.7 times faster between baseline (pre rt-PA) 
and repeat imaging at 24-36 hours in those patients with hyperglycaemia 
(glucose >140mg/dl) during occlusion time.  (1.73 versus 4.63cm³/h of 
occlusion, p=0.07). Occlusion time measured using TCD 
 
Els et al
131  <3hrs  31  Hyperglycaemia effect on 
MRI infarct size at 
admission (DWI), day 3 
(DWI) and day 7 (T2-MRI). 
Change in lesion volume between day 3 (DWI) and day 7 (T2-weighted 
MRI) increased significantly in the hyperglycaemic (admission blood 
glucose>178mg/dl) group (39.9±17.4%) versus the normoglycaemic 
group (27.1±14.1%) (p<0.05) 
 
 
Table 2.5: Effect of blood glucose on lesion volume progression measured using MRI surrogate markers in clinical studies of patients with 
acute ischaemic stroke (DWI: Diffusion weighted Imaging, PWI: Perfusion weighted imaging, TCD: Transcranial Doppler) 
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Reference  Time 
Window 
Therapeutic 
agent 
Number 
of 
patients 
Study parameters  Results 
TOAST
132  <24hours  Low molecular weight 
heparinoid versus 
placebo 
1259  Relationship between 
admission blood 
glucose and clinical 
outcome. 
 
All strokes combined: (OR =0.82 for every 100mg/dl 
increase in blood glucose; p=0.03),  
 
Non-lacunar strokes (OR 0.74 for every 100mg/dl 
increase in blood glucose; p=0.02) 
 
NINDS rt-PA 
Stroke trial
100 
<3hours  Intravenous  
rt-Pa versus placebo 
624  NIHSS change of ≥4 at 
3months or a final score 
of 0 
 
Symptomatic ICH at 
36hours* 
OR of neurological improvement per 100mg/dl 
increase in blood glucose =0.76 (0.61-0.95) (p=0.01) 
 
OR of SICH per 100mg/dl increase in blood glucose = 
1.75 (1.11-2.78) (p=0.02) 
PROACT II
133  <6hours  Intra-arterial r-proUK + 
IV heparin versus IV 
heparin alone 
180  Symptomatic ICH within 
36hours of treatment** 
Patients receiving r-proUK with admission blood 
glucose >200mg/dl experienced a 36% risk of SICH 
compared to 9% for those ≤200mg/dl (RR 4.2; 95% CI 
1.04-11.7) (p=0.022) 
CLOTBUST
134  <3hours  Intravenous 
thrombolysis with 
randomisation to TCD 
or placebo 
117  Interaction between 
admission glucose and 
ultrasound with respect 
to good clinical outcome 
(mRs 0-2) 
High admission glucose predicted a lower probability 
of good outcome in the control group but not the 
active ultrasound group, as demonstrated by an 
interaction between glucose and treatment group 
(p=0.043) 
 
Table 2.6: Relationship between admission glucose level and outcomes in clinical trials of anti-coagulant and thrombolytic agents. 
 
TOAST: Trial of ORG 10172 in Acute Stroke Treatment; NINDS: National institute of Neurological Disorders and Stroke; PROACT II: PROlyse for Acute Cerebral Thromboembolism; 
CLOTBUST: Combined Lysis Of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic tPA); r-proUK: recombinant pro-urokinase  
*SICH defined as CT documented hemorrhage within 36hours of treatment that was temporally related to clinical deterioration. 
** Presence of ICH with neurological deterioration defined as an increase of ≥4 points on the NIHSS in comparison with the preangiography score within 36hours of treatment initiation. 
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2.11 Hyperglycaemia and New Stroke Treatments (Thrombolysis) 
 
Restoration of cerebral blood flow with salvage of penumbral tissue is the 
aim  of  thrombolysis.  The  earlier  intravenous  thrombolysis  is  initiated,  the 
greater the odds of a good outcome. In the pooled analysis of the Alteplase 
Thrombolysis  for  Acute  Noninterventional  Therapy  in  Ischemic  Stroke 
(ATLANTIS) study, European Cooperative Acute Stroke Study (ECASS) and 
NINDS rt-PA stroke trial the odds ratio of a favourable outcome for patients 
treated with rt-PA compared with controls was 2.81 (95% CI 1.75-4.50) in 
those treated within 90minutes and 1.55 (95% CI 1.12-2.15) for those treated 
from 91-180 minutes
135 (Table 2.6). Patient numbers receiving intravenous 
thrombolysis remain low. Contributing factors include the short time window 
of three hours and the risk of haemorrhagic transformation. In a post-hoc 
analysis  of  the  NINDS  study  hyperglycaemic  patients  had  significantly 
increased  odds  of  symptomatic  intracerebral  haemorrhage  (OR=1.75  per 
100mg/dl increase in admission glucose, 95% CI 1.11 to 2.78, p=0.02) and 
reduced odds of a good clinical outcome (OR=0.76 per 100mg/dl increase in 
admission glucose, 95%CI 0.61 to 0.95, p=0.01). 
100  
 
Experimental  models  of  focal  brain  ischaemia  have  consistently 
demonstrated  an  association  between  hyperglycaemia  and  worse  stroke 
outcome in the setting of reperfusion following temporary vessel occlusion. 
Similar  results  have  recently  been  confirmed  in  clinical  studies  of  acute 
ischaemic  stroke  patients  receiving  intravenous  thrombolysis.  Using   68 
Transcranial Doppler (TCD) to assess recanalisation status in 73 patients 
following  thrombolysis,  hyperglycaemia  was  found  to  be  an  independent 
predictor of poor outcome at three months in patients who recanalised but 
not in patients with permanent occlusion.
136  
 
Acute hyperglycaemia has been shown to predict non-recanalisation in the 
hyperacute phase of stroke. An acute blood glucose value >8.8mmol/l (OR, 
7.3; 95% CI, 1.3 to 42.3; p=0.027) was an independent predictor of non-
recanalisation  within  two  hours  of  bolus  alteplase  administration.
137  Acute 
hyperglycaemia is thought to exert its anti-fibrinolytic effect through glycation 
of annexin II.
138 Correction of hyperglycaemia prior to recanalisation requires 
prompt blood glucose control at the time of initial presentation. Maintenance 
of euglycaemia with insulin at initial presentation and continued through to 
recanalisation  may  enhance  the  effect  of  thrombolysis.  Timing  to 
recanalisation was important with the highest odds for poor outcome in those 
patients with hyperglycaemia who recanalise within three hours  (OR, 3.1; 
95%CI,  1.8-14.3;  p=0.002).
139  In  patients  with  delayed  recanalisation  (6-
12hours)  hyperglycaemia  was  not  predictive  of  poor  outcome  (OR,  1.1; 
95%CI,  0.7-21;  p=0.43).  Using  MRI  to  measure  infarct  progression  in 
patients  receiving  intravenous  thrombolysis,  infarct  volume  increased 
significantly  more  in  hyperglycaemic  patients;  39.9  ±  17.4%  compared  to 
normoglycaemic patients 27.1 ± 14.1% (p<0.05).
131  
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Time  to  recanalisation  appears  predictive  of  haemorrhagic  type.  Early 
recanalisation  with  petechial  haemorrhage  can  predict  a  good  outcome 
whereas  delayed  recanalisation  is  associated  with  the  development  of  a 
parenchymal  haematoma  and  clinical  deterioration.
140  The  delayed 
recanalisation  associated  with  acute  hyperglycaemia  is  thought  to 
predispose  to  parenchymal  haematoma  development  and  explain  its 
relationship with hyperglycaemia.  
 
2.12 Blood Glucose lowering therapies 
 
Controversy continues as to whether acute hyperglycaemia is a cause of 
neurological deterioration or an epiphenomenon, a distinction pivotal in the 
management  of  stroke  patients  with  hyperglycaemia.  Post  stroke 
hyperglycaemia  is  common  and,  at  least  in  non-diabetic  individuals,  is 
associated with a poor stroke outcome. 
71;141 Control of hyperglycaemia has 
generally been assumed to be beneficial but prospective trial data has been 
lacking. In the absence of such evidence, clinical practice has been guided 
by  extrapolation  of  results  from  non-stroke  populations  that  inform 
consensus guidelines. 
142 The absence of quality evidence in this area has 
been  recognised  and evidence  derived  from  patients  with  acute  stroke  is 
becoming available.   70 
 
2.13 Insulin and stroke units: current practice 
 
American  and  European  guidelines  advise  active  treatment  of 
hyperglycaemia but the criteria for implementation of insulin treatment vary.  
European  Stroke  Initiative  (EUSI)  guidelines  advise  intervention  if  blood 
glucose exceeds 10mmol/l, whilst the American Stroke Association (ASA) 
guidelines have recently been updated to lower the threshold for intervention 
from 16.63mmol/l
142 to 11.0mmol/l.
46 The Royal College Guidelines simply 
state that blood glucose should be maintained within normal limits without 
specifying what the targeted range should be.
143 The SIGN guidelines make 
no reference to glucose or its proposed manipulation.
144 In an audit of acute 
neurological  stroke  care  performed  across  22  countries  by  the  European 
Federation of Neurological Societies, the mean threshold of blood glucose 
concentration  for  intervention  was  10.6mmol/l,  ranging  from  7.4  to 
14.4mmol/l in different countries.
145 The survey did not reveal the variation in 
practice among centres within individual countries, which we presume to be 
at least as great. The decision to intervene is made more complex by the risk 
of  iatrogenic  hypoglycaemia  during  insulin  treatment.  This  needs  to  be 
considered when selecting the most appropriate glucose level, the method 
and duration of insulin delivery, and the duration of glycaemic monitoring.  
 
A variety of methods of insulin administration exist, comprising continuous 
intravenous  infusion,  repeated  subcutaneous  dosing  by  sliding  scale  or   71 
intravenous (IV) delivery of a reconstituted infusion containing insulin and 
dextrose  with  potassium  supplementation  (the  GKI  regime).  Sliding  scale 
regimens are largely reactive, correcting changes as and when they occur, 
whereas GKI regimens are largely proactive predicting insulin requirements 
and  maintaining  euglycaemia  within  a  therapeutic  range.  Concurrent 
administration of insulin, potassium and glucose as a GKI infusion reduces 
the risk of hypoglycaemia arising as a result of device or infusion failure. 
 
Maintenance of euglycaemia can prove difficult in patients who are eating 
and  drinking  normally,  as  such  patients  tend  to  develop  post-prandial 
hyperglycaemia  before  the  insulin  infusion  rate  is  increased.  While  both 
sliding scale and GKI regimes have attracted criticism in the literature, 
146 no 
clearly superior alternative has yet been reported. The practical aspects and 
the safety profile of each method have been considered in different hospital 
settings  including  critical  care,  coronary  care,  general  medical  wards  and 
stroke units. In the absence of trial data sufficiently powered to examine the 
effect of insulin on clinical outcomes in a stroke population, trials of insulin 
infusions in other contexts (such as coronary and intensive care units) need 
to be considered.  
 
2.14 Insulin in hospitalised hyperglycaemic patients 
A meta-analysis of 35 randomised controlled trials involving 8,478 patients 
examined the effect of insulin on mortality in the hyperglycaemic critically ill   72 
patient.
147 Insulin was administered as a GKI Infusion in 86% of the studies, 
with  14%  using  intravenous  insulin  by  pump.  Studies  were  published 
between  1965  and  2002  and  included  patients  primarily  with  acute 
myocardial infarction. Combined data demonstrated that insulin decreased 
short-term mortality by 15% [RR 0.85; 95% CI, 0.75-0.97]. Greatest benefit 
was noted in the surgical intensive care unit (ICU) population [RR, 0.58; 95% 
CI, 0.22-0.62], when the aim of therapy was glucose control [RR, 0.71; 95% 
CI, 0.54-0.93] and in patients with Diabetes Mellitus [RR, 0.73; 95% CI, 0.58-
0.90].  
 
Two multi-centre randomised controlled trials have recently questioned the 
benefit of insulin in critical illness. Both studies used GKI infusions in acute 
myocardial  infarction.  The  Diabetes-Mellitus  Insulin-Glucose  Infusion  in 
Acute Myocardial Infarction 2 (DIGAMI 2) trial was a follow on study from 
DIGAMI.
148;149  DIGAMI  recruited  620  patients  with  diabetes  and  acute 
myocardial  infarction  to  intensive  glucose  management  or  routine  care 
during both hospital stay and the three months following discharge. Intensive 
glucose management utilised a GKI infusion for 24 hours followed by daily 
insulin injections thereafter for the duration of the study. The mean glucose 
level  at  24  hours  was  9.6  mmol/l  in  the  intervention  group  compared  to 
11.7mmol/l in the control group. After one year, 18.6% in the infusion group 
and 26.1% in the control group had died (relative mortality reduction 29%, 
p=0.027). Mortality in the first DIGAMI study was lower than expected and as   73 
such  there  was  little  statistical  power  to  detect  reasons  for  mortality 
reduction. The study was unable to answer whether the beneficial effects of 
insulin related to the acute GKI infusion or to the continuous insulin based 
metabolic control.  
 
DIGAMI  2  was  therefore  planned  in  which  1,253  patients  with  type  2 
diabetes and suspected acute myocardial infarction were randomised to one 
of three different groups: 24 hour GKI followed by long term subcutaneous 
insulin,  24  hour  GKI  followed  by  conventional  glucose  control  or  routine 
hospital  glucose  management.  Period  of follow-up  and  study  participation 
varied from six months to three years. In contrast to the findings in DIGAMI, 
GKI with or without long-term insulin failed to demonstrate survival benefit 
over routine treatment. 
149  
 
Differences existed between the two studies.  DIGAMI included patients with 
type  1  and  type  2  diabetes  and  required  an  admission  blood  glucose  of 
>11.0mmol/l as part of the inclusion criteria.  DIGAMI 2 however required the 
recruitment  of  type  2  diabetic  patients  only  without  a  predefined  glucose 
threshold. As a result, there was higher baseline blood glucose in patients in 
DIGAMI when compared to DIGAMI 2 (15.5 ± 4.5 versus 12.8±4.5mmol/l). 
The  resulting  initial  decrease  in  blood  glucose  was  more  substantial  in 
DIGAMI  than  DIGAMI  2  (-5.8mmol/l  versus  -3.4mmol/l).  DIGAMI  2  had 
originally planned to include 3,000 patients but slow recruitment lead to its   74 
premature cessation. Blood glucose control for groups 1 (9.1 ± 3.0mmol/l) 
and 2 (9.1 ± 2.8mmol/l) was significantly lower when compared to group 3 
(10.0 ± 3.6mmol/l) after 24 hours of the infusion but there was no statistically 
significant  difference  in  blood  glucose  between  any  of  the  three  groups 
beyond  this  time  point  and  the  desired  blood  glucose  control  was  not 
achieved.  Therefore,  when  compared  with  DIGAMI,  the  absence  of  an 
apparent treatment effect in DIGAMI 2 may in part be the failure to achieve 
effective  glucose  lowering  between  groups  in  the  acute  and  long-term 
period.  
 
Additional results from the merger of two multi-centre trials (The Clinical Trial 
of  Reviparin  and  Metabolic  Modulation  in  Acute  Myocardial  Infarction 
Treatment  Evaluation  and  Estudios  Cardiologicas  Latin  American  Study 
Group: CREATE-ECLA) which randomised 20,201 patients within 12 hours 
of acute ST-elevation myocardial infarction (MI) to GKI-infusion or placebo, 
found that GKI infusion had a neutral effect on mortality, cardiac arrest and 
cardiogenic  shock.
150  In  the  CREATE-ECLA  study,  mean  glucose 
concentration was consistently higher in the GKI infusion population due to a 
high glucose concentration infusion. 
 
The  publication  of  the  large  single  centre  Leuven  study  -  examining  the 
effect of insulin therapy aimed at tight glucose control in a surgical intensive 
care unit and its resultant effect on reducing mortality - has resulted in its   75 
widespread  adoption  in  many  intensive  care  facilities.  Patients  (n=1,548) 
admitted to a surgical intensive care unit were randomised to either intensive 
insulin  therapy,  with  maintenance  of  blood  glucose  between  4.4  and  6.1 
mmol/l  or  conventional  treatment  (insulin  infusion  only  if  glucose  level 
exceeded 11.9 mmol/l and maintenance of glucose at a level between 10.0 
and 11.1 mmol/l).  Intensive insulin therapy reduced mortality in intensive 
care from 8% to 4.6% (p<0.04) and reduced overall in-hospital mortality by 
34%.
151  Complication  rates  of  severe  nosocomial  infections,  acute  renal 
failure, liver dysfunction, critical illness neuropathy, muscle weakness and 
anaemia were prevented in patients treated with intensive insulin.  When the 
same group examined the effect of insulin in 1,200 patients admitted to the 
medical intensive care unit with similar targeted levels of glucose control, 
intensive  care  mortality  was  similar  for  both  groups  -  26.8%  in  the 
conventional group versus 24.2% in the intensive treatment group (p=0.31). 
In-hospital mortality was 40% for the conventional group and 37.3% in the 
intensive  insulin  group  (p=0.33).  However  for  those  patients  (n=767)  who 
stayed in the intensive care unit for three or more days, in-hospital mortality 
in  patients  receiving  intensive  insulin  therapy  (n=386)  was  reduced  from 
52.5%  to  43%  (p=0.009).  For  all  patients  undergoing  randomisation, 
intensive  insulin therapy  saw  a  reduction  in  newly  acquired  kidney  injury, 
earlier weaning from mechanical ventilation and earlier discharge from both 
ICU and hospital.
152  
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Despite the noted benefit of both studies in relation to its effect on mortality 
and morbidity in specific populations, a constant criticism relates to the lack 
of  blinding,  the  single  centre  nature  of  the study,  the  influence  of  enteral 
nutrition and the practicalities of the infusion. In addition the units protocol 
involved all admitted patients receiving a large carbohydrate load both as an 
intravenous  glucose  infusion  and  immediate  supplemental  feeding.  The 
feasibility of reproducing the intense monitoring and nurse staffing ratios (2.5 
full  time  equivalent  nurses  per  bed  in  the  ICU),  in  a  stroke  unit  setting 
appears unlikely. Both trial results have recently been pooled to examine the 
controversies  surrounding  infusion  duration,  optimal  blood  glucose 
thresholds and effect on specific sub-groups. Intensive insulin therapy (IIT) 
reduced mortality for both the intention to treat population and for patients 
staying  for  >3  days  with  no  difference  in  patients  resident  for  <3  days. 
Mortality  was  more  significantly  reduced  in  patients  with  a  blood  glucose 
<6.1mmol/l when compared to patients with a blood glucose 6.1-8.3mmol/l or 
>8.3mmol/l, despite a greater risk of hypoglycaemia. 
153Patients with known 
diabetes  were  the  only  subgroup  not  to  show  a  survival  benefit  with  IIT, 
which contrasts with the previously published meta-analysis.   
 
Attempts to reproduce results in a multi-centre trial have proved difficult. Two 
recent  European  trials  aimed  at  maintaining  tight  glycaemic  control  (4.4-
6.1mmol/l)  were  stopped  early  due  to  an  unacceptably  high  rate  of 
hypoglycaemia in the tight control group.
154;155 In 488 patients recruited to   77 
the VISEP trial examining the effect of insulin in patients with severe sepsis 
and  septic  shock,  12.1%  of  patients  receiving  insulin  had  hypoglycaemia 
(<2.2mmol/l)  compared  to  2.1%  of  patients  in  the  conventional  treatment 
group.
154 Recent evidence from the GIST-UK trial suggests that most acute 
stroke patients will have only mild to moderate increases in plasma glucose 
at  presentation  (median  7.6mmol/l,  (IQR  6.7-9.0))  with  minimal  insulin 
requirement  as  a  consequence.
156  Consequently,  without  significant 
carbohydrate loading and immediate supplemental feeding, it is unlikely that 
intensive insulin regimens could be used in acute stroke patients. 
 
A  further  multi-centre  trial  continues  recruitment  (NICE-SUGAR: 
Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose 
Algorithm Regulation) and will hopefully provide further information on the 
tolerability and efficacy of tight glycaemic control. 
157    
 
2.15 Animal models and insulin 
 
In the absence of substantial clinical trial evidence our understanding of the 
effect of insulin on ischaemic stroke has been instructed by experiments in 
models of ischaemia. 
 
Evidence  derived  from  animal  models  shows  that  during  acute  focal  and 
global ischaemia, insulin therapy reduces ischaemic brain damage and may 
be  neuroprotective.
158  It  is  postulated  that  the  neuroprotective  action  is   78 
exerted through insulin like growth factor (IGF) type receptors. Insulin and 
IGF-1 were found to reduce ischaemic damage when injected directly into 
the brain ventricles.
159 In a model of forebrain ischaemia in rats, insulin not 
only reduced histological injury but improved neurobehavioural outcome.
160 
Insulin  is  also  felt  to  exert  an  anticoagulant  effect,  through  reduced 
thromboxane production 
161 and decreased plasminogen activator inhibitor-1 
activity.
162  The  effect  of  insulin  appears  dependent  on  the  model  of 
ischaemia and also the method of insulin administration.   
 
2.16 Insulin in experimental models of focal ischemia 
 
A systematic search was undertaken with the aim of answering the question 
as  to  what  effect  insulin  had  on  infarct  volume  and  stroke  outcome  in 
experimental models of focal ischaemia. Appropriate studies were identified 
from  the  following  databases;  Pubmed  (1966-  1
st  week  in  May  2006), 
Embase (1980 to 1
st week in May 2006), web of science (1900- 1
st week in 
May 2006) and BIOSIS 1969 –1
st week in May 2006). Additional publications 
were  identified  from  reference  lists  of  all  identified  publications,  review 
articles  and  abstract  books  of  appropriate  scientific  meetings.  Additional 
information was obtained by talking to researchers involved in the field. The 
search  strategy  employed  the  following  keywords:  insulin,  ischaemia  and 
cerebral. Search criteria were restricted to animal experiments. Studies were 
included if they described focal ischemia, exogenous insulin administration   79 
and  a  measure  of  infarct  volume.  Numbers  of  articles  retrieved  from  the 
search strategy are shown in (Figure 2.2).  
 
Off the two hundred and twenty one original articles retrieved following the 
initial search strategy, forty-four studies were found to involve experimental 
models of focal ischaemia. This was further refined to twenty studies which 
had  involved  the  administration  of  insulin,  of  which  one  study  was 
subsequently excluded on the basis of there being no control group. Of the 
remaining nineteen studies, six did not have infarct volume as an outcome 
measure,  leaving  thirteen  studies  fulfilling  criteria.  The  thirteen  studies 
involved  three  different  types  of  animal  species,  rat,  cat  and  gerbil.  Six 
studies reported temporary models of ischaemia, with the remaining seven 
describing permanent models.  
 
The effect of insulin appears to differ depending on a number of parameters, 
(i)  the  timing  of  insulin  relative  to  ischaemia,  ie  whether  the  insulin 
administered was pre-, intra- or post ischaemic, (ii) the duration of ischaemia 
and  whether  it  was  permanent  or  temporary  and  (iii)  the  level  of  blood 
glucose achieved following insulin administration. In a temporary model of 
focal ischaemia using rats, elevated blood glucose at the time of ischaemia 
resulted in larger infarcts than those with a blunted glucose effect. 
163 In a 
separate study, development of hypoglycaemia (mean blood glucose in the 
range  3.2-3.8mmol/l)  following  treatment  with  insulin,  in  a  cat  model  of   80 
temporary focal ischaemia, found larger infarcts and an increased death rate 
when  compared  to  euglycaemic  controls.
164  A  summary  of  the  studies 
selected in the systematic review with outcomes are shown in Table 2.7.     81 
Figure 2.2: Consort chart for the selection of original articles following initial search criteria 
examining the effect of insulin on experimental models of focal ischaemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identified Articles 
N=221 
 
Cerebral Ischemia Induced 
N=115 
Ischemia not induced 
N=106 
 
Focal Ischemia 
N=44 
Non-Focal Ischemia 
N=71 
Insulin Administered 
N=20 
Insulin not administered 
N=24 
 
No control group 
N=1 
Control Group 
N=19 
Infarct measured 
N=13 
Infarct not described 
N=6   82 
Reference  Species  Site  of 
Ischaemia 
Occlusion 
Type 
Results 
Yip et al
163  Rat  MCAO  Temporary  Intra-ischaemic  normoglycaemia  resulted  in 
significantly  smaller  infarct  volumes  than 
hypoglycaemic rats  
Zhu et al
165  Rat  MCAO  Temporary  Insulin  was  not  beneficial  in  reducing 
infarction  size.  The  increased  damage 
induced  by  insulin  occurred  in  animals  with 
very low blood glucose (2-3mmol/l) 
Hamilton  et 
al
166  
Rat  MCAO  Temporary  Reduction in blood glucose to the low normal 
range  (3-4mmol/l)  reduced  infarction  size, 
whereas  insulin  administration  without 
hypoglycaemia did not.  
Fukuoka  et 
al
167  
Gerbil  UCCO  Temporary 
 
Daily insulin injections without hypoglycaemia 
resulted in least infarction on histology. 
Zhao et al
168  Rat  MCAO  Temporary   Oedema  formation  was  less  in  rats  treated 
with  insulin  that  resulted  in  normal  blood 
glucose levels.  
Temporary   Insulin  induced  hypoglycaemia  resulted  in 
increased infarct size in cat survivors.  
De  Courten-
Myers et al
164 
 
Cat 
 
MCAO 
Permanent  Hyperglycaemic  cats  receiving  insulin  had 
larger infarct sizes than cats receiving normal 
saline. 
Nedergaard  et 
al
169 
Rat  MCAO  Permanent  Volume  of  infarction  was  decreased  in 
hypoglycaemic animals. 
Bomont et al
170  Rat  MCAO  Permanent  Insulin  treatment in  diabetic  rats  significantly 
reduced  infarct  volume  (by  approximately 
30%). 
Izumi et al
171  Rat  MCAO  Permanent  Insulin  and  Magnesium  Chloride  in 
combination maximally reduced infarct volume 
size. 
Izumi et al
172  Rat  MCAO  Permanent  Insulin  given  after  MCA  occlusion  reduced 
infarction  volume  without  inducing  sustained 
hypoglycaemia 
Kazan et al
173  Rat  MCAO  Permanent  Infarct  Volume  was  significantly  reduced  for 
rats  receiving  insulin  when  compared  to 
controls 
Combs et al
174   Cat  MCAO  Permanent  No  significant  difference  in  infarct  size 
between  hyperglycaemic  rats  and  rats  with 
hyperglycaemia receiving insulin.  
Table  2.7:  Experimental  models  of  focal  ischaemia,  documenting  species,  site  of 
ischaemia, occlusion type and results of insulin administration. Papers obtained from 
systematic review of available literature 
 
 
 
2.17 Insulin use in brain-injured patients 
 
Limited evidence exists on the action of insulin in humans with CNS injury. 
Post hoc analysis of 63 patients with isolated brain injury from the larger 
Leuven  cohort  of  1,548  surgical  ICU  patients  receiving  intensive  insulin   83 
therapy  examined  the  effect  of  insulin  therapy  on  intracranial  pressure, 
diabetes insipidus, seizures and long-term rehabilitation at 6 and 12 months 
follow-up.  57%  of  patients  included  had  intracerebral  or  subarachnoid 
haemorrhage with 19% being classified as having brain ischaemia. When 
the  conventional  treatment  population  (n=30)  was  compared  to  the 
intensively treated population (n=33), patients receiving insulin had reduced 
mean  and  maximal  intracranial  pressure,  fewer  acute  seizures  and  at  12 
months  brain  injured  survivors  were  more  likely  to  be  self-caring.    Non-
neurological  morbidity  was  also  reduced  in  the  insulin  group  reflected  by 
reduced  duration  of  mechanical  ventilation,  ICU  stay,  hospital  stay  and 
reduced incidence of systemic sepsis. 
175  
 
In a retrospective study of 960 patients with thromboembolic stroke, patients 
who had initial hyperglycaemia (blood glucose >7.2mmol/l) that settled on 
repeated testing at 24 and 48hours had similar mortality rates to patients 
with persistent euglycaemia.
176 Insulin, oral hypoglycaemic agents or both 
were  used  in  63.7%  of  patients  developing  euglycaemia  after  admission. 
These  results  although  taken  from  a  retrospective  study  suggest  some 
benefit of blood glucose control, providing justification for prospective work in 
this area.    84 
 
2.18 Recent evidence in stroke patients 
 
The GIST-UK study recruited patients with acute stroke and blood glucose 
between 6.1 and 17mmol/l, regardless of whether or not they were known to 
have diabetes, although insulin requiring diabetic patients were excluded. 
95 
Patients were randomised to either placebo (normal saline) or a GKI infusion 
for 24 hours. The objective of the GKI treatment was to maintain capillary 
blood  glucose  between  4  and  7mmol/l.  The  trial’s  primary  end-point  was 
mortality at day 90. The GKI regime in GIST-UK comprised 500mls of 10% 
dextrose, 20mmol KCL and 16 units (initial) of soluble recombinant human 
insulin.  Since  the  GKI  regime  involved  100ml/h  IV  infusion,  patients  with 
renal or significant congestive cardiac failure were excluded. Whilst these 
volumes of fluid may present difficulties for older patients with co-morbidity 
there  was  only  a  3%  incidence  of  symptomatic  heart  failure  reported.  At 
infusion  initiation  blood  glucose  monitoring  was  undertaken  hourly  until 
euglycaemia  was  reached  and  then  changed  to  two-hourly.  Dosage 
escalations or reductions required bag disposal and adjustment due to the 
inflexibility of insulin titration independent of glucose, although the median 
number of bag changes over the 24 hours was two per patient. This regimen 
can prove difficult in patients who are eating or drinking normally, requiring 
increased levels of insulin during the day and at times of meals with reduced 
requirements  at  night.  This  difficulty  of  dose  titration  is  more  relevant  for   85 
prolonged infusions and is relevant to infusion duration. The GKI regime is 
therefore very labour-intensive. 
 
The  main  results  of  GIST-UK  have  recently  been  published
156,  with  933 
patients randomly being assigned treatment between 1998 and March 31st 
2006.  Of  the  464  acute  stroke  patients  who  were  treated  with  the  GKI 
infusion,  30%  died  within  90  days  compared  with  27.3%  among  the  469 
patients who were randomised to receive saline solution (p = 0.37).  Median 
time  to  infusion  was  less  than  14  hours  for  both  groups.  Similarly,  no 
significant effect of GKI infusion upon prevalence of severe disability at 90 
days was identified.  One unexpected finding was an effect of GKI infusion 
upon  blood  pressure.  Treatment  with  GKI  was  associated  with  significant 
decreases in blood pressure beyond that of medical therapy, with a mean fall 
in systolic blood pressure of 9.03 mmHg. Although insulin is known to exert a 
vasodilatory  effect  upon  resistance  vessels 
177,  alternative  explanations 
include the effect of potassium as part of the trial infusion or the pressor 
effect of saline. 
156 This observation requires further investigation.  
 
Despite the neutral result, the trial remains the first clinical trial of glucose 
modulation in acute stroke and subsequent trials will be informed through its 
results. The trial recruited 933 patients of a proposed sample size of 2,355 
patients and as such was underpowered to detect the pre-specified mortality 
difference  between  groups.  As  previously  discussed,  despite  a  glucose   86 
enrolment  range  of  6.0-17mmol/l,  the  majority  recruited  had  mild 
hyperglycaemia; median blood glucose 7.8mmol/l (6.8-9.2) in the GKI group 
and 7.6mmol/l (6.7-8.8) in the placebo group. The effect of GKI on patients 
with  moderate  to  severe  hyperglycaemia  remains  uncertain,  with  current 
practice  still  being  guided  by  consensus  guidelines.  In  contrast  to  the 
previously published meta-analyses on insulin, which demonstrated benefit 
in  patients  when  the  goal  of  therapy  was  glucose  lowering,  GKI  lowered 
glucose but the effect was only modest (difference between GKI and saline 
groups of 0.57mmol/l) and glucose concentration fell spontaneously with IV 
saline alone.   
 
It is interesting to compare the neutral result of GIST-UK with the neutral 
result  of  DIGAMI  II,  which  saw  a  0.9mmol/l  difference  in  blood  glucose 
between the insulin and placebo groups, 
149 while the first DIGAMI study had 
achieved a 2.1mmol/l reduction in glucose.
148 A post-hoc analysis of GIST-
UK  investigating  the  safety  of  glucose  lowering  on  outcome  found  that 
patients receiving GKI with a 2mmol/l or more decrease in blood glucose 
between  baseline  and  24hours  had  a  higher  mortality  at  24hours  (34% 
(53/154)) when compared to patients with a glucose reduction of less than 
2mmol/l over the same period (22% (41/188)) (p=0.009). The time window 
for  targeted  acute  stroke  therapy  remains  uncertain,  with  previous 
neuroprotective and thrombolytic trials utilising a typical time limit of up to six 
hours from ictus to maximise the opportunity to attenuate tissue injury. 
178;179.    87 
In the GIST-UK study only eight patients were treated within three hours, 
with  108  patients  being  treated  within  six  hours.  No  patients  in  GIST-UK 
received thrombolysis and as such any potential synergistic effect with GKI 
could not be assessed.    
 
An  alternative  method  of  insulin  administration  was  examined  in  a 
randomised controlled pilot study.
180  Intravenous (IV) insulin was given at a 
variable rate, adjusted for target glucose concentration of 5-8 mmol/l, and 
run simultaneously with a crystalloid infusion of either normal saline or 5% 
dextrose.    Patients  within  24  hours  of  an  acute  ischaemic  stroke  with 
hyperglycaemia  (8-20mmol/l)  were  randomised  to  receive  rigorous 
glycaemic control or standard management for 48hours.  25 patients were 
recruited, with 13 randomised to insulin infusion. Over the course of the trial, 
one episode of transient hypoglycaemia occurred, which responded well to 
oral glucose.  
 
In  a  separate  study  a  different  method  of  IV  insulin  administration  was 
used.
181  24  patients  (88%  known  diabetic)  recruited  within  12hours  of  an 
acute  ischaemic  stroke,  with  blood  glucose  in  the  range  9.4-22.2mmol/l, 
received insulin for a mean of 54 hours (range 17-72 hours). The insulin 
protocol  was  adjusted  after  every  3-7  patients  to  prevent  hypoglycaemia, 
with  potential  post-prandial  hyperglycaemia  being  covered  with 
subcutaneous insulin 0.12 units/kg before each meal in those patients with   88 
oral intake. Target glucose range was 3.9 - 7.2mmol/l. Hypoglycaemia was 
defined as <3.0mmol/l. At least one episode of hypoglycaemia occurred in 
11 (46%) patients, with symptomatic hypoglycaemia in 5 (21%). All episodes 
were  rapidly  detected  with  regular  monitoring  and  symptoms  resolved 
completely  with  glucose  management  as  required.    Protocol  deviations 
accounted  for  3  of  19  episodes  of  hypoglycaemia.  A  potential  technical 
problem  with  this  method  of  insulin  delivery  is  that  blockage  of  the 
accompanying intravenous cannula may allow insulin delivery alone and the 
risk of hypoglycaemia.   
 
Two further trials are examining the effect of insulin in the presence of acute 
ischaemic  stroke:  the  Glucose  Regulation  in  Acute  Stroke  Patients  Trial 
(GRASP)  which  is  continuing  recruitment  and  the  Treatment  of 
Hyperglycaemia  in  Ischaemic  Stroke  trial  (THIS)  which  has  completed 
recruitment but not yet presented its results. 
182;183 In GRASP, patients with 
hyperglycaemia (glucose >6.1mmol/l) within 24 hours of symptom onset are 
randomised  to tight  glucose  control  (3.9-6.1mmol/l),  loose  glucose  control 
(6.1-11.1mmol/l)  or  usual  care.  The  infusion  will  be  in  the  form  of  a  GKI 
infusion and titrated to capillary glucose. The primary outcome is the rate of 
hypoglycaemic events (glucose < 3.05mmol/l).  
 
THIS is a randomised, multi-centre trial which recruited patients with acute 
ischemic  stroke  within  12  hours  of  symptom  onset  to  usual  treatment   89 
(subcutaneous insulin four times daily) or aggressive treatment (continuous 
intravenous  insulin  to  a  target  glucose  range  6.1-  7.2mmol/l).  The 
experimental  interventions  continue  for  72hours.  The  primary  outcomes 
measures were the modified Rankin scale, Barthel Index, NIH stroke scale 
and a stroke specific quality of life scale assessed at 90 days. Results are 
awaited. The study recruited 45 patients and as such it seems unlikely that 
any  significant  clinical  measure  of  outcome  will  be  discernible  between 
groups. 
 
2.19 Insulin and mode of action 
 
There is evidence to support a beneficial effect of insulin administration to 
achieve euglycaemia in both preclinical models of ischaemia and in selected 
clinical scenarios
184;185.  Animal studies confirm that this benefit is lost when 
hypoglycaemia occurs. 
165 Uncertainty remains as to whether insulin has an 
effect independent of its action of glucose and evidence exists of alternative 
mechanisms.  These  include  a  potential  direct  neuro-protective  effect, 
independent of euglycaemia. In a rat model of transient forebrain ischaemia, 
insulin administered with glucose significantly reduced cortical and striatal 
neuronal  necrosis  in  the  presence  of  normoglycaemia,  suggestive  of  a 
neuroprotective  effect  of  insulin. 
186  Various  methods  of  neuroprotection 
have  been  proposed,  including  a  direct  interaction  with  CNS  tissue  via  a 
growth factor effect. Use of a continuous intra-ventricular infusion of insulin 
or  insulin  like  growth  factor  1  (IGF-1)  in  a  transient  forebrain  model  of   90 
ischaemia,  reduced  neuropathological  injury  at  one  week  compared  to 
placebo. 
187  Further,  an  anti-inflammatory  effect  of  insulin  has  been 
proposed.  Insulin  infusion  during  acute  myocardial  infarction  improves 
clinical outcomes, and although the mechanism remains elusive, it has been 
suggested that the suppression of plasma free fatty acid (FFA) concentration 
may  play  a  role.  High  catecholamine  levels  during  acute  myocardial 
infarction result in an increase in FFA. Circulating levels of FFA and their 
myocardial uptake is reduced by the GKI infusion. 
188 This may be significant 
as elevated FFA causes endothelial dysfunction. 
189  
 
It  has  previously  been  demonstrated  that  insulin  has  a  powerful  anti-
inflammatory  effect  on  endothelial  cells  in  vitro  and  on  circulating 
mononuclear cells in vivo when infused at a dose of 2.5 U/h in obese non-
diabetic subjects. Insulin incubated with cultured human aortic endothelial 
cells (HAEC) exerted an inhibitory effect on the cardinal pro-inflammatory 
transcription  factor  NFκB  and  the  pro-inflammatory  chemokine  MCP-1.  
These  effects  suggest  an  anti-inflammatory  and  potentially  atherogenic 
effect  of  insulin. 
190  Thirty-two  patients  with  acute  myocardial  infarction 
receiving  reteplase  were  randomly  assigned  infusions  of  either  insulin  at 
2.5u/h, dextrose and potassium (GKI) or normal saline and potassium for 
48hours.
191 Mean time to insulin infusion was 23 ± 3minutes after the first 
bolus  of  reteplase.  Plasma  concentration  of  high  sensitivity  C-reactive 
protein  (CRP),  serum  amyloid  A  (SAA),  plasminogen  activator  inhibitor-1   91 
(PAI-1), creatine kinase (CK) and CK-MB were measured at baseline and 
sequentially  for  48  hours.  Baseline  CRP  and  SAA  were  significantly 
increased at 24 and 48 hours in each group.  However in the insulin group 
there was a significant attenuation of the absolute rise in concentration of 
CRP and SAA from baseline. The absolute increase of CRP and SAA was 
reduced by 40% (CRP) and 50% (SAA) at 24 and at 48 hours compared with 
the  control  group.  The  absolute  increase  in  PAI-1  from  baseline  was 
significantly  lower  (p<0.05)  in  the  insulin  treated  group.  CK-MB  peaked 
earlier and tended to be lower in insulin treated subjects.  
 
One  further  mechanism  underlying  the  anti-inflammatory  role  of  insulin 
relates to the release of nitric oxide (NO). Insulin has been shown to induce 
an increase in the expression of nitric oxide (NO) synthase, the enzyme that 
generates  NO.  NO  has  been  shown  to  down-regulate  the  expression  of 
endothelial cell adhesion molecules as well as proinflammatory cytokines, 
resulting  in  vasodilatation  and  improved  blood  flow. 
192  Insulin  also  has 
anabolic  properties,  with  stimulation  of  skeletal  muscle  protein  synthesis 
promoting tissue repair and potentially affecting rehabilitation. 
193  
 
In addition to the potential mechanistic benefits of insulin, it is important to 
consider possible detrimental affects that could result in infarct progression. 
Experimental  models  have  consistently  shown  that  animals  made 
hyperglycaemic  prior  to  ischaemia  have  higher  levels  of  lactate  than   92 
euglycaemic controls. 
113;194 There is currently no direct proof that lactate is 
detrimental to the ischaemic brain. Using PET scanning it has been shown 
that  lactate  may  be  the  preferred  energy  supply  to  the  brain,  especially 
during  times  of  stress.
195  This  is  relevant  to  the  management  of 
hyperglycaemia in acute ischaemic stroke patients. If the ischaemic brain is 
dependent  on  lactate for  its  source of  energy,  targeted euglycaemia may 
result in a decreased glucose load to the brain and thus less substrate for 
anaerobic  metabolism  and  attenuated  lactate  production.  Peri-infarct 
depolarisations (PIDS) are now known to contribute to infarct expansion in 
focal  models  of  ischaemia. 
196  In  a  cat  model  of  middle  cerebral  artery 
occlusion a highly significant inverse relationship was seen between plasma 
glucose  and  frequency  of  PIDS  (measured  by  fluorescence  imaging),  i.e. 
reduced cortical glucose loads resulted in more frequent PIDS and a worse 
clinical outcome. 
197 The same group have demonstrated, in a single patient 
with  traumatic  brain  injury,  complete  disappearance  of  cortical  glucose 
dialysate  coinciding  with  a  period  of  hypoglycaemia  associated  with  an 
insulin infusion. 
198 This is consistent with the effect of hypoglycaemia on 
infarct progression in animal models and emphasises importance of strict 
monitoring in patients receiving insulin. The lower limit for glucose control in 
current randomised trials is 3.9-4.0mmol/l 
95;181 but this may be associated 
with infarct progression and a safe lower limit may be higher. Evidence for 
this higher threshold in stroke patients may come from the post-hoc analysis 
of GIST-UK where a blood glucose reduction of greater than 2mmol/l from   93 
baseline resulted in increased 24hour mortality. 
156  
 
2.20 Conclusion 
 
Post  Stroke  Hyperglycaemia  is  common  and  is  generally  accepted  as  a 
prognostic indicator of poor stroke outcome. Uncertainty remains as to the 
mechanism  by  which  hyperglycaemia  is  associated  with  poor  stroke 
outcome  and  thus  its  aetiology.  Prevalence  of  abnormalities  in  glucose 
metabolism  in  stroke  patients  is  high  but  routine  screening  is  often  not 
undertaken.  Recent  years  have  seen  advances  in  magnetic  resonance 
imaging  and  thrombolytic  treatment.  Timing  to  recanalisation  appears 
important  for  infarct  progression  and  haematoma  development  in 
hyperglycaemic  patients.  It  has  recently  been  suggested  that  contrary  to 
hyperglycaemia being detrimental in all strokes, it may actually be beneficial 
in lacunar infarction. In contrast to patients with acute myocardial infarction 
or requiring intensive care, where trial evidence permits recommendations 
for the use of insulin in the management of hyperglycaemia, there is a lack of 
evidence  to  support  its  use  in  stroke  units.  Current  guidelines  advise 
lowering  of  blood  glucose  but  disagree  on  the  threshold  at  which  to 
intervene, and make no comment on specific insulin treatment regimes or 
treatment targets. Results from GIST-UK, the largest trial of GKI in acute 
stroke has contributed to our understanding of hyperglycaemia management 
in acute stroke. Intervention with insulin in  the form of GKI would not be 
recommended  on  the  basis  of  recent  trial  evidence  and  current  clinical 
practice continues to be guided by consensus guidelines.   94 
 
 
 
 
 
Chapter 3: Magnetic Resonance 
Imaging in Stroke 
   95 
 
3.1 Introduction 
 
Current Royal College guidelines recommend CT scanning within 24 hours 
of  stroke  onset.
143  In  the  recent  2006  national  stroke  audit,  only  42%  of 
patients had brain imaging to confirm their diagnosis within the desired 24 
hours. For those patients with a definite onset and scanning time, only 9% 
were imaged within the hyperacute three hour phase.
35 Unfortunately access 
to imaging in the United Kingdom, for which CT is considered the modality of 
choice, remains a significant problem.  MRI is superior to CT in the detection 
of acute ischaemia, with many centres in Europe and North America using it 
as the primary imaging method.  Within the UK less than 1% of hospitals had 
access to MRI within four hours of stroke onset, increasing to 15% for the 
period 5-24hours.
35 Early access to imaging is essential for the provision of 
intravenous thrombolysis but despite advances in both CT and MRI, current 
licensing is based on the interpretation of an unenhanced CT scan within 
three hours of ictus.
22 Improvement in current accessibilty to hyperacute CT 
imaging  in  the  UK  is  the  primary  aim  for  increasing  the  availabilty  of 
thrombolysis.  That  said,  assisted  imaging  modalities  in  MRI  including 
Diffusion Weighted Imaging (DWI), Perfusion Weighted Imaging (PWI) and 
Magnetic Resonance Angiography (MRA) have improved sensitivity of lesion 
localisation, recognition of potentially reversible tissue and identification of 
occlusion site and recanalisation.  
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3.2 Diffusion weighted imaging (DWI) 
 
In early ischaemic stroke, cells swell and absorb water from the extracellular 
space and diffusion is restricted. Although the exact mechanism leading to 
the restricted diffusion has not been completely established, it is currently 
suggested that breakdown of the H+ ATPase pump leads to large shifts in 
water between the extracellular and intracellular space.
199  DWI measures 
the random movement of water molecules with restricted diffusion appearing 
hyperintense or echobright.
200 In animal studies, DWI has detected changes 
within  minutes  of  arterial  occlusion.
201    Water  apparent  diffusion  is 
measurably slower in regions of ischaemia compared to normal brain.  
 
Information about the severity of the ischaemic lesion can be determined by 
the  apparent  diffusion  coefficient  (ADC)  value.  Lower  ADC  values  being 
associated  with  greater  degrees  of  ischaemic  injury  and  less  chance  of 
reversibility.
202 By demonstrating hyperacute brain ischaemia within minutes 
of  stroke  onset,  DWI  is  important  in  the  assessment  of  stroke  patients. 
Identification of early ischaemia contrasts to both CT and conventional T2 
weighted imaging, which require several hours to become positive.
203 
 
In addition to early recognition of ischaemia, DWI has been shown to be 
better than conventional MRI in localising acute ischaemic lesions in stroke 
patients. Compared to T2-weighted and fluid attenuated inversion recovery   97 
(FLAIR) which identified acute lesions in 71% to 80%, DWI identified 94%.
204 
Standard  clinical  classification  systems  for  stroke  type  have  shown  a 
discrepancy  with  DWI-MRI  findings.  Using  DWI  only  41  (44.1%)  of  93 
patients found to have subcortical or brainstem lesions <1.5cm on imaging 
were originally classified as having a lacunar stroke.
205 
  
Various studies have utilised DWI in predicting stroke outcome.  Using a 
predictive three point model including NIHSS score as a clinical measure, 
time in hours to MR DWI and the lesion volume on admission DWI, it was 
possible to predict stroke recovery.  It was found that the combination was 
better than any individual factor.
206 In a separate study looking at 63 patients 
with non-lacunar stroke and undertaking a logistic regression model, DWI 
volume within 48 hours of onset at baseline was an independent predictor of 
outcome together with age and NIHSS score.
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3.3 Perfusion Weighted Imaging (PWI)  
 
Perfusion is the flow of blood through the capillary circulation of an organ or 
tissue  region,  quantified  in  terms  of  the  flow  rate  (millilitres  per  minute) 
normalised to the tissue mass (typically per 100g). The normal gray matter is 
perfused at the rate of 50-60ml/100g/min.
199  Perfusion weighted magnetic 
resonance imaging can detect hypoperfused regions of brain and as such is 
able to give a measure of changes at a cellular level.  
   98 
There are two main methods of obtaining PWI.  The first involves monitoring 
the  transit  of  a  rapidly  injected  contrast  agent,  e.g.  gadolinium,  during 
ultrafast  T2  or  T2*  acquistions.  Serial  images  are  obtained  every  1  to  2 
seconds  over  approximately  two  minutes,  to  monitor  the  signal  decay 
associated with the passage of contrast.
208 An alternative method involves 
arterial  spin  labelling  (ASL)  in  which  endogenous  blood  is  magnetically 
labelled by pulsed radiofrequency energy as a diffusable tracer. When these 
labelled water protons exchange with tissue water at the capillary level, they 
alter the magnetic property of the tissue which can then be measured and 
translated  into  quantitative  flow  data.  In  regions  distal  to  an  arterial 
occlusion, the arrival of the contrast agent or the tagged water molecules in 
blood may be delayed.  
 
Once the data set is acquired a plot of signal intensity change with time is 
obtained.
199  This  can  be  converted  into  a  concentration  time  curve  from 
which several parameters relative to perfusion imaging can be calculated. 
These  include:  Cerebral  Blood  Flow  (CBF),  the  amount  of  blood  moving 
through  a  certain  amount  of  tissue  per  unit  time,  measured  in  ml/g/min; 
Cerebral Blood Volume (CBV), the amount of blood in a given amount of 
tissue at any time (mls/g); and Mean Transit Time (MTT), the average time 
required  for  a  particle  of  tracer  in  that  region  to  traverse  the  capillary 
circulation
209. The three parameters are related by the equation
199: 
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CBV = CBF X MTT 
 
Using both PWI and DWI in acute ischaemic stroke - with PWI hypoperfused 
tissue  and  DWI  the  irreversible  ischaemic  core  -  the  concept  of  an  MRI 
delineated  ischaemic  penumbra  has  been  developed.
210  The  correlation 
between areas measured by DWI and PWI (predominantly the MTT map) 
results in either a match (PWI = DWI), or mismatch (PWI>DWI or PWI<DWI). 
The mismatch PWI>DWI has been proposed as a definition of the ischaemic 
penumbra.  Increased experience with the use of DWI and PWI has seen 
two  modifications  to  the  definition.    The  first  relates  to  knowledge  of  the 
variability in hypoperfusion, a MTT ≥6seconds in the affected hemisphere 
compared to the contralateral hemisphere is more likely to result in infarction 
with  lesser  degrees  of  hypoperfusion  more  likely  to  result  in  tissue 
survival.
210 The second is recognition that the DWI does not always progress 
to infarction.
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3.4 Magnetic Resonance Angiography (MRA) 
 
MRA is useful in demonstrating the macroscopic vasculature and is able to 
detect morphological changes in blood vessels including levels of occlusion, 
degrees of stenosis and dissections.  Digital subtraction angiography is still 
accepted as the gold standard vascular imaging modality but the anatomical   100 
information provided by non-invasive MRA makes it an attractive alternative.  
There are three main MRA techiques, (i) Time of Flight, (ii) Phase contrast 
and  (iii)  Contrast  enhanced
212.  The  physics  underlying  each  method  is 
beyond the scope of this review but each modality is based on the principle 
that contrast between blood vessels and stationary tissues is as a result of 
blood  motion.    Phase  contrast  MRA  provides  acceptable  images  of  the 
terminal  internal  carotid  arteries,  vertebrobasilar  system  and  the  Circle  of 
Willis in a matter of minutes. Time of Flight (TOF) takes slightly longer but 
provides  more  detailed  anatomical  images  including  third  order  middle 
cerebral branches. Contrast enhanced MRA has increased the accuracy of 
determining the degree of stenosis at the carotid artery bifurcation, with the 
disadvantage that a contrast agent needs administered.
203  
 
3.5 FLAIR (Fluid Attenuated Inversion Recovery) 
 
FLAIR produces heavily weighted T2 images with selective nulling of CSF 
and other fluids to give good anatomical images of the parenchyma.  As a 
result  it  has  been  used  for  the  identification  of  periventricular  lesions 
including demyelinating plaques.
203 Because of the parenchmal detail FLAIR 
scans  have  been  used  for  lesion  volume  measurements  as  surrogate 
markers of stroke outcome.
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3.6 Gradient Echo 
 
While conventional T1 and T2 weighted MRI pulse sequences are sensitive 
for the detection of subacute and chronic blood, they are less sensitive to 
parenchymal haemorrhage during the initial six hours after stroke symptom 
onset.
213 Recognition of blood in the hyperacute phase is essential for any 
decisions regarding thrombolysis.  It has recently been demonstrated that 
gradient recalled echo sequences detect hyperacute blood and has resulted 
in its addition to MRI stroke screening protocols.
214   
 
Initial  concerns  about  the  inability  of  MRI  to  delineate  haemorrhage  from 
infarct  in  the  hyperacute  stroke  phase  have  proven  unfounded.    In  a 
prospective  multicentre  study,  patients  presenting  with  focal  stroke 
symptoms within six hours of onset underwent brain MRI followed by non-
contrast CT.  Two hundred patients were enrolled of which MRI was positive 
in 71 patients with CT positive in 29 (p<0.001).  For the diagnosis of acute 
haemorrhage, MRI and CT were equivalent but was more accurate than CT 
for the detection of chronic intracerebral haemorrhage.
215 In a more recent 
study including 357 patients assessed for acute stroke of which 217 had a 
final  clinical diagnosis  of acute  stroke,  MRI  as  in  the  previous  study  was 
similar to CT for the detection of acute intracranial haemorrhage but, MRI 
detected acute ischaemic stroke in 164 of 353 patients (46%; 95% CI 41-
51%) compared with CT in 35 of 356 patients (10%; 7-14%). In the subset of   102 
patients scanned within three hours of symptom onset, MRI detected acute 
ischaemic stroke in 41 of 90 patients  (46%; 35-56%) with CT in 6 of 90 (7%; 
3-14%).
216  
 
3.7 Use of MRI as surrogate markers   
 
Trials of neuroprotectant agents in experimental animal studies with positive 
results have failed to translate into similar results when tested in humans. 
This has been emphasised with the failure of the earlier reported Stroke-
Acute-Ischaemic  NXY  Treatment  II  (SAINT  II)  trial
32.  The  application  of 
relatively  non-strict  criteria  for  patient  recruitment  has  resulted  in  a 
heterogenous population which has been used as possible explanation for 
trial failures. With the aim of selecting a more homogenous stroke population 
to study trial drug effectiveness there is currently a push for the use of MRI 
modalities to aid the selection process. This will faciliatate recruitment of a 
smaller  target  population,  compared  to  trials  of  similar  therapeutic  agents 
which  rely  purely  on  clinical  measures.  In  addition  to  use  for  patient 
selection,  MRI  measurements  are  being  used  as  surrrogate  markers  of 
outcome.
217 
 
As described earlier, imaging modalities including DWI/PWI have been used 
in trials of thrombolysis aimed at assessing the feasability of extending the 
time window beyond three hours
210 (Table 1). In the EPITHET (Echoplanar 
Imaging  Thrombolytic  Evaluation  Trial)  pilot  study,  19  patients  underwent   103 
DWI and PWI prior to thrombolysis and within six hours of stroke ictus, with 
repeat  imaging  at  days  3-5  and  day  90.  Patients  with  MR  evidence  of 
mismatch (PWI>DWI) demonstrated a significant degree of recanalisation, 
reperfusion and tissue salvage in addition to improvement in clinical outcome 
measures, when compared to a group of historical controls.
218   
 
Further  trials  have  examined  the  effect  of  neuroprotectants  on  lesion 
progression using infarct size as a surrogate marker of outcome. Trials of 
citicoline in acute ischemic stroke have shown that change in lesion volume 
is a marker of clinical improvement. Patients showing clinical improvement 
from  baseline  to  week  12  of  at  least  seven  points  on  the  NIHSS,  had  a 
significantly  greater  relative  reduction  in  lesion  volume  compared  with 
patients who did not attain a similar level of clinical improvement.
219  In the 
MRI  sub-study  of  the  GAIN  (Glycine  Antagonist  in  Neuroprotection)  trial, 
gavestinel  (GV150526)  a  selective  antagonist  at  the  glycine  site  of  the 
NMDA  (N-methyl-D-aspartate)  receptor  was  found  to  have  no  effect  on 
infarct volume at three months. Results were similar to the larger GAIN study 
(population 2,171) which had used clinical outcome measures. In addition 
,significant  correlations  were  found  between  NIHSS  and  lesion volume  at 
baseline and between clinical outcome measures (NIHSS, modified Rankin 
scale and Barthel Index) and lesion volume at three months.
220 As in the 
citicoline study, there was a significant relationship between lesion volume 
decrease and an improvement in NIHSS by ≥7points (p<0.0001).    104 
MRI permits the serial measurements of lesion volumes and thus allows an 
assessment of the effect of thrombolysis or neuroprotective drugs on lesion 
progression. In relying on lesion volume measurements, it is important to be 
aware of the variability in analysis which could ultimately affect results. In an 
assessment  of  the  reliability  of  both  intrarater  and  interrater  MRI  lesion 
volume measurements  of  DWI,  PWI  (mean  transit  time) and  FLAIR,  both 
acutely and at later time points in a stroke population, there was found to be 
good  concordance  in  measurements  across  the  different  MR  imaging 
modalities.
221 A more recent study in a smaller population has suggested 
that inter-rater measurement of DWI lesion volumes may vary depending on 
lesion volume morphology.  That is, there is least agreement for multifocal ill 
defined  lesions  compared  to  solitary  defined  lesions  and  greatest 
discrepancy  between  early  scans,  ie  at  less  than  six  hours  compared  to 
scans beyond 12 hours.
222  
 
3.8 Conclusion 
 
Advances in MRI have seen it replace CT as the imaging modality of choice 
in the hyperacute assessment of stroke patients.  The additional information 
obtained in lesion localisation, recognition of hypoperfused tissue and site of 
occlusion assists both clinical decisions and increases the potential for its 
use in stroke drug development.  
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Chapter 4: Magnetic Resonance 
Spectroscopy in Stroke 
   106 
4.1 Introduction 
 
 
Magnetic Resonance Imaging (MRI) provides high resolution spatial images 
to  generate  anatomical  information,  whereas  Magnetic  Resonance 
Spectroscopy  (MRS)  is  a  non-invasive  method  of  studying  biochemical 
changes within tissues.  For MRI acquisition, signals obtained from water, fat 
and  other  hydrogen  containing  metabolites  within  the  magnetic  field  are 
interpreted  together,  with  individual  signals  not  being  distinguished.  In 
contrast,  MRS  aims  to  discriminate  between  different  metabolites  and 
water.
223  
 
Individual metabolites consist of nuclei which themselves are surrounded by 
electron clouds.  In the presence of an external magnetic field, the electron 
clouds create their own magnetic field that opposes the external field. The 
strength  of  an  individual  magnetic  field  is  determined  by  the  chemical 
environment of the individual metabolite.  Since the resonance frequency of 
a particular nucleus is proportional to the strength of the magnetic field that 
the  nucleus  experiences,  nuclei  in  different  chemical  environments  can 
resonate  at  slightly  different  frequencies  resulting  in  the  phenomenon  of 
chemical shift.
223;224 
 
Interpretation of metabolites obtained using MRS requires knowledge of the 
region of interest within the brain from which the data was acquired. Two 
main methods of spatial localisation are routinely used.
225    107 
 
(a) Single Voxel Spectroscopy (SVS): Signals are obtained from a small 
volume of tissue defined by the intersection of three orthogonal planes.  SVS 
produces  a  single  spectrum  from  a  single  localised  volume  in  one 
measurement sequence (Figure 4.1).. Comparison of individual spectra from 
different regions of the brain requires additional image time  
 
 
Figure 4.1 Single voxel spectroscopy from patient recruited to the SELESTIAL trial 
demonstrating  peaks  at  N-acetyl  aspartate(NAA),  Lactate(LAC),  creatine(CR)  and 
choline(CHO).  
 
(b)  Chemical  Shift  Imaging  (CSI):  A  method  of  collecting  spectroscopic 
data from multiple adjacent voxels covering a large volume of interest in a 
single measurement. An example of a multi-voxel spectrum spanning both 
hemispheres and including the DWI abnormaility is demonstrated. (Figure 
4.2). 
 
Figure  4.2  Multivoxel  spectroscopy  from  SELESTIAL  trial,  demonstrating  a  larger 
voxel  superimposed  across  both  hemispheres  with  DWI  involvement  right 
hemisphere.     108 
 
 
4.2 Cerebral Metabolites 
 
MRS  data  is  usually  presented  as  line  spectra,  with  automated  software 
programs providing almost immediate access for visual analysis. The major 
metabolites  detected  on  [
1H]  Spectroscopy  are  N-acetylaspartate  (NAA); 
total  choline  (Cho);  total  creatine  (Cr),  including  Phosphocreatine  (PCr); 
myo-Inositol (mI) and glutamate plus glutamine (Glx). Lactate is not routinely 
found in measurable amounts in normal brain (chemical structure figure 4.3). 
The metabolites are important components in brain energy metabolism and 
the location of the peaks on individual spectra result from chemical shifts as 
described earlier. The area under each peak represents the relative number 
of nuclei detected for a given metabolite.  All metabolites are assigned a 
specific  chemical  shift  δ,  which  is  expressed  in  units  of  parts  per  million 
(ppm) relative to a reference compound.  In [
1H] Spectroscopy, the chemical 
shift  reference  is  tetramethylsilane  (TMS),  which  is  assigned  a  value 
δ=0.0.
223 
 
 
 
 
 
 
 
 
Figure 4.3 Chemical stucture of lactate identified on MRS. The asterix denotes the protons 
contributing to the major peak on MR spectroscopy.   109 
 
Lactate (1.33ppm) 
Lactate is not found in measurable amounts in normally functioning brain 
tissue  but  is  particularly  relevant  to  stroke.    An  end  product  of  anerobic 
metabolism,  lactate  accumulates  in  tissues  of  patients  with  ischaemia  or 
hypoxia.  On MRS lactate is a doublet peak and depending on the echo time 
(TE)  used,  the  peak  will  either  be  upright  (TE=270msec)  or  inverted 
(TE=230msec).
223 Lactate has also been detected in mitochondrial diseases 
and brain tumours.
223;226 
 
N-Acetyl Aspartate (2.02ppm) 
Although its function is not known, NAA is found only in the brain and spinal 
cord.  Its presence and level acts as a marker of healthy neurons.  Reduction 
in the size of the NAA peak provides a useful indicator of neuronal disease.  
NAA has been shown to increase during brain development after birth and 
during child development  and to decrease in old age. 
223  
 
Total Creatine (3.03ppm) 
Both creatine (Cr) and Phosphocreatine (PCr) are found in neurones and 
glial cells and are involved in ATP metabolism. The Total Creatine (Cr/PCr) 
peak on [
1H] Spectroscopy is used as a baseline reference level for other 
metabolites, as it is relatively unchanged in most disease processes. 
223 
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Choline (3.22ppm) 
In normal brain the choline (Cho) peak is thought to consist predominantly of 
glycerolphosphocholine and phosphocholine.  Both compounds are involved 
in membrane synthesis and degradation.  Choline is thought of as a product 
of myelin breakdown.  In adult brain an increase in the choline peak area is 
associated with Alzheimers disease, chronic hypoxia and epilepsy, while a 
decrease is seen in hepatic encephalopathy.
226  
 
 
myo-Inositol (3.6ppm) 
Only seen at short TE, myo-Inositol is thought to be involved in regulation of 
cellular transport across cell membranes. Its concentration fluctuates more 
than any of the other major metabolites, with significant elevation in newborn 
infants  and  hypernatremia  and  almost  undetectable  levels  in  hepatic 
encepahlopathy.
223 
 
Glutamate and Glutamine (2.1-2.5ppm) 
Both  glutamate  and  glutamine  are  excitatory  neurotransmitters  and  are 
elevated in hepatic diseases.
226 
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4.3 Quantification of Metabolites 
 
Absolute  measurements  of  cerebral  metabolites  is  difficult  and  requires 
additional assays of known internal or external reference standards referred 
to  as  phantoms.    Using  these  known  reference  compounds,  the  absolute 
quantification of metabolites is calculated.  In view of the difficulty obtaining 
and  performing  absolute  quantification,  most  centres  describe  metabolite 
concentration  relative  to  an  internal  constant.    Total  creatine  is  generally 
accepted  as  an  appropriate  reference  compound,  although  other  studies 
have quoted metabolite levels relative to Choline
129 or as a fraction of the 
sum of all metabolites.  
 
 
4.4 MR Spectroscopy in practice 
 
Applications  of  MRS  are  increasing,  helped  by  the  advances  in  MRS 
acquistion and software analysis.  Although still primarily seen as a research 
tool, its use has extended  to the evaluation of patients with demyelination, 
neuro-oncology,  neurodegenerative  conditions  and  focal  brain  lesions  in 
AIDS.
226 Of particular interest is the role of MRS in stroke and its contribution 
to our understanding of changes in cerebral metabolism in acute ischaemia.  
 
4.5 Stroke studies using MR Spectroscopy 
 
Early clinical studies using MRS examined the natural history of NAA and 
lactate in patients following ischaemic stroke.  Six out of 16 patients recruited   112 
within three weeks of the incident event, with MRS at baseline, underwent a 
follow-up  study.    Lactate  was  shown  to  be  persistently  elevated  in  5/6 
patients up to 251 days post infarction.
227 Work from the same group but 
involving  10  patients  within  60  hours  of  ictus  found  a  lactate  peak  in  all 
patients,  with  a  reduced  NAA  peak  relative  to  the  contralateral  normal 
hemisphere in all but two patients.  On follow-up studies between days 8 to 
17 in seven of the patients, a significant decline in both lactate (-36%±11%) 
and NAA signals (-29%±9%) occurred.
228 In a separate study using multiple 
logistic  regression,  reduction  in  NAA  on  sequential  scanning  was 
significantly  associated  with  the  extent  of  the  infarct  (p=0.03)  and  the 
presence of lactate (p=0.04).
229 
 
When  specific  areas  within  the  brain  were  examined  in  11  patients  with 
middle cerebral artery occlusion within 24  hours of ictus, regions  with T2 
hyperintensity on MRI were found to contain elevated levels of lactate and 
reduced  NAA,  compared  to  the  contralateral  unaffected  hemisphere.  
Lactate  levels  in  regions  adjacent  to  T2  hyperintensities  were  not 
significantly  different  from  those  of  infarcted  brain,  whilst  NAA  were 
significantly lower in regions of infarction compared with peri-infarct tissue.
230 
In a more recent study looking at areas within the ADC (Apparent Diffusion 
Coefficient)  of  six  patients  within  seven  hours  of  stroke  onset,  a  33% 
decrease in mean ADC within the narrow range 0.60-0.40 was associated 
with a 122% increase in the Lactate/NAA ratio.
231 The significant variability in   113 
metabolite concentrations reveals the spectrum of ischaemia seen with the 
ADC lesion and may explain its potential for reversibility.  
 
Both NAA and lactate have been studied as potential predictors of stroke 
outcome.  In  32  patients  undergoing  MRS  an  average  of  4.9  days  after 
symptom onset, lactate was highly correlated with stroke severity and clinical 
outcome as measured by the barthel index on hospital discharge.  NAA was 
also predictive of stroke severity and functional outcome but less so than 
lactate.
232 
 
When  both  MRS  and  lesion  volume  measurements  were  examined  as 
predictors  of  clinical  outcome,  acute  lactate/choline  ratio  correlated  more 
strongly  with clinical outcome scores than final infarct size, acute DWI or 
acute  NAA/choline  ratio.    Combination  of  acute  lactate/choline  and  DWI 
lesion volume improved prediction of all outcome scores.
233 
 
More  recent  studies  have  utilised  MRS  to  help  understand  the 
pathophysiology of stroke progression.  Experimental models of reversible 
ischaemia  have  consistently  demonstrated  an  association  between 
hyperglycaemia,  lactic  acidosis  and  conversion  of  penumbral  tissue  to 
infarction.
54;113 Using perfusion/diffusion weighted MRI in 63 patients, acute 
hyperglycaemia was found to correlate with reduced salvage of mismatch 
tissue from infarction, greater final infarct size and worse functional outcome   114 
in  patients  noted  to  have  an  acute  perfusion/diffusion  mismatch  at 
baseline.
129 In a sub-study of 33 patients who underwent MRS, higher acute 
blood  glucose  in  patients  with  mismatch  was  associated  with  greater 
acute/subacute  lactate  production  and  reduced  salvage  of  mismatch 
tissue.
129 For patients with no mismatch, there was no correlation between 
acute  blood  glucose  and  outcome  measures  or  with  acute-subacute 
increases in lactate.  
 
A recent and novel application for MRS has been its use in the measurement 
of cerebral temperature.  Higher cerebral temperature was noted in lesions 
that  were  large,  had  reduced  cerebral  blood  flow  and  in  patients  with 
clinically severe strokes.
234  
 
The effect of Normobaric oxygen (NBO) on cerebral metabolites was studied 
using multi-voxel based MRS and diffusion/perfusion MRI in seven patients 
with  acute  ischaemic  stroke.
235    It  has  been  suggested  that  NBO  is  a 
potential  neuroprotective  agent.    One patient  was  excluded from  analysis 
due to poor spectral acquistion, leaving four patients receiving NBO and two 
controls.    Baseline  imaging  was  performed  within  12  hours  of  ictus  at 
+4hours  and  +24hours.    NBO  was  found  to  reduce  brain  lactate  and 
preserve  NAA,  suggesting  that  NBO  improves  aerobic  metabolism  and 
preserves neuronal integrity.  Lactate expressed as a ratio secondary to the 
sum  of  metabolites  decreased  during  the  period  of  normobaric  oxygen   115 
delivery,  whereas  in  patients  with  reperfusion  lactate  decreased  further, 
suggesting that the beneficial effect may not be sustainable with persistent 
hypoperfusion.  The change in lactate from baseline to four hours tended to 
be  different  between  groups  and  occurred  mainly  in  DWI  bright  regions 
rather than mismatch regions.
235 This study is significant in demonstrating 
the potential use of MRS in obtaining data that may act as surrogate markers 
for therapeutic interventions.  
 
Despite  possible  optimism  for  the  use  of  MRS  in  future  clinical  trials, 
previous studies have highlighted a difficulty in complete data acquistion.  In 
50  patients  recruited  to  an  MRS  study  with  planned  screening  on  three 
separate occasions, metabolite results were available for 22 patients with 
one scan, 11 patients with two scans and only 7 patients with three scans. 
Contributing factors to the incomplete data set cited by the authors include 
local availability of the scanner, tolerability of their patient population to the 
time required for imaging and the quality of the data obtained.
229  
 
 
4.6 Conclusion  
 
Magnetic  Resonance  Spectroscopy  can  enhance  our  understanding  of 
stroke pathophysiology.  Despite recognised difficulties in data acquistion, 
MRS allows monitoring of the effect of therapeutic interventions on chemical 
changes  within  the  MR  delineated  penumbra  and  infarct  core.    This  can   116 
include  neuroprotectant  and  thrombolytic  agents,  but  also  the  effect  of 
adjustment  in  physiological  parameters  (temperature,  oxygen  and  blood 
glucose) on a metabolite level in the ischaemic brain.  
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Chapter 5: SELESTIAL 
(Spectroscopic Evaluation of Lesion 
Evolution in Stroke: Trial of Insulin for 
Acute Lactic acidosis) 
   118 
5.1 Introduction 
 
Post stroke hyperglycaemia is recognised as an independent risk factor for 
poor  outcome  following  stroke.
236  Interventions  to  control  hyperglycaemia 
vary in clinical practice with routine management being guided by consensus 
guidelines.
142  There  is  a  paucity  of  evidence  to  support  blood  glucose 
management in acute stroke with clinical decisions based on extrapolation of 
data from non-stroke populations.
148;237 Controversy remains as to whether 
hyperglycaemia is purely an epiphenomenon of worsening stroke severity 
and underlying abnormal glucose metabolism
238 or alternatively has a direct 
neurotoxic effect on the ischaemic brain.
70  
 
Experimental models have shown a consistent correlation between acidosis, 
hyperglycaemia and brain injury.
113;239 Animals made hyperglycaemic prior to 
focal  ischaemia  have  higher  levels  of  lactate  than  euglycaemic 
controls.
240;241 If the neurotoxic hypothesis is true, then manipulation of blood 
glucose  may  have  a  beneficial  effect  on  stroke  outcome.    The  recently 
published UK Glucose Insulin in Stroke Trial (GIST-UK) was the first multi-
centre trial to examine the effect of insulin on 90 day mortality.
156 Patients 
randomised to glucose-potassium-insulin (GKI) infusion for 24 hours were 
found to have no mortality benefit when compared to placebo.
156 The neutral 
result is consistent with the results of other phase III trials in stroke, which 
have failed to confirm promising experimental results in clinical studies, and 
raise the question of whether clinical trial methodology is at fault. Given the   119 
clinical heterogeneity of stroke, large, simple trials may be a poor vehicle for 
understanding mechanisms.  Imaging, particularly MRI, provides surrogate 
markers that are potentially valuable in “proof of concept” studies.  Using 
MRI measures of lesion volume at baseline and a later time point, it may be 
possible to assess the effect on this surrogate outcome measure.  This has 
previously been shown with recombinant tissue plasminogen activator.
218 In 
addition to lesion volume analysis, magnetic resonance spectroscopy allows 
the  in  vivo  study  of  cerebral  metabolites.  As  described  earlier  the 
mechanistic  link  between  lactate  and  stroke  outcome  remains  uncertain, 
MRS  allows  quantification  of  cerebral  lactate  in  the  ischaemic  brain  and 
allows  testing  of  the  hypothesis.  Can  manipulation  of  lactate  through 
maintenance of euglycaemia in the early phase of stroke affect outcome..
129 
 
We  undertook  a  single  centre,  randomised,  placebo-controlled  trial  to 
examine  the  effect  of  insulin  on  lesion  volume  progression  in  acute 
ischaemic stroke.  Using 
1H MRS we also studied the effect of insulin on 
brain  lactate  concentrations.  The  trial  acronym  was  SELESTIAL 
(Spectroscopic Evaluation of Lesion Evolution in Stroke: Trial of Insulin for 
Acute Lactic acidosis) and was funded by the Stroke Association of the UK 
(TSA 06/03) 
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5.2 Methods 
 
Patient recruitment:  
Patients with sudden onset of focal neurological deficit felt consistent with an 
ischaemic  event,  hyperglycaemia  defined  as  capillary  blood  glucose 
>7.0mmol/l,  presenting  within  24hours  of  stroke  onset  and  a  diffusion 
weighted  imaging  abnormality  on  MRI  were  prospectively  recruited  from 
those admitted to the South Glasgow Stroke service over a 25 month period 
(December 2003-January 2006).  Time of onset was defined as the last time 
the patient was known to be without neurological deficit.  MR Imaging was 
performed  at  presentation  (<24hours  from  onset),  on  day  3(±1)  and  day 
7(±2).  Following  initial  imaging,  patients  were  randomised  to  glucose-
potassium-insulin (GKI) infusion or placebo.  
 
Patients were excluded from randomisation if there was a contraindication to 
MRI, evidence of cerebral haemorrhage on imaging, capillary blood glucose 
≤7.0mmol/l  or  either  patients  or  the  next  of  kin  were  unable  to  provide 
consent or assent respectively.  The study was approved by the Multicentre 
Research  Ethics  Committee  for  Scotland  (A)  and  by  the  local  ethics 
committee.  
 
Randomisation:  
Randomisation was by means of computer-generated random numbers.  A 
lead in pilot study aimed to recruit 10 patients with 1:1 treatment allocation,   121 
placebo  (saline)  or  GKI  for  48h.  The  purpose  of  the  pilot  study  was  to 
familiarise  nursing,  medical  and  radiography  staff  with  the  protocol.  The 
initial phase high-lighted difficulties in trial recruitment with only one patient 
randomised  within  the  first  6months.  To  address  this  problem  a  blood 
glucose  monitoring  protocol  was  introduced  to  the  stroke  unit  with  repeat 
CBG profiling every 4hours. Results from the screening protocol provide the 
basis of chapter 6. Trial recruitment improved through the remainder of the 
pilot study and into the main trial phase, whereby allocation was in a 1:1:1 
ratio  to  placebo  (saline),  GKI  infusion  for  24h  or  GKI  infusion  for  72h.  
Allocation  was  concealed  in  consecutively  numbered,  sealed  opaque 
envelopes. A 57% relative reduction in the proportion of patients exhibiting 
lesion volume expansion between baseline and day 7 (from 70% to 30%) 
can be detected with 80% power (2p=0.05) and 15 subjects per group. Total 
sample size suggested is 45 patients.  
 
 
Clinical assessment 
Stroke severity  was determined by the National Institute of Health Stroke 
Scale (NIHSS)
242 on days 1, 3 and 7 to coincide with corresponding MRI 
scans.    Strokes  were  classified  using  the  Oxfordshire  Community  Stroke 
Project  (OCSP)  system.
243  Outcome  was  measured  clinically  using  the 
modified Rankin Scale structured interview questionnaire
244 at one month.  A 
single  clinical  research  fellow  trained  in  the  administration  of  the  scales   122 
undertook all clinical assessments.  Stroke progression was defined as a 
worsening in stroke severity on the NIHSS of four or more points, between 
baseline and infusion discontinuation on day three. 
 
Infusion 
Placebo  consisted  of  0.9%  normal  saline  (154mmol/l  sodium).    The  GKI 
infusion consisted of 500mls 10% dextrose, 20mmol KCL and 16 units of 
soluble recombinant human insulin.  Infusion bags ran at 100mls/hour.  The 
GKI infusion in the initial pilot study ran for 48 hours and in the main study 
was for either 72 or 24 hours as per randomisation.  For patients receiving 
GKI for 24hours, normal saline was instituted for the subsequent 48 hours.   
 
The dose of insulin was titrated as per a protocol dependent on capillary 
blood  glucose  measurements  (appendix)  by  medical  and  nursing  staff 
blinded  to  imaging  and  clinical  measurement  scores.  The  protocol  was 
adapted from the GIST-UK
156 study protocol with the only difference being 
the duration of  infusion.    Capillary  blood  glucose  readings  were recorded 
using  a  Medisense  monitor  (Germany).    For  patients  receiving  placebo, 
glucose  monitoring  was  performed  four-hourly.  Readings  were  performed 
hourly in patients receiving the GKI infusion until euglycaemia was achieved 
and thereafter checked two-hourly.  Euglycaemia was defined as a capillary 
blood glucose reading of 4.0-7.0mmol/l.   
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-  If capillary blood glucose was above the targeted treatment range, the 
500mls  of  the  GKI  infusion  were  discarded  and  a  new  infusion 
commenced with an additional four units of insulin added.  In addition, 
monitoring frequency was increased to hourly until euglycaemia was 
achieved or the infusion concentration needed to be adjusted.  
 
-  If the capillary glucose fell to less than 4mmol/l the GKI infusion was 
discontinued. The capillary blood glucose was rechecked at 15 and 
30  minutes  and  if  the  repeat  blood  glucose  was  greater  than 
4.0mmol/l  a  GKI  solution  containing  four  units  less  insulin  was 
commenced.  If hypoglycaemia, defined as a capillary blood glucose 
<4.0mmol/l, persisted for 30 minutes, 10 mls of 50% dextrose was 
administered.   
 
Capillary blood glucose readings, blood pressure and pulse were recorded 
on a standardised form for the duration of the infusion. Blood pressure and 
pulse rate were recorded digitally four-hourly for all patients, by nursing staff 
allocated to the acute stroke unit. The blood pressure cuff was applied to the 
non affected limb for repeated measurements.  
 
Plasma blood glucose (drawn in sodium fluoride bottles and analysed using 
glucose oxidase method with Abbott diagnostics), urea and electrolytes were 
recorded on admission along with glycosylated haemoglobin, (HbA1c) (high   124 
performance  liquid  chromatography  on  a  Menarini  analyser).  Plasma 
glucose and electrolytes were repeated at 24 and 48 hours.  
 
Imaging 
All MR scans were obtained using a 1.5-Tesla echoplanar-imaging-equipped 
whole body scanner (Signa NVi; General Electric, software level excite 11.0). 
Images  were  obtained  using  an  eight  channel  head  coil  using  a  protocol 
consisting  of  an  initial  T1-weighted  sagittal  localiser,  a  diffusion  weighted 
planning sequence, diffusion HD b1000 Axial, T2 FLAIR axial, T2 gradient 
echo  axial,  oblique  3D  time  of  flight,  axial  PROBE  (proton  brain  exam) 
chemical  shift  imaging  144  multi-voxel  spectroscopy,  and  axial  PROBE 
single voxel spectroscopy centred in the diffusion lesion.  Repeat sequences 
were performed at day 3 and day 7, with outcome scans including a day 7 
axial FLAIR.  
 
Diffusion Weighted Imaging (DWI) was performed using a multi-slice, single 
shot, spin echo EPI (echo planar imaging) sequence.  Slice thickness was 
5mm with a 1.5mm gap, with 24 slices set to include the whole brain. Matrix 
size was 128x128; field of view 26 cm X 20.8cm; TR=8000ms; TE = 70.9; 
NEX (number of excitations) = 4. 2; b values of b=1000s/mm2 and b=0.  
Post  image  acquisition,  DWI  and  FLAIR  scans  were  anonymised  and 
allocated  random  numbers  by  an  independent  MR  physicist,  who  was 
blinded to clinical data.  For intra-rater reliability, twenty four duplicates were   125 
included in the data set with interpretation of scans undertaken by myself 
(MMcC) blinded to clinical identifiers and timing of scans.   
 
Lesion  volume  measurements  in  cubic  centimetres  were  made  using  the 
semi-automated  Cheshire  software  (Perceptive  Informatics,  PAREXEL, 
USA).    Instruction  and  training  in  the  use  of  the  software  was  facilitated 
through a secondment to the Stroke-MRI laboratory of the NIH, Bethesda, 
Washington DC.  Initial analysis of an independent data set was performed 
and validated against pre-existing measurements. Following re-analysis of 
the introductory data set and further instruction, an additional set of images 
was interpreted and used as the test set to confirm satisfactory completion of 
training. 
 
Volume  measurements  involved  identification  of  a  lesion  by  visual 
inspection, initial semi-automated segmentation, followed by editing of the 
region of interest.  All DWI scans were measured.  Day 7 outcome FLAIR 
scans were then measured with knowledge of the corresponding day 1 DWI 
scan,  to  enable  measurement  of  acute  lesions.    Time  of  flight  MR 
angiography (MRA) was analysed by a consultant neuroradiologist, blinded 
to clinical data, with each MRA classified as per the AOL (Arterial Occlusive 
Lesion) criteria (AOL 0: No recanalisation of the primary occlusion; AOL 1: 
Incomplete or partial recanalisation of the primary occlusion with no distal 
flow;  AOL  2:  Incomplete or  partial  recanalisation of the  primary  occlusion   126 
with distal flow and AOL 3: Complete recanalisation of the primary occlusion 
with distal flow).
245   
 
Spectroscopy 
The DWI slice with the largest diffusion lesion visually was used to place a 
voxel  within  the  centre  of  the  infarct  core  for  ¹H  MRS.  In  the  majority  of 
cases, voxel size was 2 X 2 X 2 cm, but in small infarcts, the voxel volume 
was adjusted to fit within the infarct core (Figure 5.16).  For single voxel, TR 
= 1500ms, TE = 144ms, NEX =8.  Global auto-shimming was performed. 
Repeated  measurements  on  subsequent  scans  were  performed  using 
knowledge of location of the single voxel on previous imaging.   Acquired 
data was processed with spectral analysis software. The LC model software 
carries out automatic quantification of in-vivo proton spectra. In-vivo spectra 
are  analysed  as  a  linear  combination  of  a  basic  set  of  complete  model 
spectra of individual metabolite solutions in vitro. LC model allows a high 
degree  of  automation,  which  removes  operator  bias.  Calibration  has  not 
been performed and the concentrations calculated by LC model are not in 
absolute units. The sequential study design allows us to use the results in 
terms of institutional units for the purposes of comparison. LC model creates 
an output for each voxel within the localisation volume. Data was analysed 
over the window 4.0ppm to 1.0ppm.  
 
Metabolites measured include lactate, n-acetyl aspartate and creatine. The 
creatine peak integrated area from the voxel within the ischaemic region was   127 
used as the internal reference for each patient.  Values are expressed as 
ratios relative to creatine.  
 
5.3 Statistical analysis 
 
SPSS  version  13.0  was  used  for  data  analysis.    Demographic  data  and 
baseline  variables  are  expressed  as  medians  with  corresponding 
interquartile  ranges.  Effect  of  GKI  infusion  versus  placebo  on  change  in 
lesion  volume  dependent  on  recanalisation  status  (AOL  criteria)  were 
determined  using  Kruskal-Wallis  across  groups,  with  intra-group 
comparisons made using the Mann-Whitney U test.  For repeated measures 
of  capillary  blood  glucose,  systolic  and diastolic  blood  pressure data  was 
presented as parametric measures and analysed using one way anova. The 
appropriate use of parametric or non-parametric measures was determined 
using  the  Kolmogorov-Smirnov  test  for  normal  distribution.    Results  were 
considered statistically significant at the 5% level.  Intra-rater assessment of 
lesion  volumes  where  assessed  by  including  24  duplicates  within  the 
anonymised  data  set  with  differences  in  volume  measurements  analysed 
using  the  paired  t-test.  Results  were  displayed  using  a  modified  Bland-
Altman  plot.  Quantification  of  spectroscopy  data  for  lactate  and  N-acetyl-
aspartate  were  recorded  relative  to  creatine.  Correlation  between 
spectroscopy results and outcome measures were compared to admission 
clinical  and  MRI  based  measures.  As  for  lesion  volumes  LCR  (lactate 
creatine  ratios  were  compared  using  the  Mann-Whitney  U  test  at  the 
respective imaging points.      128 
 
5.4 Results 
 
Of the 1,002 admissions to the stroke unit over the period of recruitment, 
530/1002 (53%) had an ischaemic stroke.  Of these, 80/530 (15%) fulfilling 
inclusion criteria and for whom access to MRI was potentially feasible, were 
approached  for  recruitment,  64  patients  consented  to  the  study  and  50 
patients  underwent  baseline  MRI,  with  40  patients  randomised  to  trial 
infusion.    Reasons  cited  for  non-study  participation  of  all  64  patients 
consented are described in Figure 5.1.  Ten patients were recruited to the 
pilot phase and 30 patients to the main phase.  Thirty-seven patients had 
MRI scans performed at all three designated time points, two patients had an 
acute MRI scan only with no follow-up imaging (one worsened clinically and 
one refused).  A single patient was unable to get the Day 3 scan but did 
have a Day 7 scan.  
 
Of  the  40  patients  randomised  to  trial  infusion,  13  (33%)  had  a  pre-
admission  diagnosis  of  diabetes.  Thirteen  (33%)  received  intravenous 
recombinant  tissue  plasminogen  activator.    Baseline  demographics,  along 
with time to admission, time to imaging and infarct volume, are shown in 
Table  5.1.    There  was  no  difference  between  groups  in  relation  to  age, 
stroke severity or time to presentation. Time to infusion was less in patients 
receiving  insulin  (20.8hours  (IQR:  12.9-24.5))  than  in  those  receiving 
placebo (23hours (IQR: 18.5-25.5): p<0.001)*. 
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Figure 5.1: Consort chart for number of patients screened, recruited and imaged for the 
SELESTIAL study. Patients consented and then reasons for completing the study are shown 
in  adjacent  boxes.  Randomisation  for  pilot  and  main  study  shown  along  with  numbers 
completing imaging protocol (under scan time in brackets)  
 
Pilot GKI (48) 
(n=5) 
GKI (24) 
(n=10) 
Placebo 
(n=10) 
MRI (day3) 
(n=10) 
 
MRI (day3) 
(n=9) 
Pilot Placebo 
(n=5) 
MRI (day3) 
(n=5) 
MRI (day3) 
(n=5) 
 
MRI (day7) 
(n=5) 
MRI (day 7) 
(n=10) 
 
MRI (day 7) 
(n=10) 
64 patients consented to study 
50 patients underwent baseline 
MRI 
2 patients died 
1 patient’s condition 
deteriorated prior to 
scanning 
2 patients withdrew 
consent 
9 patients unable to get 
scan within time window 
40 patients randomised to infusion 
2 unable to tolerate scan 
2 no DWI lesion 
1 Posterior Circulation Stroke 
4 non-strokes 
1 Withdrew consent after baseline 
scan 
1,002 Admissions Dec ’03 – Jan ‘06 
530 patients with acute ischaemic stroke 
80 patients fulfilling eligibility criteria 
MRI (day7) 
(n=8) 
MRI (day 7) 
(n=5) 
MRI (day3) 
(n=8) 
GKI (72) 
(n=10)   130 
 
 
Table 5.1: Baseline demographics, clinical assessment, blood glucose and imaging time for 
patients recruited to the SELESTIAL trial. Values expressed as median with interquartile 
ranges.  Risk factor profiles and OCSP classification described as proportions. There was 
no significant difference between groups. Time to infusion was significantly shorter to GKI 
than for placebo (p<0.001) (Mann Whitney U assessment of non-parametric measures) 
  Insulin 
(n=25) 
Placebo 
(n=15) 
Combined 
(n=40) 
Age (Years) (IQR)  76 (67,83)  74 (71,86)  75 (68,81) 
Diabetes  7 (28%)  6 (40%)  13 (33%) 
Atrial Fibrillation  6 (24%)  6 (40%)  12 (30%) 
Hypertension  19 (76%)  13 (87%)  32 (80%) 
Hyperlipidaemia  6 (24%)  4 (27%)  10 (25%) 
Ischaemic Heart Disease   5 (20%)  4 (27%)  9 (23%) 
Thrombolysis  8 (32%)  5 (33%)  13 (33%) 
Mean (±SD) Admission CBG  8.4 (2.3) mmol/l  8.1 (1.8) mmol/l  8.3 (2.1) mmol/l 
Mean (±SD) Admission blood 
glucose 
8.3 (2.7)mmol/l  7.3 (1.3) mmol/l   8.0 (2.3)mmol/l 
NIHSS (IQR)  11 (7,16)  14 (6,19)  11 (6,18) 
TACS  10 (40%)  9 (60%)  19 (47.5%) 
PACS  10 (40%)  2 (13%)  12 (30%) 
LACS  5 (20%)  3 (20%)  8 (20%) 
POCS  0 (0%)  1 (7%)  1 (2.5%) 
Time to admission (hrs) (IQR)  2.5 
(1.9,6.5) 
3.3 
(2.5,9.6) 
3.1 
(2.1,6.5) 
Time  to  infusion  (hrs)  (IQR) 
(measured from stroke onset) 
20.8* 
(12.9,24.5) 
23* 
(18.5,25.5) 
21 
(13.8,25) 
MRI within 6hours   2 (8%)  0 (0%)  2 (5%) 
MRI within 12hours  7 (28%)  3 (20%)  10 (25%) 
MRI (1) hours (IQR)  19.3 
(10.5,22.9) 
21 
(17.3,23) 
19.9 
(11.3,22.5) 
MRI (2) days (IQR)  3 (2,4)  3.5 (2,4)  3 (2,4) 
MRI (3) days (IQR)  7 (6,8)  7 (6,8)  7 (6,8)   131 
 
Insulin infusion 
 
Fifteen patients were randomised to placebo and 25 patients to GKI infusion. 
This  included  10  patients  from  the  pilot  study  (5  placebo  and  5  to  GKI), 
where GKI and Placebo infusions ran for 48hours. The remaining 30 patients 
consisted of 10 randomised to placebo for 72hours, 10 receiving GKI for 72 
hours  and  10  receiving  GKI  for  24hours,  followed  by  placebo  for  the 
remaining  48hours.    The  mean  amount  of  hourly  insulin  required  was 
3.4±1.3units.    The  mean  number  of  additional  bag  changes  to  permit 
adjustment of insulin dose to maintain euglycaemia was 4.8±3.2.   
 
Although there was no difference in capillary blood glucose at baseline, it 
was significantly lower in the GKI group versus placebo at 6hours (5.4mmol/l 
versus  6.9mmol/l;  p<0.001)  and  12hours  (5.8mmol/l  versus  7.0mmol/l; 
p=0.008).  There was no difference in mean capillary blood glucose between 
insulin groups combined and placebo for the remainder of the infusion period 
(Figures 5.2 & 5.3). Following commencement of trial infusions, 68% (17/25) 
of patients receiving GKI had an increase in capillary blood glucose between 
baseline and 6hours (Median change (IQR) in CBG for the GKI group was 
0.43 (-0.67, 0.8) mmol/l).  For patients receiving placebo 60% (9/15) had a 
reduction in capillary blood glucose between the two time points (Median 
change for the placebo group -0.25 (-0.36,0.00)mmol/l.  
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Figure  5.2:  Capillary  Blood  Glucose  variation  (mean±SEM)  with  time  for  GKI  infusions 
combined versus placebo. Number of patients recruited per group shown in key. (*includes 
patients in GKI-24 group with saline introduced post 24hours). Number of patients with data 
available shown in brackets below time points on X-axis.  
Figure  5.3:  Capillary  Blood  Glucose  variation  (mean±SEM)  with  time  for  individual  GKI 
infusions  versus  placebo.  Number  of  patients  recruited  to  each  group  shown  in  key. 
(*includes patients in GKI-24 group with saline introduced post 24hours). Number of data 
points available for analysis shown below time points on Y-axis.   133 
  
Mean  systolic  blood  pressure  was  significantly  lower  in  the  insulin  (GKI) 
group versus placebo at 12hours, 48hours, 60 hours and 72hours (figure 
5.4) There was no statistically significant difference in overall mean diastolic 
blood pressure throughout the infusion period for GKI infusions combined 
versus  placebo  (Figure  5.5).  Corresponding  figures  for  individual  GKI 
infusions versus placebo are shown in Figures 5.6 and 5.7.   
 
 
Figure  5.4:  Changes  in  Systolic  Blood  Pressure  (mean±SEM)  mmHg)  for  GKI  infusions 
combined  versus  placebo  with  time  documented  from  infusion  commencement  in  hours. 
Number of patients recruited to each group shown in key. (*includes patients given normal 
saline following 24hours of GKI infusion). Number of data points at respective time points 
shown in brackets under the time in hours from infusion commencement. Systolic blood 
pressure  was  significantly  lower  in  the  GKI  group  at  12hours,  48hours,  60hours  and 
72hours. Mean values compared using student t-test.  
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Figure  5.5:  Changes  in  Diastolic  Blood  Pressure  (mean±SEM)  mmHg  for  GKI  infusions 
combined  versus  placebo,  with  time  from  infusion  commencement  measured  in  hours. 
Number  of  patients  recruited  to  each  group  shown  in  legend.  (*includes  patients  given 
normal saline following 24hours of GKI infusion). Number of data points at respective time 
points shown in brackets (n=?) under the time in hours from infusion commencement. There 
was no significant difference between diastolic blood pressure for GKI and placebo at any of 
the time points. Mean values compared using student t-test.  
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Figure  5.6:    Changes  in  systolic  blood  pressure  (mean±SEM)  mmHg  for  individual  GKI 
infusions  versus  placebo  with  time  from  infusion  commencement  in  hours.  (*includes 
patients given normal saline following 24hours of GKI infusion). Number of data points at 
respective  time  points  shown  in  brackets  under  the  time  in  hours  from  infusion 
commencement. 
 
 
Figure  5.7:  Changes  in  diastolic  blood  pressure  (mean±SEM)  for  individual  GKI  infusion 
versus placebo with time from commencement of infusion documented in hours. (*includes 
patients given normal saline following 24hours of GKI infusion). Number of data points at 
respective  time  points  shown  in  brackets  under  the  time  in  hours  from  infusion 
commencement. 
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Primary Lesion Volume Outcome Analysis 
 
(1) MRI volume measurements 
 
Median DWI infarct volumes for placebo and insulin groups are shown at 
baseline and Day 3, along with FLAIR volumes at Day 7.  There was no 
statistically  significant  difference  between  lesion  volume  measurements 
between  placebo  and  GKI  groups  combined  at  each  of  the  imaging  time 
points (Figure 5.8).  
 
 
 
 
 
 
 
 
 
Figure 5.8: lesion volumes expressed as a median ±interquartile range for placebo versus 
insulin groups combined (GKI) for day 1 DWI (d1), day 3 DWI (d3) and outcome FLAIR at 
Day 7 (d7). Patient numbers for whom lesion volume measurements are available are 
shown in boxes above each respective column.  
 
When median change in lesion volume expressed was considered for the 
thirty-seven patients with all three scanning sequences available, there was 
no significant difference for acute ((Day 1-Day 3) or outcome (Day1-Day7) 
n=15 
n=25 
n=14 
n=23 
n=15 
n=21   137 
scans for  GKI  combined  versus  placebo  groups  (Figure  5.9).  Example  of 
images obtained shown in (Figure 5.10) 
 
Figure 5.9: Change in lesion volume (cc) expressed as median± interquartile range between 
DWI at Day 1 and Day 3 (d1-d3) and between day 1 DWI and Day 7 FLAIR (d1-d7) for 
placebo versus insulin groups combined. Number of patients with available results is shown 
in the boxes above each respective column. There was no statistically significant difference 
between groups, compared using Mann-Whitney U test.   
 
 
 
 
 
 
DWI 1  DWI 3  FLAIR 7 
Figure 5.10: Example of MRI scans in a patient recruited to the SELESTIAL trial, demonstrating DWI at 
days 1 and 3 and day 7 FLAIR.   138 
(2) Secondary imaging analysis 
Recanalisation data using the AOL criteria on the initial MRA was available 
for thirty-one patients (11/31 (35%) AOL 0, 1/31 (3%) AOL 1, 9/31 (29%) 
AOL 2, 10/31 (32%) AOL3).  See Figure 5.11 for MRA appearances for the 
relative AOL criteria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in lesion volume measurements between admission and days 3 or 
7,  with  accompanying  AOL  criteria  were  available for  29  and  28  patients 
respectively.  Although  median  stroke  severity  was  higher  in  patients  with 
complete occlusion, there was no statistically significant difference across 
AOL 0:  
No Recanalisation of the Primary Occlusion 
 
AOL 1:  
Incomplete or partial recanalisation of the 
primary occlusion with no distal flow 
 
AOL 2:  
Incomplete or partial recanalisation of the 
primary occlusion with distal flow 
 
AOL 3:  
Complete recanalisation of the primary 
occlusion with distal flow 
 
Figure 5.11: Arterial Occlusive Lesion (AOL) classification for admission MRA images.  
Reconstructed images shown alongside the corresponding definition   139 
groups. Numbers thrombolysed were similar across all AOL criteria (Tables 
5.2 and 5.3).  
 
AOL criteria for patients with lesion volume measurements 
(Day1 DWI –Day 3 DWI) (n=29) 
 
  AOL 0 
(n=10) 
AOL (1/2) 
(n=9) 
AOL 3 
(n=10) 
Placebo  4 (40%)  4 (44%)  3 (30%) 
GKI-24  2 (20%)  3 (33%)  3 (30%) 
GKI-48  2 (20%)  1 (11%)  1 (10%) 
GKI-72  2 (20%)  1 (11%)  3 (30%) 
Thrombolysis  4 (40%)  4 (44%)  3 (30%) 
NIHSS (IQR)  16 (9,20)  14 (7,17)  9 (4,14) 
Table 5.2: Number of patients in each group based on AOL criteria with details on infusion 
type and duration of infusion for those patients with DWI lesion volume measurements at 
days  1  and  3.  Percentages  are  shown  in  brackets  within  each  group.    The  number  of 
patients receiving thrombolysis is documented, with percentage in brackets. Stroke severity 
measured using NIHSS is expressed as a median with interquartile range in brackets.  
 
 
 
AOL criteria for patients with lesion volume measurements 
(Day1 DWI –Day 7 FLAIR) (n=28) 
 
  AOL 0 
(n=10) 
AOL (1/2) 
(n=10) 
AOL 3 
(n=8) 
Placebo  4 (40%)  5 (50%)  2 (25%) 
GKI-24  2 (20%)  3 (30%)  2 (25%) 
GKI-48  2 (20%)  1 (10%)  1 (12.5%) 
GKI-72  2 (20%)  1 (10%)  3 (32.5%) 
Thrombolysis  4 (40%)  4 (40%)  2 (25%) 
NIHSS (IQR)  16 (9,20)  14 (7,17)  9 (4,14) 
Table 5.3: Number of patients in each group based on AOL criteria with details on infusion 
type and duration of infusion for those patients with DWI lesion volume measurement at 
days 1 and day 7 FLAIR. Percentages are shown in brackets within each group. Patients 
receiving thrombolysis documented as percentage. Stroke severity measured using NIHSS 
is expressed as a median with interquartile range in brackets.  
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When  median  percentage  change  in  lesion  volume  measurements  was 
considered for both acute (difference between DWI lesion volumes days 1 
and 3) and outcome (difference between DWI lesion volume day 1 and day 7 
FLAIR), there was a significant difference dependent on infusion type and 
level of recanalisation (Figures 5.12 & 5.13). 
 
For  the  acute  scanning  time  points,  patients  receiving  placebo  had  no 
significant  difference  in  lesion  progression  across  AOL  type,  however  for 
those patients receiving GKI there was a significant difference dependent on 
level of recanalisation. Patients with complete occlusion were more likely to 
have a greater increase in infarct progression when compared to partial and 
complete recanalisers (p=0.013) (Kruskal Wallis). When GKI was compared 
with placebo within individual AOL groups, there was a significant difference 
between  insulin  and  placebo  for  both  AOL  0  (p=0.019)  and  AOL  (1/2) 
(p=0.014) (Mann Whitney U) (Figure 5.12). 
 
Similar  results  were  found  when  change  between  baseline  and  day  7 
outcome were considered. On this occasion the only significant difference 
between GKI and placebo was for patients in the complete occlusion group 
(p=0.033) (Mann Whitney U) (Figure 5.13). 
 
 
   141 
Figure  5.12:  Change  in  median  infarct  volume  between  days  1  and  3:  expressed  as  a 
percentage dependent on vessel patency at recruitment.  There was a significant difference 
between  insulin  (GKI)  and  placebo  for  both  the  occlusion  (p=0.019)  and  partial 
recanalisation  (p=0.014)  groups.    There  was  a  significant  difference  across  groups 
dependent on level of recanalisation (p=0.013) (Kruskal-Wallis). Numbers included shown 
above respective columns. 
 
 
Figure 5.13: Change in median lesion volume between days 1 and 7, (DWI and FLAIR) 
expressed as a percentage for both insulin and placebo groups.  There was a significant 
difference between placebo and insulin groups in the occlusion group (p=0.033) only.  There 
was a significant difference across groups dependent on level of recanalisation (p=0.017) 
(Kruskal-Wallis). Numbers in each group expressed above respective columns. 
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Intra rater reliability 
Anonymised  scans  included  24  repeats  to  assess  intra-rater  reliability  of 
measurements.  For the 24 scans with duplicates, there were 18 DWI and 
six FLAIR scans.  For all scans included the mean difference between scans 
was 3.6 ±12.0 cm³ (95%CI; -1.5, 8.6 cm³).  The test statistic for the paired t-
test  was  1.46,  (degrees  of  freedom  23;  p=0.158).  The  British  Standards 
Institution  repeatability  coefficient  was  24.    A  graphical  representation  is 
shown with little variation in readings from zero (Figure 5.14). 
 
 
 
 
 
 
 
 
Difference between first and second lesion volume measurements plotted against the average reading for 
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Figure 5.14:  Difference between first and second lesion volume readings plotted against the 
average for the anonymised 24 duplicate scans (DWI and FLAIR)   143 
 
 
Primary Spectroscopy Outcome Analysis 
 
Baseline  single  voxel  spectroscopy  was  available  for  36  patients  (90%).  
Figure 5.15 demonstrates a typical single voxel spectra obtained and the 
positioning of the voxel within a DWI region during data acquisition.   
 
 
 
 
 
 
 
 
 
 
 
Individual values for cerebral metabolites were obtained using the LC model, 
methodology  described  earlier.  Table  5.4  documents  the  median  values 
obtained  for  the  respective  groups,  with  the  numbers  available  for  each 
randomised infusion. Interquartile ranges are expressed in brackets.  Only 
one patient in the GKI-48hour group had spectroscopy data fit for measuring 
and results are shown for that individual patient.  
 
Figure 5.15: (a) Single voxel placement in a Day 1 DWI abnormality within the right hemisphere and 
(b) Typical Single voxel spectra demonstrating metabolite peaks of Lactate (LAC), Creatine (CR), N-
Acetyl Aspartate (NAA) and Choline (CHO). 
(a)  (b)   144 
 
 
 
 
Table 5.4: Median cerebral metabolite levels for MRS, on days (1), (3) and (7), with IQR in 
brackets. Number of patients is shown for each infusion type at the top of each column. 
Creatine is expressed as a combination of Creatine and Phosphocreatine and refers to total 
creatine and is used as the internal reference point.  
 
 
  Placebo 
(n=4) 
GKI-24 
(n=6) 
GKI-48 
(n=1) 
GKI-72 
(n=8) 
Lactate (day 1)  8.3 
(4.1,12.4) 
5.5 
(2.9,12.3)  10.5  5.3 
(3.6,8.1) 
Lactate (day 3)  2.8 (1.5,4.7)  3.1 
(2.4,4.0)  5.7  3.6 
(2.4,5.8) 
Lactate (day 7)  3.0 
(1.8, 4.4) 
2.3 
(1.4,4.2)  4.4  3.2 
(2.4,4.0) 
NAA     (day 1)  6.6 
(4.9,8.2) 
10.8 
(10.1,14.7)  8.3  10.7 
(4.8,12.8) 
NAA     (day 3)  2.2 
(0.4,5.8) 
9.2 
(8.4,11.9)  5.8  4.7 
(0.8,7.2) 
NAA     (day 7)  2.7 
(0.5,6.2) 
11.5 
(8.5, 12.5)  5.1  3.5 
(0.4,5.6) 
Cr+PCr (day 1)  5.0 
(3.9,6.0) 
6.9 
(6.7,7.8)  5.9  6.7 
(4.9,8.5) 
Cr+PCr (day 3)  2.1 
(0.9,3.8) 
5.9 
(5.0,7.6)  4.0  2.9 
(2.3,5.3) 
Cr+PCr (day 7)  2.7 
(1.2,4.5) 
6.7 
(6.6,7.6)  5.5  2.6 
(0.9,4.3)   145 
Lactate/  Creatine  ratio  (LCR)  was  significantly  higher  on  initial  MRS  in 
patients  with  more  severe  strokes  (NIHSS>15),  at  1.64  (IQR  0.75,  4.51) 
versus  1.02  (0.25,  3.18)  (p=0.04),  and  correlated  with  final  infarct  size 
(R=0.71; p<0.001) (Table 5.5).  In addition to analysis of correlation with final 
infarct  size  or  exploratory  analysis  were  used  included  association  with 
measures of stroke severity and clinical outcome measures. 
  Outcome 
Modified Rankin Scale 
(range 2-6) 
Outcome  
FLAIR 
(range 1.2-445cm³) 
Acute Studies MRI (day 1)     
NIHSS 
(range 3-24)  0.48 (0.002)  0.53 (0.001) 
DWI 
(range 1.0-350cm³)  0.39 (0.014)  0.85 (<0.001) 
Lactate/Creat 
(range 0.1- 3.8)  0.35 (0.038)  0.71 (<0.001) 
NAA/ Creat 
(range 0.2-2.0)  -0.38 (0.022)  -0.62 (<0.001) 
Sub-acute Studies MRI 
(day 3) 
   
DWI 
(range 1.0-462cm³) 
0.39 (0.014)  0.99 (<0.001) 
Lactate/Creat 
(range 0.2-9.3) 
0.24 (0.249)  0.78 (<0.001) 
NAA/ Creat 
(range 0.1-2.0) 
-0.26 (0.194)  -0.68 (<0.001) 
Outcome MRI (day 7)     
FLAIR 
(range 1.2-445cm³) 
0.36 (0.032)   
Lactate/Creat 
(range 0.0-12.8) 
0.39 (0.093)  0.85 (<0.001) 
NAA/ Creat 
(range 0.1-1.9) 
-0.42 (0.069)  -0.79 (<0.001) 
Table  5.5:  Correlation  between  clinical  and  imaging  measurements  for  one  month  outcome 
(modified  Rankin  scale)  and  Day  7FLAIR.  Figure  in  brackets  is  the  p  value  for  statistical 
significance. Ranges are expressed in brackets for each parameter.    146 
Repeat measurements at all the three time points were available for only 19 
patients, whilst repeated measurements at Day 1 and Day 3, were available 
for  25  patients.  There  was  no  significant  difference  in  median 
Lactate/Creatine ratio between insulin and placebo groups at days 1, 3 and 7 
(Figure  5.16).  The  number  of  patients  with  available  single  voxel 
spectroscopy at each of the respective time points for placebo and insulin 
(GKI) groups combined is shown below.  
 
 
Figure 5.16: Median lactate/Creatine ratio (± IQR) for placebo and insulin groups combined 
for spectroscopy results on days 1, 3 and 7. The lactate/creatinine ratio is printed above 
each  column.  Number  of  patients  with  data  available  for  measurement  of  cerebral 
metabolites is shown in the box above the error bar for each respective column.  
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Median change in LCR acutely between days 1 and 3 was 0.44 (IQR -0.28, 
5.56) for placebo and -0.16 (-0.42, 1.06) for GKI. Median change in LCR 
between day 1 and 7 was 2.11 (IQR –0.51, 4.34) for placebo and –0.12 (-
0.75, 0.34) for GKI (p=0.22). When considered as a percentage change in 
LCR from baseline at days 3 and 7, patients receiving placebo, had a larger 
increase  in  LCR  when  compared  to  patients  receiving  GKI  (Figure  5.17). 
This did not achieve statistical significance. Interestingly despite this trend, 
mean  blood  glucose  concentration  for  the  72hour  period  was  similar  for 
placebo  (7.0±0.9mmol/l)  versus  GKI-24  (7.6±1.6mmol/l)  versus  GKI-72 
(6.7±1.1mmol/l) (p=0.395, one way ANOVA).  
 
Figure  5.17:  Median  percentage  change  in  lactate/creatine  ratio  between  days  1  and  3 
(MRS 1-3) and days 1 and 7 (MRS 1-7), for patients receiving insulin (GKI) or placebo. 
Numbers for each group are shown adjacent to the respective columns. Large numbers at 
the top of each column are the median percentage changes from baseline. There was a 
non-significant trend for a greater increase in LCR for placebo versus GKI groups between 
days 1 and 3 (MRS 1-3; p=0.542) and days 1 and 7 (MRS 1-7; p=0.423) (both Kruskal 
Wallis). 
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Clinical outcomes/ adverse events 
 
Modified Rankin was available for all 40 patients at one month.  There was 
no statistically significant difference between insulin and placebo groups.  In 
patients receiving GKI, 16% were independent (modified Rankin 0-2), 76% 
dependent (modified Rankin 3-5) and 8% dead at one month.  In the placebo 
group, 13% were independent, 87% dependent and there were no deaths. 
Stroke progression defined as a worsening in stroke severity on the NIHSS 
of four or more points, between baseline and infusion discontinuation on day 
three, occurred in 8% of patients receiving insulin and in none of the placebo 
group.    
 
Neither patient who had died in the GKI group had fulfilled the criteria for 
stroke  progression  (worsening  in  stroke  severity  on  the  NIHSS of four  or 
more points, between baseline and infusion discontinuation on day three). 
One patient had a severe stroke (NIHSS 24) at presentation and died of 
pneumonia without completing follow-up imaging at days 3 and 7. A further 
patient died from acute respiratory failure.  
 
There were 42 episodes of hypoglycaemia in 20/25 (80%) patients receiving 
insulin, only one of these being symptomatic.  Seventy four percent of the 
episodes  of  hypoglycaemia  occurred  between  midnight  and  8am,  24% 
between  16:00  and  midnight,  and  2%  between  08:00  and  16:00.   There 
were no episodes of heart failure documented.    149 
 
Perfusion and Multi-voxel Spectroscopy 
 
Incomplete data acquisition secondary to failure to complete the full imaging 
protocol  resulted  in  limited  data for  analysis  on  both perfusion and multi-
voxel spectroscopy.  Reasons documented include poor patient tolerability of 
the scanner secondary to the prolonged scanning time and lack of staffing 
familiarisation with these additional non-routine imaging sequences.    150 
 
5.5 Discussion  
 
The consistent negative impact of hyperglycaemia on outcomes after stroke, 
and evidence supporting a mechanistic basis for this, has led many clinicians 
to  regard  active  intervention  to  lower  blood  glucose  as  an  integral 
component of stroke unit care.  However, the absence of benefit in the GIST-
UK trial, and potential hazards of hypoglycaemia identified in GIST-UK and 
also in trials of aggressive glucose control in intensive care settings, must 
raise concerns about the advisability of insulin treatment. 
 
Using MRI surrogate outcome measures we were unable to show that insulin 
in  the  form  of  a  GKI  infusion  attenuated  lesion  volume  progression  in 
hyperglycaemic patients with acute ischaemic stroke.  Indeed, the significant 
interaction between GKI treatment and large artery patency suggests that 
insulin  treatment  may  harm  patients  with  persistent  occlusion  of  a  major 
vessel.    GKI  was  associated  with  significant  increases  in  median  lesion 
volume  at  both  day  3  and  day  7  compared  to  ple  lacebo.  While  this 
observation  should  be  interpreted  with  caution  as  it  was  an  exploratory 
analysis and group sizes are very small, the median percentage change in 
infarct volume appeared to be dependent on degree of occlusion, and results 
were consistent for both baseline versus day 3 and baseline versus day 7 
comparisons.  These findings are also consistent with animal model data.  In 
a cat animal model of permanent middle cerebral artery occlusion (MCAO),   151 
hyperglycaemic  animals  receiving  dextrose  and  insulin  died  acutely  of 
hemispheric  oedema  and  brainstem  compression  significantly  more 
frequently than did normoglycaemic maintained animals.
164 Animal survivors 
in the dextrose/ insulin group were more likely to have larger infarct sizes 
than  similar  survivors  in  the  placebo  group.    Interestingly  although  blood 
glucose  concentration  in  the  dextrose/insulin  group  was  within  the 
hyperglycaemic  range  at  the  time  of  occlusion,  it  was  rendered 
hypoglycaemic  shortly  thereafter,  whilst  the  control  group  maintained 
normoglycaemia throughout.  There was no significant difference in either 
rectal temperature or mean arterial pressure between groups throughout the 
period of the study. Patients receiving thrombolysis accounted for one third 
of  the  sample  population  with  no  significant  differences  across  groups 
defined on the basis of AOL criteria. The timing of the baseline MRA could 
not  exclude  the  effect  of  spontaneous  recanalisation  and  the  studies 
methodology did not attempt to examine efficacy of alteplase. That said the 
results suggest that there may be a synergistic effect between successful 
recanalisation with alteplase and GKI in reducing final infarct size.  Future 
trials should consider combination therapy with knowledge of recanalisation 
being provided with MRA and real time trans-cranial Doppler. Previous work 
has  described  the  association  between  hyperglycaemia  and  worse  stroke 
outcome in patients receiving thrombolytic therapy with respect to infarct size 
and haemorrhagic conversion. The study was not designed to test similar 
outcome measures, with no specific grading of haemorrhagic conversion on   152 
follow-up imaging. In addition sample numbers were too small to examine 
any attenuated effect on lactate/creatine ratio with GKI or placebo dependent 
on level of recanalisation.  
For  the  primary  Magnetic  Resonance  Spectroscopy  (MRS)  endpoints  we 
were  unable  to  demonstrate  a  significant  reduction  in  lactate  across  the 
three measured time points. A possible explanation results from failure to 
demonstrate a persistent significant difference in peripheral blood glucose 
manipulation between the placebo and GKI groups. Increased brain lactate 
as a consequence of anaerobic metabolism of glucose is postulated to be a 
mechanism for the neurotoxicity of hyperglycaemia.  It has been confirmed in 
experimental models of focal ischaemia that hyperglycaemic animals have 
higher  brain  lactate  levels  and  correspondingly  reduced  pH
113;246  when 
compared with euglycaemic controls.  Acidosis may mediate neuronal injury 
through  enhanced  free  radical  formation,  activation  of  pH  dependent 
endonucleases  and  glutamate  release  with  subsequent  alteration  of 
intracellular Ca++ regulation and mitochondrial failure.
113;120;247;248  
 
Previous MRS work in patients with acute ischaemic stroke has reported that 
hyperglycaemia  was  associated  with  elevated  lactate  concentration  in  a 
single  voxel  placed  within  the  DWI  lesion,  and  that  lactate  predicted 
conversion  of  penumbral  tissue  to  infarction.
129    Neither  the  study  by 
Parsons et al [2002]
129 or our study is ideal from a mechanistic perspective, 
since  the  DWI  lesion  is  generally  held  to  represent  predominantly  infarct   153 
core, and infarct expansion is predominantly a consequence of conversion of 
the ischaemic penumbra to infarct. Lactate concentration in the penumbra is 
therefore  of  greater  pathophysiological  interest.  Unfortunately,  we  were 
unable to acquire perfusion MRI in the majority of our patients to allow voxel 
placement in the region of DWI-PWI mismatch, the most widely used index 
of  the  penumbra.  We  attempted  multivoxel  spectroscopy,  but  found  no 
significant differences in lactate concentration in voxels at the margins of the 
DWI  lesion,  and  inconsistent  placement  of  voxels  between  examinations 
together with lack of information on the anatomical location of the penumbra 
in individuals prevented meaningful interpretation of these data.  There is 
currently no direct proof that lactate is detrimental to the ischaemic brain.  
The “glucose paradox” questions why glucose, the main energy substrate for 
the brain, causes demise of brain tissue at the time of cerebral ischemia.  In-
vitro  work  using  murine  hippocampal  slices  has  shown  that  glucose  and 
acidosis  are  detrimental  to  cells  whereas  lactate  is  not.
122  Using  PET 
scanning it has been shown that lactate may in fact be the preferred energy 
substrate for the brain, especially during times of stress.
249 In a rat model of 
global  ischaemia,  insulin-induced  hypoglycaemia  markedly  inhibited  lactic 
acid  production  but  had  no  effect  on  intracellular  brain  pH  as  measured 
using 
31P MRS
241.This is relevant to the management of hyperglycaemia in 
acute  ischaemic  stroke  patients.    If  the  ischaemic  brain  is  dependent  on 
lactate  for  its  source  of  energy,  targeted  euglycaemia  may  result  in  less   154 
glucose load to the brain and thus less substrate for anaerobic metabolism 
and attenuated lactate production.  
 
Limitations 
 
Only two patients had MRI within six hours of stroke onset, and 10 patients 
within  12  hours  of  ictus.  The  late  average  time  to  imaging  may  have 
prevented us from finding  an  effect  of treatment  if  one  assumes  that  the 
major detrimental effects of hyperglycaemia are on survival of the ischaemic 
penumbra,  and  therefore  most  relevant  in  the first  few  hours  after  stroke 
onset. In 42 patients undergoing MRI within 60 hours of an acute ischaemic 
event, patients imaged within 12 hours of symptom onset using DWI had 
significantly  smaller  lesion  volumes  (mean  lesion  size  35mls)  when 
compared  to  follow-up  outcome  MRI  scans  (mean  lesion  size,  45ml) 
(p<0.05).  Patients imaged beyond 12 hours of symptom onset had mean 
lesion volumes not significantly altered on follow-up scans.
250 Later imaging 
may fail to establish any discernible difference in lesion volumes that may be 
present  when  hyper-acute  imaging  (<6hours)  is  performed.    If  we 
hypothesise that insulin has a direct neuroprotective effect on the ischaemic 
brain  through  its  action  on  the  ischaemic  penumbra,  knowledge  of  the 
duration  of  the  penumbra  is  important.    Previous  imaging  studies  have 
suggested  that  the  penumbra  duration  varies.    PET  techniques  have 
demonstrated  44%  penumbral  tissue  at  about  18hours
251  with  some 
penumbral presence being documented up to 42 or 48hours.
252    155 
 
The timing of the final follow-up imaging studies at day 7 may have been too 
early to assess final infarct volume correctly. At this stage, it is possible that 
persistent  swelling  may  have  obscured  any  effect  on  tissue  salvage. 
However, there is currently no generally accepted optimal time for measuring 
outcome infarct volumes, and Day 7 FLAIR was chosen in order to minimise 
losses to follow-up that confound results at later time points, and especially 
so for more severe strokes.   
 
Despite  initial  single  voxel  spectroscopy  results  being  available  for  36 
patients,  repeat  data  were  available  at  day  3  for  only  25  patients  and 
complete  data  at  all  three  time  points  available  for  20  patients.    Voxel 
placement in follow-up scans was dependent on visual comparison with the 
baseline examination and some variation in positioning within the DWI lesion 
is inevitable.  In small DWI lesions, the voxel will include data from adjacent 
normal  brain  tissue,  and  possibly  other  tissues.  Timing  of  repeated  MRS 
measurements  was  standard  and  did  not  control  for  the  different  insulin 
infusion durations and thus the relative cerebral metabolite concentrations at 
these respective end points.   
 
Clinical information. 
Consistent with the GIST-UK study, the majority of patients screened had 
only mild hyperglycaemia.  Previous studies of the natural history of blood   156 
glucose have found reduction in blood glucose over the first 24 hours after 
stroke onset
95;128, which might be consequent to fasting in patients unable to 
swallow,  and  the  common  practice  to  avoid  dextrose  infusions  in  acute 
stroke. The mean fall in capillary blood glucose (±SD) in the placebo patients 
between baseline and 24hours in this study was small (0.6±1.44mmol/l) and 
the maximal difference between placebo and GKI treatment similar to that 
previously reported (maximal mean difference 1.33±0.23mmol/l at 6h/12h).  
Capillary blood glucose was lower at 6 and 12 hours of GKI infusion but 
thereafter there was no significant difference from the placebo (saline only) 
arm.  In contrast with the Leuven surgical ITU trial, the difference between 
active  and  control  arms  is  therefore  small,  the  intensity  of  euglycaemia 
possibly less and the duration of treatment shorter. Arguably, these factors 
may all have contributed to the failure to find benefit in this and previous 
stroke  trials.    Previous  observational  studies  have  reported  that 
hyperglycaemia within 72 hours of stroke onset is associated with a worse 
stroke outcome, and therefore logically prolonged infusions may be required 
to  provide  benefit.
50  However,  in  the  stroke  population  there  are  likely 
concerns with longer durations of tight glycaemia control. Further evidence 
that blood glucose lowering may not be beneficial to stroke outcome arises 
from a post-hoc analysis of the GIST-UK study. In the GKI-treated patients, 
the  overall  mean  change  in  glucose  concentration  between  baseline  and 
24hours was -1.48mmol/l (SD 2.85) in survivors at 90days compared with     
-2.53mmol/l (SD 2.68) in those who died (p<0.002). Using a cut-off point of -  157 
2mmol/l for the mean change in plasma glucose in the GKI group, mortality 
was 34% (53/154) at 24hours in patients with a decrease in plasma glucose 
of  2mmol/l  or  more  compared  to  22%(41/188)  in  patients  who  had  a 
decrease of less than 2mmol/l (p=0.009).
156  
 
Symptomatic  hypoglycaemia  was  rare,  but  asymptomatic  hypoglycaemia 
occurred in most patients receiving the GKI infusion. In our own population, 
hypoglycaemia was found to be more common during the hours of midnight 
to 8am. Hypoglycaemia may be particularly hazardous in brain ischaemia, 
and has been frequent even in clinical trials undertaken in intensive care 
settings.
151,154 In a rat model of temporary focal ischaemia, insulin reduced 
infarct volume,
166 but in a separate study with the same model, infarct size 
was  increased  when  hypoglycaemia  developed.
165  In  contrast  to  other 
populations whereby insulin is administered to patients receiving enteral or 
parenteral nutrition,
253 the heterogeneity of the stroke population means that 
nutritional intake varies, with many cases of hyperglycaemia associated with 
the  post-prandial  phase  and  hypoglycaemia  during  periods  of  fasting.  
Recognising variation in insulin requirements has led some authors to adjust 
overnight insulin regimes in stroke patients.
181 The feasibility of monitoring 
prolonged  insulin  infusions  within  stroke  units  is  also  of  concern,  since 
nursing staff ratios are generally lower than in ITU environments. Despite 
close monitoring in a clinical trial setting within a hyperacute unit, we found a 
worryingly  high  incidence  of  hypoglycaemia,  albeit  predominantly   158 
asymptomatic.    In  addition  to  the  potential  hazard  of  hypoglycaemia, 
prolonged insulin infusions may restrict early mobilisation in stroke units, an 
important factor in analysis of the benefits of stroke unit care, 
254 and again 
different from both coronary care and ITU populations.   
 
It  remains  possible  that,  in  common  with  other  trial  interventions,  it  is  a 
mistake  to  consider  stroke  as  a  single  homogeneous  condition.    In  a 
retrospective study of 1,375 patients with acute ischaemic stroke, moderate 
hyperglycaemia  (>8.0mmol/l  –12.0mmol/l)  was  associated  with  increased 
odds of a favourable outcome in patients with lacunar stroke (multivariate 
OR 2.70; 95% CI 1.01-7.13, P=0.048) and decreased odds of a favourable 
outcome  in  non-lacunar  stroke  (OR  0.60;  95%  CI  0.41-0.88,  P=0.009).
255 
Hence  the  requirement  for  glucose  manipulation  might  be  dependent  on 
stroke type.  
 
Consistent  with  the  GIST-UK  data,  we  found  that  insulin  resulted  in  a 
reduction of systolic blood pressure when compared with placebo at several 
time points.
256 Whether this is a consequence of increased blood pressure in 
the saline control arm, or to lowered BP in the GKI arm, possibly due to a 
vasodilatory effect of insulin or of potassium within the GKI infusion, is not 
known.    Management  of  blood  pressure  in  the  acute  phase  of  stroke  is 
currently the subject of several clinical trials.  There is concern that lowering 
BP may be detrimental since reduced cerebral perfusion pressure within the   159 
non-autoregulating  ischaemic  penumbra  may  be  harmful.    Alternatively, 
higher  BP  might  increase  the  risk  of  cerebral  oedema.    It  is  at  least  a 
plausible hypothesis that reduced BP might be more detrimental in those 
with persistent arterial occlusion since the penumbra in these individuals is 
wholly  dependent  on  collateral  flow,  as  compared  with  those  with  partial 
recanalisation of the parent artery.   
 
 
5.6 Conclusion 
 
We found no evidence that GKI infusion attenuated infarct growth in patients 
with moderate hyperglycaemia within 24 hours of acute ischaemic stroke.  A 
non-significant trend towards attenuation of increased lactate concentration 
in the ischaemic brain was evident in the GKI treatment arm.  Consistent 
with previous studies, GKI infusion was associated with lower blood pressure 
and modest reductions in blood glucose.  Asymptomatic hypoglycaemia was 
common despite frequent monitoring within a well-controlled environment.  
 
Exploratory analyses raised the possibility that GKI infusion might in fact be 
harmful  in  patients  with  persistent  arterial  occlusion;  this  could  simply 
represent a Type 1 error and requires confirmation, but is consistent with 
some experimental data. Sample size was too small to discriminate between 
populations  on  the  effect  of  recanalisation  status  and  possible  lactate 
attenuation.    160 
 
Intervention  with  GKI  infusion  to  treat  moderate  hyperglycaemia  in  acute 
ischaemic stroke requires further trials before it should be considered. These 
trials  should  be  designed  with  knowledge  of  recanalisation,  inclusion  of 
thrombolysis and real time monitoring of vessel patency.     161 
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6.1 Introduction 
 
Studies  examining  the  role  of  hyperglycaemia  in  acute  stroke  have  used 
inconsistent  definitions  with  the  temporal  profile  of  blood  glucose 
incompletely  understood.    Post  stroke  hyperglycaemia  (PSH)  has  been 
defined  using  values  between  6.1  and  8.0  mmol/l,  based  on  random  or 
fasting  blood  glucose  levels  at  various  time  points  from  stroke  onset.
53;55 
Previous observational studies have included patients presenting up to 72 
hours from ictus,
50 with limited information on blood glucose profiles within 
the initial 6-12 hours.  The contribution of undiagnosed diabetes or impaired 
glucose metabolism to the hyperglycaemia of acute stroke remains poorly 
understood. Previous studies have defined patients as diabetic on the basis 
of preceding history or elevated admission blood glucose in the context of 
elevated  glycosylated  haemoglobin  or  fructosamine,  with  “stress 
hyperglycaemia” describing patients with elevated admission glucose in the 
presence  of  normal  indices. We  now  know  that  many  patients  previously 
defined as “stress hyperglycaemia” have underlying abnormalities in glucose 
metabolism  when  screened  at  later  time  points.
90;257  The  association 
between  stroke  severity,  stress  hyperglycaemia  at  initial  presentation  and 
the true prevalence of abnormal glucose metabolism is poorly understood.  
Earlier studies have had poor correlation between stroke severity, timing of 
hyperglycaemia in the acute phase and oral glucose tolerance test results at 
later time points.  
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The aim of this study was to describe the capillary blood glucose profile in 
acute  stroke  over  a  48hour  period.    The  study  sought  to  define  the 
prevalence  of  hyperglycaemia  at  different  time  points  from  stroke  onset, 
describe its association with stroke severity, stroke type, and the contribution 
of  feeding  to  hyperglycaemia.    The  study  also  aimed  to  define  the  true 
prevalence  of  impaired  glucose  metabolism  and  metabolic  syndrome  in 
patients manifesting hyperglycaemia within 48hours of stroke onset and to 
describe its association with “stress hyperglycaemia” and stroke severity at 
initial presentation.  
 
6.2 Methods 
 
Hyperglycaemia was defined for the purposes of the study as capillary or 
venous blood glucose (CBG) concentration greater than 7.0mmol/l. 
 
Part 1: Retrospective Observational Study 
 
We undertook a retrospective review of routinely gathered clinical data in 
patients  admitted  to  our  acute  stroke  unit.   Data  was  included  if  patients 
presented  with  suspected  acute  ischaemic  stroke  within  24  hours  of 
symptom  onset,  CBG  was  not  significantly  elevated  (≥17mmol/l)  and/or 
insulin  was  not  administered  during  the monitoring  period.    The  inclusion 
criteria were selected to exclude those patients for whom the blood glucose 
profile may have been affected by the use of insulin. In accordance with the 
stroke  unit  protocol  patients  routinely  underwent  capillary  blood  glucose 
(CBG)  concentration  measurements  every  4  hours  for  48  hours  using  a   164 
Medisense  precision  glucose  meter  (United  Kingdom)  with  readings 
recorded  by  nursing  staff  on  a  specified  form.    Baseline  demographics 
including  age,  sex  and  risk  factor  profile  were  recorded.    Diabetes  was 
defined  on  the  basis  of  a  recorded  history  of  diabetes,  or  treatment  with 
glucose lowering therapies pre-stroke.  Stress hyperglycaemia was defined 
as hyperglycaemia in the first 48h after stroke onset, in the absence of a 
documented history of diabetes consistent with previous definitions. Strokes 
were  classified  using  the  Oxfordshire  Community  Stroke  Project  (OCSP) 
classification  system,
243  and  stroke  severity  was  measured  using  the 
National Institutes of Health Stroke Scale (NIHSS) score.
258 The NIHSS was 
further categorised into mild (NIHSS 0-6), moderate (NIHSS 7-15) or severe 
(NIHSS>15).  Time of stroke onset was defined, as the time the patient was 
last known to be well. 
 
A  sub-set  of  patients  recruited  to  the  SELESTIAL  trial,  presented  in  an 
earlier chapter, were excluded from the continuous monitoring phase of the 
study  but  were  eligible  for  admission  descriptive  purposes  and  the 
prospective follow up study. 
 
Feeding was documented as either staged oral diet or nil by mouth (NBM), 
in conjunction with speech and language therapists’ notes or written orders 
documented in the nursing notes. Patients classified as NBM had confirmed 
documentation of nil orally as per fluid balance sheet and food chart on note   165 
review.    As  the  monitoring  period  was  48  hours  from  ictus,  nasogastric 
feeding had not been commenced in any patients studied.  
 
 
 
Part 2: Prospective review and convalescent glycaemic status 
 
Ethical  approval  for  the  prospective  study  was  obtained  from  the  local 
research  and  ethics  committee  in  October  2005.    Patients  demonstrating 
hyperglycaemia  within  48  hours  off  ictus  were  invited  for  follow-up  to 
determine underlying  glycaemic  status.    Patients  were  approached  at the 
time of incident admission, or by postal contact following discharge.  In the 
case of postal invitation, non-respondents received a further invitation after a 
4-week gap.   
 
Patients were eligible for screening if the incident event occurred within a 
minimum of 3 months and no later than one year from the anticipated Oral 
Glucose Tolerance Test (OGTT) date, provided the patient was 1) alive; 2) 
had a modified Rankin Scale score of ≤4 (i.e. not severely dependent); 3) 
lived within reasonable travelling distance of the stroke centre - thus patients 
requiring air-transport or prolonged journey times were deemed ineligible; 4) 
had confirmed hyperglycaemia (defined as an elevated capillary or venous 
blood glucose greater then 7 mmol/l) at least once within 48hours of stroke 
ictus and 6) was able to give consent.  Exclusion criteria included 1) Patients 
known to be diabetic at the time of the incident event, 2) Patients with inter-  166 
current  illness  at  the  time  of  the  planned  test  and  3)  Patients  on 
corticosteroids.  Consort chart for the protocol used in recruiting patients to 
the prospective study is shown in figure 6.1. 
 
 
Figure 6.1: Consort chart demonstrating recruitment protocol for patients being screened for 
the  prospective  study  examining  the  prevalence  of  abnormal  glucose  metabolism  and 
metabolic syndrome in patients manifesting hyperglycaemia at acute stroke presentation.  
 
  
YES 
YES 
Hyperglycaemia 
CBG >7.0mmol/l 
OR 
Venous Blood Glucose 
>7.0mmol/l 
Within 48hours of admission 
 
Confirmed Ischaemic Stroke 
or TIA 
YES 
Non-Diabetic 
YES 
Acute stroke 
admission 
(a) Modified Rankin Scale ≤ ≤ ≤ ≤4 
(b) Travelling distance of Hospital 
(c) Able to give consent 
(d) Within 3-12months of stroke ictus  
Eligible for OGTT and 
Anthropometric measurements   167 
 
Testing  was  performed  in  the  day  procedure  unit  of  the  Institute  of 
Neurological  Sciences  or  in  the  patient’s  home  if  requested.    Using 
International  Diabetes  Federation  (IDF)  criteria,  abnormal  glucose 
metabolism was defined using a 75g oral glucose tolerance test (OGTT).  
Patients  were  fasted  overnight  before  a  blood  sample  was  withdrawn  for 
fasting glucose in a 2ml fluoride/oxalate container, shaken to ensure fluoride 
inhibits  glycolysis  and  labelled  “fasting”.    A  separate  fasting  sample  was 
obtained  for  a  lipid  profile.    Smoking,  eating  or  moving  around  was  not 
allowed during the test.  A further blood sample was taken 120 minutes after 
the 75g oral glucose load for the two-hour post-prandial glucose level.   
 
Waist  circumference was  measured  in  centimetres using  a  tape  measure 
placed horizontally at the smallest area measured on exhalation between the 
ribs  and  the  iliac  crest.  Three  readings  were  recorded  with  the  average 
reading  being  used.    Blood  pressure  was  recorded  with  the  patient  in  a 
seated position using a fully automatic upper arm blood pressure monitor 
(OMRON  M7)  with  a  comfort  ML  cuff.    The  average  of  three  recorded 
readings was used.  Glycosylated Haemoglobin (HbA1c) concentration was 
recorded at the time of the OGTT for all patients (High performance liquid 
chromatography on a Menarini analyzer)  
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Abnormal  glucose  metabolism  was  defined  as  Impaired  Fasting  Glucose 
(IFG): fasting blood glucose 5.6 to 6.9 mmol/l), Impaired Glucose Tolerance 
(IGT): 2hour post-prandial sample 7.8 to 11.0 mmol/l or Diabetes Mellitus 
(DM): Fasting blood glucose greater than or equal to 7.0 mmol/l or two hour 
post  prandial  sample  greater  than  or  equal  to  11.1  mmol/l).    Metabolic 
syndrome was defined on the basis of the IDF consensus document: central 
obesity  (defined  as  waist  circumference  greater  than  or  equal  to  94 
centimetres for Europid men and greater than or equal to 80 centimetres for 
Europid women, with ethnicity specific values for other groups) plus two of 
the following four factors (elevated triglycerides (≥ 1.7mmol/l), reduced HDL-
cholesterol  (<  1.03  mmol/l  in  males  and  <  1.29mmol/l  in  females), 
Hypertension  (Systolic  Blood  Pressure  ≥130mmHg  or  Diastolic  Blood 
Pressure ≥85mmHg) or raised fasting plasma glucose (≥5.6mmol/l)
259.   
 
6.3 Analysis 
 
Summary  statistics  include  mean  ±  standard  deviation  for  normally 
distributed data (age, blood glucose concentration, HbA1c), or median and 
interquartile range for non-normally distributed variables.  Baseline features 
of the population studied were recorded as percentages relative to the total 
population.    Subject  proportions  were  compared  by  Chi-squared  tests.  
Significance was taken to be p<0.05 in all instances.  Continuous capillary 
blood glucose profiling was recorded for patients with OGTT and displayed 
on a line chart, as the mean ±SEM at distinct time points from ictus and   169 
compared on the basis of normal glucose metabolism or abnormal glucose 
metabolism.   
 
Regression analysis was used to examine predictors of hyperglycaemia in 
the  acute  phase  of  stroke.    Characteristics  of  patients  manifesting 
hyperglycaemia on admission were compared to those who developed late 
hyperglycaemia  using  the  Chi-squared  and  the  student’s  t-test.  Late 
hyperglycaemia  was  defined  as  the  detection  of  hyperglycaemia  within 
48hours of presentation when the initial admission blood glucose was within 
the euglycaemic range.  
 
6.4 Results 
 
Part 1 
Eight hundred and eighty six patients were admitted to the acute stroke unit 
between  April  2004  and  January  2006.    Four  hundred  and  twenty  nine 
patients with suspected acute ischaemic stroke, presenting within 24 hours 
of stroke onset underwent four-hourly capillary blood glucose profiling.  As 
per the consort chart (Figure 6.1), 76 patients were excluded, leaving 353 
patients with data for analysis.  Of the 353 patients, 337 had acute ischaemic 
stroke.    This  comprised  76%  (337/445)  of  all  acute  ischaemic  stroke 
admissions to the unit over the study period. Sixteen patients undergoing 
CBG  monitoring  from  admission  were  subsequently  shown  to  have 
haemorrhage on radiological imaging.     170 
 
886 patients admitted 
April-04 to January-06 
429 patients with 
suspected AIS presenting 
<24hours underwent CBG 
screening 
353 patients with complete 
clinical and 48hour 
glucose profiling 
completed 
25   Incomplete data Collection forms 
10   Incomplete Clinical Data 
16   uncertain time of onset 
5   Late presentation 
 
18 Non-strokes 
2 Patients requiring insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Consort chart for patients admitted to the stroke unit between April 2004 and 
January 2006 inclusive and subsequently included in the capillary blood glucose monitoring 
study. AIS = acute ischaemic stroke. Reasons cited for patient exclusion shown in text 
boxes.  
 
The mean age was 70.43±12.6 years and mean NIHSS 8±7.  An established 
diagnosis of Diabetes was present in 18% (63/353) of patients.  Median time 
from  documented  stroke  onset  to  initial  CBG  was  240  minutes  (IQR 
165,520mins) (Table 6.1). Glycosylated haemoglobin concentration (HbA1c) 
was available for 56% (196/353) of subjects.  
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Total 
 
Non-
Diabetic 
Diabetic  p 
Number of patients  353  290 (82%)  63 (18%)   
Mean Age (± ± ± ±SD) (Yrs)  69.9 ±12.8  70.6 ± 13.0  66.1 ± 10.4  0.129 
Mean NIHSS (± ± ± ±SD)   8.0 ± 6.6  8.3 ± 6.8  6.8 ± 5.1  0.103 
Stroke Type 
Ischaemic Stroke 
PICH 
 
337 (95%) 
16 (5%) 
 
276 (95%) 
14 (5%) 
 
61 (97%) 
2 (3%) 
 
0.246 
OCSP  
TACS 
PACS 
LACS 
POCS 
TIA 
 
80 (23%) 
108 (31%) 
121 (34%) 
33 (9%) 
11 (3%) 
 
70 (24%) 
89 (31%) 
96 (33%) 
24 (8%) 
11 (4%) 
 
10 (16%) 
19 (30%) 
25 (40%) 
9   (14%) 
0   (0%) 
 
 
 
Admission CBG (mmol/l)  6.8 ± 2.3  6.3 ± 1.3  9.1 ± 3.8  <0.001 
Admission Hyperglycaemia 
CBG>7.0mmol/l (%) 
103 (29%)  64 (22%)  39 (62%)   
 
Table 6.1: Baseline patient data for blood glucose monitoring study including age, blood 
glucose and stroke severity (NIHSS). All expressed as means±SD. Stroke classification 
based on OCSP criteria and expressed as percentages. Stroke type also expressed as 
percentages. Means compared using one way ANOVA, with percentages compared using 
chi-square.  
 
 
 
Admission Hyperglycaemia 
 
The overall prevalence of hyperglycaemia on admission for both diabetic and 
non-diabetic  patients  was  29%  (102/353).  For  established  diabetics  62% 
(39/63) were hyperglycaemic and 38% (24/63) euglycaemic. In non-diabetic 
patients 22% (64/290) had stress hyperglycaemia at presentation. For the 
0.20   172 
entire population studied, the prevalence of stress hyperglycaemia was 18% 
(64/353).  In  the  subset  of  196  patients  with  documented  HbA1c,  HbA1c 
levels  differed  significantly  according  to  age  and  stroke  severity.  Patients 
with euglycaemia on admission had a lower HbA1c than patients with stress 
hyperglycaemia, who in turn had a lower HbA1c than patients with diabetes. 
(Table 6.2) 
 
  Euglycaemic  Stress 
Hyperglycaemia 
Diabetic 
(Euglycaemic) 
Diabetic 
(Hyperglycaemic) 
p 
N (n=196)  100 (51%)  49 (25%)  17 (9%)  30 (15%)   
Median Age 
(IQR) 
69 (58,79)  74 (66,80)  64 (58,74)  71 (65, 79)  0.162 
MedianNIHSS 
(IQR) 
9 (4,13)  6 (4,16)  5 (4,9)  6 (4,10)  0.660 
MedianHbA1c 
(IQR) % 
5.9 (5.6, 6.2)  6.2 (5.8,6.7)  7.1 (6.5,7.6)  7.9 (7.1, 8.8)  <0.001 
 
Table 6.2 Association between Stroke Severity (NIHSS), Age, Glycosylated Haemoglobin (HbA1c) 
and Admission Hyperglycaemia for 196 patients. Data expressed as medians plus interquartile 
ranges, categorised at baseline as euglycaemic, stress hyperglycaemia, diabetic euglycaemia and 
diabetic hyperglycaemia.  Median values compared across groups using Kruskal-Wallis test.  
 
Continuous monitoring 
Thirty-six patients were randomised to the previously reported SELESTIAL 
trial and were excluded from the CBG profiling.  48h profiles were available 
for 317 patients.  The median time to first CBG reading was 238 minutes 
(165,494 minutes) and the median number of readings over the monitoring 
period  was  13  (10,13).    Hyperglycaemia  was  further  divided  into  isolated   173 
hyperglycaemia (only one episode of hyperglycaemia in the 48hour period) 
or sustained hyperglycaemia (two or more episodes over the 48hours).  For 
the  monitoring  period,  25%  of  patients  remained  euglycaemic  with  22% 
having isolated hyperglycaemia and 53% sustained hyperglycaemia. (Figure 
6.3) 
 
353 patients with clinical and 
48hour CBG profiling available 
196 patients with HbA1c available 
on admission 
157 patients with no recorded 
HbA1c on admission 
141 Non-
Diabetics 
149 Non-
Diabetics 
16 Diabetics  47 Diabetics 
36 SELESTIAL 
patients excluded 
HbA1c available 
for 50% of 
patients 
(40/80) 
HbA1c available 
for 46% of 
patients 
(32/69) 
HbA1c available 
for 54% of 
patients 
(90/168) 
317 patients with continuous monitoring profiles 
Euglycaemia 
throughout 
25% (80/317) 
Isolated 
Hyperglycaemia 
22% (69/317) 
Sustained 
Hyperglycaemia 
53% (168/317) 
Figure 6.3: Consort chart showing breakdown of sample population into 
diabetics and non-diabetics, along with classification into euglycaemia, 
isolated hyperglycaemia and sustained hyperglycaemia. Proportion with 
HbA1c available also shown.    174 
 
When the 162 patients with HbA1c results available were categorised into 
isolated  hyperglycaemia,  sustained  hyperglycaemia  or  euglycaemia  there 
was  a  statistically  significant  difference  in  stroke  severity  (NIHSS)  and 
HbA1c  across  groups.    HbA1c  was  lower  and  strokes  more  severe  in 
patients who remained euglycaemic during the observation period.  Using 
binary  logistic  regression  HbA1c  was  predictive  of  the  development  of 
hyperglycaemia  in  the  48hour  period  OR  3.64  (95%CI  1.633-8.122) 
(p=0.002) whereas stroke severity (NIHSS) showed a trend but did not reach 
statistical significance OR 0.936 (95% CI 0.877-1.000) (p=0.051).  
 
 
Euglycaemia  Isolated 
Hyperglycaemia 
 
Sustained 
Hyperglycaemia 
 
P 
 
Number of 
patients 
 
 
40 
 
32 
 
90 
 
--- 
Median Age  
(IQR) 
67 
(58,77) 
70 
(58,80) 
71 
(59,78) 
0.126 
Median NIHSS 
(IQR) 
10 
(5,15) 
7 
(4,12) 
5 
(3,10) 
0.001 
Median HbA1c 
(IQR) 
5.8 
(5.6,6.1) 
6.2 
(5.6, 6.6) 
6.2 
(5.8,7.0) 
0.009 
 
Table 6.3 Association between Median Stroke severity (NIHSS), Age, Glycosylated 
Haemoglobin (HbA1c) and Hyperglycaemic status over the 48hour-monitoring period for 
those patients with complete results (n=162). Values expressed as medians with (IQR). 
Statistical analysis undertaken using Kruskal-Wallis.  
 
   175 
 
Time post Ictus 
One hundred and sixty seven patients with a definite time of onset had blood 
glucose  profiles  analysed  relative  to  stroke  ictus.    One  hundred  and  fifty 
patients  were  excluded  due  to  no  definite  time  of  onset,  which  included 
patients  with  stroke  on  waking,  late  presentation  or  incomplete  readings.  
The natural history of the overall mean blood glucose profile is shown in 
Figure 6.4.   
 
 
 
Figure 6.4 Temporal profile of capillary blood glucose (mean+SEM)(mmol/l) relative to 
time from ictus for those patients with a confirmed time of stroke onset (n=167) for 
the 48hour period of monitoring.   176 
 
 
Blood  glucose  profiles  are  also  shown  for  groups  classified  using  OCSP 
(Figure 6.5).  
 
 
Figure 6.5 Temporal profile of capillary blood glucose (mean +SEM) relative to time 
from ictus, classified on the basis of the OSCP stroke classification system. 
 
Patients with TACS (Total Anterior Circulating Syndrome) had a lower mean 
blood  glucose  at  24,  36  and  48  hours  compared  to  the  other  groups, 
although it did not meet statistical significance.   
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Using the NIHSS and defining groups as mild, moderate or severe (Figure 
6.6), there was a significant difference in CBG across groups at 36 and 48 
hours (t=36hours; F=3.218; p=0.042; t=48hours; F=3.997; p=0.020 (one way 
Anova).  In post-hoc analysis mean CBG was statistically lower in patients 
with severe stroke (NIHSS>15) compared to the mild stroke group (NIHSS 0-
6) (p=0.016).  
 
Figure 6.6 Temporal profile of capillary blood glucose (mean+SEM) relative to time 
from ictus for patients with definite times of stroke onset, classified on the basis of 
admission stroke severity (NIHSS).   178 
Feeding 
Information  on  feeding  status  was  available  for  214  patients.  38  patients 
(18%)  remained  Nil  by  Mouth  (NBM)  for  the  monitoring  period  with  the 
remaining 176/214(82%) of patients having staged oral intake (Table 6.4). 
There was a statistically significant difference between groups, with 20% of 
patients with staged oral intake euglycaemic compared to 40% of patients in 
the nil by mouth group (χ
2=6.69; p≤0.01).   
 
Blood Glucose 
  Hyperglycaemia  Euglycaemia  Total 
Staged diet  141  35  176  Feeding 
NBM  23  15  38 
Total  164  50  214 
 
Table 6.4: Development of hyperglycaemia within the 48hour monitoring period for patients 
defined on the basis of oral intake. Staged diet versus nil by mouth (NBM) (n=214).  
 
 
The median NIHSS in the NBM group was 15 (IQR 9,19) compared to 5 
(IQR 3,10) in the oral intake group (p<0.001). For the 19 patients in the NBM 
group with definite time of onset, mean CBG decreased to a nadir at 24hours 
and  then  increased.  For  patients  with  defined  oral  intake  the  mean  CBG 
initially increased then decreased to a nadir at 12 hours with a further peak 
at 48hours (Figure 6.7).  Mean CBG was significantly lower in the oral intake 
group  at  the  48hours  time  point  (6.4mmol/l  versus  6.6mmol/l;  p  =  0.032 
(F=4.719)).   179 
 
Figure 6.7 Temporal profile of capillary blood glucose (mean+SEM) relative to time 
from ictus, dependent on feeding status across the 48hour period of monitoring.  
Patients were subdivided into nil by mouth (no oral intake for the observed period) or 
staged oral diet and fluids (confirmed oral intake for the monitoring period, as 
documented in the case note review). 
 
 
 
 
 
 
   180 
Part 2: Prevalence of Convalescent Abnormal glucose metabolism 
One hundred and eighty three patients were identified with hyperglycaemia 
for  the  period  October  2004  to  January  2006.  Thirty-eight  patients  were 
ineligible for follow-up (five patients who lived at significant distances from 
the hospital made repeat testing difficult and they were therefore excluded, 
see Figure 6.6). One hundred and forty five patients were approached. Sixty-
seven of 91 respondents (46%) agreed to study participation and underwent 
the OGTT.  
12 patients died
5 PEG feeding
5 distance
12 known diabetics
4 PNH residents
14 patients not agreeable to study
10 DNA
One non stroke excluded One patient with PICH excluded
Results available for 65 patients
67 underwent  OGTT
77 consented to study
91 Respondents
145 potentially eligible patients
Letter sent X 2
Phoned when number available
183 patients with Hyperglycaemia
Oct'04 and Jan'06
Figure 6.8 Consort chart for Hyperglycaemic patients 
approached and screened with the OGTT.   181 
Two patients were excluded, one a non-stroke diagnosis and the other a 
diagnosis of PICH. Of the 65 remaining patients baseline demographics and 
clinical  features  are  shown  in  table  6.5.  Four  patients  were  unable  to 
complete the glucose ingestion, but data was retained to facilitate diagnostic 
criteria for the metabolic syndrome.  Full OGTT information was available for 
61  patients  from  the  original  183  non-diabetic  patients  approached  for 
screening.  
Demographic details  N=65 
Median Age (IQR)  70 (61, 76) 
Gender (male/female)  25/40 
Median time to OGTT post stroke (days)(IQR)  176 (108, 240) 
Clinical Stroke Classification 
TACS 
PACS 
LACS 
POCS 
TIA 
 
11 (17%) 
14 (22%) 
30 (46%) 
9 (14%) 
1 (2%) 
Prevalence of Stroke Risk Factors 
Hypertension 
Hyperlipidaemia 
IHD 
Cigarette smoking (current/ex-smoker) 
Previous Stroke/TIA 
Atrial Fibrillation 
 
27 (42%) 
16 (25%) 
12 (18%) 
20 (31%) / 6 (9%) 
11 (17%) 
15 (23%) 
 
Table 6.5: Demographic profile of patients undergoing oral glucose tolerance testing. Values 
expressed as percentages or medians (IQR).  
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The  results  of  the  OGTT  are  shown  in  (Table  6.6).    52%  (32/61)  had 
abnormalities  of  glucose  metabolism  with  21%  (13/61)  of  patients  being 
diagnosed  with  diabetes  and  31%  (19/61)  had  either  impaired  fasting 
glucose  or  impaired  glucose  tolerance.   When  baseline  clinical  data  was 
examined  there  was  no  statistically  significant  difference  in  age  or  stroke 
severity  between  patients.  Admission  capillary  blood  glucose  was 
significantly higher in patients who were found to have Diabetes, compared 
to  patients  with  confirmed  normal  or  impaired  glucose  tolerance/impaired 
fasting glucose (P=0.002).  
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Normal Glucose Metabolism 
Impaired Fasting Glucose or Impaired Glucose Tolerance 
Diabetes Mellitus 
Table 6.6 Results for the 75g Oral Glucose Tolerance test. Abnormal 
glucose metabolism defined using IDF criteria as shown.   183 
Mean (± ± ± ±SD)  Normal  IGT/IFG  Diabetes 
Mellitus 
 
F  p 
Age (Years)  64±10  73±10  66±14  2.068  0.138 
 
Admission 
NIHSS 
 
8±5 
 
7±7 
 
7±5 
 
0.865 
 
0.145 
 
Admission 
CBG (mmol/l) 
 
 
6.3±1.4 
 
6.7±1.2 
 
8.2±2.3 
 
6.962 
 
0.002 
HbA1c (%)  5.7±0.3  5.8±0.4  6.6±0.7  15.649  <0.001 
Rankin 
(3mths) 
2±1  2±1  2±1  0.402  0.671 
 
Waist (cm) 
circumference 
 
91±15 
 
92±9 
 
103±20 
 
0.953 
 
0.393 
 
Fasting BG 
(mmol/l) 
 
5.0±0.3 
 
5.5±0.5 
 
6.7±1.8 
 
13.622 
 
<0.001 
 
Triglycerides 
 
1.05±0.27 
 
1.43±0.62 
 
1.79±0.99 
 
6.878 
 
0.002 
 
HDL-C. 
 
1.23±0.35 
 
1.27±0.18 
 
0.93±0.19 
 
6.353 
 
0.004 
 
SBP (mmHg) 
 
145±25 
 
147±18 
 
143±18 
 
0.099 
 
0.906 
 
DBP (mmHg) 
 
85±17 
 
83±14 
 
79±12 
 
0.884 
 
0.420 
 
Table 6.7: Baseline demographics on admission (light grey) and subsequent clinical findings 
and laboratory characteristics of the 61 patients at scheduled follow-up for OGTT and 
anthropometric measurements. Groups are categorised  on the basis of OGTT findings as 
per IDF criteria (normal glucose metabolism, Impaired Glucose Tolerance (IGT)/Impaired 
Fasting Glucose (IFG) or diabetes). Data are expressed as mean±SD. Means compared 
across groups using one way ANOVA. Significance is defined as p<0.05.  
 
At  the  time  of  initial  screening  there  was  significant  differences  between 
groups for HbA1c, fasting blood glucose and lipid abnormalities (Table6.7).   
   184 
Screening of patients who presented with admission hyperglycaemia found 
Diabetes or IGT/IFG in 68% of cases.   39% of patients with normal blood 
glucose at presentation developed hyperglycaemia in the monitoring phase 
and were found to have abnormal glucose metabolism at follow-up. Patients 
with  hyperglycaemia  on  admission  presented  significantly  earlier  than 
patients  with  initial  normoglycaemia  (4.8±4.5hrs)  versus 
(7.7±7.4hrs)(p<0.001)(Table6.8).  For the 65 patients screened for metabolic 
syndrome, complete data was available to aid diagnosis for 63 patients, of 
which 51% (32/63) had metabolic syndrome.  Metabolic syndrome was again 
more prevalent in patients with manifest hyperglycaemia on admission (70% 
versus 40% in the normoglycaemic group; p≤0.025). 
 
 
 
 
 
 
 
 
 
 
 
 
  Admission CBG 
>7.0mmol/l (n=22 +1) 
Admission CBG 
≤ ≤ ≤ ≤ 7.0mmol/l (n=39 +1) 
p 
Diabetes 
Mellitus 
 
IGT/IFG 
  
Normal 
Glucose 
Tolerance 
8 (36%) 
 
 
7 (32%) 
 
7 (32%) 
5 (13%) 
 
 
10 (26%) 
 
24 (61%) 
 
 
P≤ ≤ ≤ ≤0.05 
 
 
 
Χ Χ Χ Χ²=6.17 
Mean Time to 
admission±SD 
285mins± ± ± ±268mins  462mins± ± ± ±442mins  P<0.001 
Mean 
NIHSS±SD  
9± ± ± ± 7  7± ± ± ± 4  ns 
Metabolic 
Syndrome 
16/23 (70%)  16/40 (40%)  p≤ ≤ ≤ ≤0.025 
 
Χ²=5.11 
 Table 6.8 Underlying abnormalities in glucose metabolism and metabolic syndrome relative to 
patients defined as having Hyperglycaemia on initial or subsequent testing within the 48hour-
screening period. (One patient included had incomplete data for definition of glucose tolerance 
state, but was included in defining the metabolic syndrome population). CBG: capillary blood 
glucose. Differences in mean time and NIHSS measured using the student t-test. The percentage 
breakdown for abnormalities in glucose metabolism and metabolic syndrome compared for 
admission hyperglycaemia and late hyperglycaemia using the chi-squared test.    185 
When baseline capillary blood glucose profiles were examined for patients 
who subsequently underwent OGTT, complete profiles were available for 30 
patients. Twenty patients had normal glucose metabolism with 10 patients 
having abnormal glucose metabolism (one with impaired fasting glucose, five 
with  Impaired  Glucose  Tolerance  and  four  with  Diabetes  Mellitus).  In 
contrast to patients with normal glucose metabolism where mean glucose fell 
in  the  first  24hours,  patients  with  dysglycaemia  had  an  initial  increase  in 
mean glucose in the first 8hours, prior to a similar decline reaching a nadir at 
24hours.    Both  populations  demonstrated  an  increase  in  blood  glucose 
between 24 and 48hours (Figure 6.7).  
 
Baseline temporal mean capillary blood glucose profiles for those patients with 
OGTT results available (n=30) 
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Figure 6.9: Capillary blood 
Glucose (mean±SEM) 
profiles for patients at the 
time of admission divided on 
the basis of OGTT results at 
screening.   186 
6.5 Discussion 
Post-stroke  hyperglycaemia  is  more  common  than  previously  suggested 
when  repeated  blood  glucose  monitoring  is  performed  in  the  early  acute 
stroke  phase.    Sustained  or  isolated  hyperglycaemia  affected  more  than 
70%  of  stroke  patients  screened  following  admission  to  our  stroke  unit. 
Blood  glucose  concentration  was  influenced  by  time  from  ictus,  stroke 
severity,  prior  glycaemic  status  and  feeding  status,  with  complex  and 
sometimes  counter-intuitive  relationships  between  factors.  The  results 
presented need to be interpreted in the context of the study protocol and its 
real  time  recording  within  an  acute  stroke  service.  Confounding  factors 
include  lack  of  additional  glucometer  calibration  outside  the  routine  ward 
protocol, a deficiency in reported quality monitoring and assessment of intra 
and inter-rater observations. The reproducibility of isolated hyperglycaemia 
needs  to  be  considered  relative  to  feeding  status  at  the  time  of  the 
measurement.  Many  of  the  inconsistencies  in  cited  prevalence  rates  in 
previous literature may be explained in part by our findings.  In addition to 
the high prevalence of acute post-stroke hyperglycaemia, we also found a 
high  prevalence  of  impaired  glucose  tolerance,  diabetes  mellitus  and 
metabolic syndrome. This finding raises the importance of dysglycaemia to 
PSH and its possible contribution to a worse stroke outcome.  An additional 
aspect of this finding is the identification of patients who may benefit from 
additional secondary preventative measures.     
   187 
Prevalence rates for PSH are generally quoted on the basis of single blood 
glucose  measurements.  Observational  studies  examining  the  association 
between  hyperglycaemia  and  stroke  outcome  have  routinely  not 
documented repeated measures as part of the study methodology. Only five 
of  the  clinical  studies  included  in  the  systematic  review  by  Capes  et  al 
described routine attempts to profile the blood glucose over time.
58;64;65;68;74 
A more recent study has added to our understanding of the temporal profile 
of glucose by using a subcutaneous monitor over a 72-hour period.
96 Blood 
glucose  was  shown  to  increase  within  12hours  of  ictus,  then  decrease 
reaching a nadir at 14 hours with a further peak at 66-88hours.
74;95;96 Only 
one  study  has  identified  patients  within  six  hours  of  acute  stroke  but 
inconsistencies  in  the  measurement  of  the  blood  glucose  may  refute  the 
generalised increase in blood glucose over the desired time period.  In the 
study by Christensen et al, the median time to initial blood glucose testing 
was  2.5  hours  (IQR  1.6,4.0)  with  the  second  blood  glucose  tested  at 
3.2hours  (2.0,5.2).
74  Blood  glucose  analysis  was  performed  using  two 
separate methods, which may explain discrepancies in the blood glucose 
results. The consistent measurement methodology used for blood glucose 
monitoring in our study was a positive aspect, with blood glucose relatively 
constant within the first four to eight hours and then reducing to a nadir at 
12hours.  These results are similar to previous published work which also 
used  consistent  repeated  measures.
96  If  blood  glucose  does  remain 
relatively constant within the first eight hours post ictus, it is hypothesised   188 
that blood glucose on admission reflects underlying  glycaemic or diabetic 
status. This was confirmed from our population when admission HbA1c was 
found to be significantly lower in patients with euglycaemia at presentation 
and also throughout the entire monitoring period. 
 
Although the study’s aim did not focus on stroke outcomes, identification of 
hyperglycaemia predictors is important in deciphering the controversy that 
continues  to  exist  surrounding  its  poor  prognostic  association.  The 
suggestion  that  hyperglycaemia  is  purely  an  epiphenomenon  of  stroke 
severity is not consistent.  PSH is prevalent across all clinical sub-types and 
severities  of  stroke  and  is  not  just  restricted  to  those  most  severely 
affected.
71  Serum cortisol has been shown to correlate with stroke severity, 
blood glucose and temperature and be an independent predictor of short-
term outcome,
260 whilst plasma catecholamines associated with both stroke 
severity and hypertension were found to have no correlation with glucose.
68 
In patients randomised to the National Institutes of Neurological Disorders 
and  Stroke  (NINDS)  trial  of  recombinant  tissue  plasminogen  activator  (rt-
PA), there was no correlation between blood glucose within three hours of 
stroke  onset  and  stroke  severity.
100  Abnormalities  in  glucose  metabolism, 
time to clinical presentation, fasting and blood sampling appear important.  In 
our own population, stroke severity was higher in patients with euglycaemia 
when  compared  to  patients  with  hyperglycaemia.  This  was  consistent  for 
both  admission  hyperglycaemia  and  for  patients  who  manifest   189 
hyperglycaemia at some stage within the 48 hours. Interestingly, mean blood 
glucose was significantly lower in patients with more severe strokes when 
compared to the milder stroke population at 48 hours. This can be explained 
on the basis of feeding with the more severe stroke patients remaining nil by 
mouth throughout the monitoring period.   
Despite  the  neutral  result  from  the  recently  published  GIST-UK  study,
156 
maintenance of euglycaemia may present a challenge if future stroke trials 
show benefit of glucose lowering therapy.  Maintenance of euglycaemia in 
populations with variable oral intake and the expected post-prandial variation 
presents  a  greater  challenge  than  for  patients  with  targeted  parenteral 
nutrition as seen in the ICU population.
261 This variation in blood glucose has 
seen adjustment of insulin scales to coincide with meals and prolonged fasts 
and thus be predictive not reactive.
181  
 
In  patients  with  presumed  “stress  hyperglycaemia”,  we  found  a  high 
prevalence of impaired glucose tolerance, impaired fasting glucose, diabetes 
mellitus  and  metabolic  syndrome.    The  cited  point  prevalence  for  “stress 
hyperglycaemia” in studies is between 5.7% to 32%
55;66 depending on the 
diagnostic  criteria  and  population  studied.   Patients  previously  defined as 
having relatively normal HbA1c levels and deemed to have hyperglycaemia 
secondary  to  the  stressful  insult  are  likely  to  have  had  underlying 
abnormalities in glucose metabolism.  Thirty-seven percent of patients with 
HbA1c levels 5.0% to 5.4% were found to have abnormal glucose tolerance   190 
(32% had either IGT or isolated IFG and 5% had Type 2 diabetes mellitus)
262 
when  screened  following  a  stroke  or  TIA.    Fasting  Blood  glucose  levels 
>5.6mmol/l in patients with pre-existing atherothrombotic disease has been 
shown  to  increase  the  risk  of  cerebral  ischaemic  events.
83  For  patients 
recruited to the Dutch TIA trial with TIA or minor stroke, stratified on the 
basis  of  non-fasting  blood  glucose  with  impaired  glucose  tolerance  (IGT) 
defined  as  a  random  blood  glucose  7.8-11.0mmol/l,  the  risk  of  recurrent 
stroke  was  nearly  doubled  in  patients  with  IGT  compared  to  those  with 
normal  blood  glucose  levels  (hazard  ratio  1.8,  95%CI  1.1  to  3.0).
263  Of 
patients recruited to the Glucose tolerance in Patients with Acute Myocardial 
Infarction (GAMI) study with OGTT performed prior to discharge, 67% had 
abnormal glucose tolerance.  The probability of patients remaining free from 
cardiovascular events (Heart Failure, Re-infarction, Stroke or cardiovascular 
death) was significantly higher in patients with normal rather than abnormal 
glucose  tolerance  (p=0.002).
264  The  exact  mechanism  by  which  impaired 
glucose tolerance contributes to increased risk is not completely understood 
but  it  has  been  shown  to  alter  platelet  function  and  accelerate 
atherosclerosis.
265;266 The prevalence of metabolic risk factors including low 
HDL-cholesterol and elevated systolic blood pressure has been reported to 
increase linearly according to post-challenge glucose concentration.
267  
 
The recognition of mild to moderate hyperglycaemia in the setting of acute 
stroke  is  both  a  prognostic  indicator  of  stroke  outcome  and  a  potential   191 
predictor of abnormal glucose metabolism.  In 62 patients screened at three 
months following an acute ischaemic stroke and admission blood glucose ≥ 
6.1mmol/l,  21%  had  diabetes  mellitus  and  37%  had  impaired  glucose 
tolerance.  A blood glucose ≥6.1mmol/l and HbA1c ≥6.2% on admission was 
found to have an 80% positive predictive value for diabetes at 12 weeks.
90  
In our own study, patients were eligible if CBG was >7.0mmol/l at any stage 
within the 48hour monitoring period.  Results demonstrated a similar overall 
diabetes prevalence of 21%.  However, when patients with only admission 
hyperglycaemia  were  considered,  36%  had  diabetes  with  a  further  32% 
having impaired glucose metabolism or impaired fasting glucose.  Thirty-nine 
percent of patients initially euglycaemic but demonstrating hyperglycaemia 
following admission had abnormal glucose metabolism.  Similar figures were 
obtained  for  metabolic  syndrome,  being  present  in  70%  of  patients  with 
admission hyperglycaemia and 40% of patients with late hyperglycaemia.  
 
One possible explanation for the discrepancy in screening results between 
early  and  late  hyperglycaemia  relates  to  time of presentation.  Despite no 
statistical  difference  in  stroke  severity  at  presentation,  patients  with 
hyperglycaemia on admission presented earlier at 4.8±4.5hrs compared to 
the 7.7±7.4hrs in patients with late hyperglycaemia.  Our understanding of 
the temporal profile of blood glucose has confirmed that blood glucose tends 
to  fluctuate  with  a  nadir  between  12  and  24  hours,  before  re-feeding 
commences and thus explaining the subsequent peak.
96 Presentation during   192 
this period may miss the elevated blood glucose excursions and emphasises 
the  importance  of  repeated  screening.    An  additional  explanation  for  the 
development of late hyperglycaemia relates to the impact of feeding.  Post-
prandial  glucose  levels  are  known  to  increase  earlier  than  fasting  blood 
glucose levels for the same value of HbA1c, as individuals progress towards 
diabetes.
268  A  late  hyperglycaemic  phase  has  been  detected  in  patients 
undergoing  serial  blood  glucose  screening,  with  diabetes,  insular  cortex 
involvement and age being identified as predictors, although the authors do 
comment  that  their  results  could  not  negate  a  role  for  feeding  in  its 
development.
96 Difficulties in the use of capillary blood glucose monitoring 
for serial monitoring relate to preparation, analytical method and timing of the 
sample.  CBG testing has been shown to underestimate fasting or random 
samples  and  overestimate  two-hour  post  glucose  ingestion  loading  when 
compared to venous sampling.
269  The study’s protocol specified four-hourly 
CBG monitoring but did not clarify the timing of the test relative to oral intake 
and  as  such  erratic  blood  glucose  values  may  reflect  post-prandial 
excursions.  
 
Reliance  on  a  single  fasting  blood  glucose  sample  in  the  convalescent 
period would not have sufficed as an appropriate screening method in our 
population.  Fifteen patients with normal fasting glucose at follow-up were 
found  to  have  impaired  glucose  tolerance  or  diabetes  on  post-prandial 
testing of which four patients with diabetes would have been misclassified as   193 
normal.    Post-prandial  hyperglycaemia  is  a  recognised  predictor  of 
cardiovascular risk.  In the Diabetes Epidemiology: Collaborative Analysis of 
Diagnostic criteria in Europe study (DECODE), two-hour serum glucose level 
predicted  increased  all  cause  mortality  and  was  a  better  predictor  than 
fasting  glucose.
270  Following  Myocardial  Infarction  (MI),  abnormal  glucose 
tolerance  was  the  second  strongest  predictor  after  previous  MI  for  future 
cardiovascular  events  (hazard  ratio  4.18;CI  1.26-13.84;p=0.019).
264 
Extrapolation  of  these  results  would  advocate  the  use  of  OGTT  as  a 
screening method in the high risk stroke population.  The test results in our 
study were based in the majority on single assessment measurement.  As 
per local guidelines, testing should be repeated to confirm or disprove the 
biochemical findings. The study development and recruitment did not involve 
repeated  assessment  but  the  primary  care  physician  of  the  patients  with 
abnormal results were informed and advised about appropriate follow-up.  
 
One  criticism  reflecting  the  logistics  of  the  study  is  that  almost  45%  of 
patients screened had a lacunar stroke syndrome at initial presentation.  In 
the European BIOMED stroke study, diabetic patients were more likely to 
have lacunar infarction when compared to non-diabetic groups (p=0.03).
271  
Our results, based on a study sample with a high proportion of patients with 
lacunar  infarction,  may  overestimate  the  overall  prevalence  of  abnormal 
glucose metabolism and may not be applicable to a typical stroke population. 
It was not feasible due to swallowing difficulties, significant comorbidity or   194 
interim mortality to include larger proportions of patients with total syndromes 
(TACS).  The reproducibility of our trial data to populations outside the UK 
also  has  to  be  considered.    In  the  Oxford  Stroke  Community  Project 
(OCSP)
243 and the Oxford Vascular study (OXVASC)
272 the prevalence of 
established diabetes was 10.5% and 9.5% respectively.  In the North East 
Melbourne Epidemiological and Stroke Incidence Study (NEMESIS)
273 it was 
19%, similar to the 18% in our own population, but much less than the 36% 
seen in the Northern Manhattan Stroke Study (NOMASS)
274.   
 
The unadjusted relative risk of in-hospital or 30-day mortality associated with 
admission glucose levels ≥6.0 to 8.0mmol/l has been estimated at 3.07 (95% 
CI, 2.50 to 3.79) in non-diabetic patients and 1.30 (95% CI, 0.49 to 3.43) in 
diabetic patients.
236 Extrapolation of these results may suggest that a label of 
diabetes  on  admission  ensures  repeated  blood  glucose  monitoring  and 
correction with insulin or oral hypoglycaemics.  In a retrospective study of 
patients admitted with thrombo-embolic stroke, glycaemic control defined as 
normalisation of blood glucose to <7.2mmol/l was associated with a 4.6 fold 
decrease  in  mortality  risk  as  compared  to  patients  with  persistent 
hyperglycaemia  (Blood  Glucose  ≥7.2mmol/l)(p<0.001).
176  As  our  study 
demonstrates,  21%  of  patients  with  stress  hyperglycaemia  had  unknown 
diabetes and therefore interventions and monitoring would not have been 
routinely undertaken. We would advocate that repeated monitoring of blood 
glucose  in  patients  admitted  with  stroke  is  required.    Detection  of   195 
hyperglycaemia  on  admission  is  a  predictor  of  abnormal  glucose 
metabolism.    Detection  of  such  hyperglycaemia  demands  the  need  for 
follow-up  upon  discharge  to  confirm  or  disprove  abnormalities  of  glucose 
metabolism.  The detection of impaired glucose tolerance is important, as 
several trials have looked at intervening and preventing the development of 
diabetes.    In  the  US  diabetes  prevention  program,  an  intensive  lifestyle 
intervention  among  persons  with  IGT  reduced  the  incidence  of  diabetes 
compared  to  placebo  by  58%.
275  Non-lifestyle  measures  have  also  been 
used  with  acarbose  (an  ∝-glucosidase  inhibitor)  with  reduction  in  major 
cardiovascular events by 49% in persons with impaired glucose tolerance in 
the Study to prevent Non Insulin Dependent Diabetes Mellitus trial (STOP-
NIDDM). 
276  
 
6.6 Conclusion 
Post Stroke Hyperglycaemia is common. Repeated blood glucose measures 
will  result  in  the  detection  of  a  higher  proportion  of  patients  with  PSH.  
Understanding its aetiology is vital in deciphering the need for intervention 
and  a  possible  role  in  manipulating  stroke  outcome.  Our  study  does  not 
support hyperglycaemia being an epiphenomenon of stroke severity.  We 
found no association between the development of PSH and stroke severity, 
measured  using  the  NIHSS.  In  contrast  hyperglycaemia  was  found  to  be 
dependent on underlying glycaemic status, being influenced by undiagnosed 
dysglycaemia  and  manifest  through post-prandial  rises.  Knowledge  of  the   196 
effect  of  fasting  on  blood  glucose  lowering  and  its  possible  role  on  the 
ischaemic  brain  may  encourage  earlier  feeding  in  more  severe  strokes. 
Alternatively  post-prandial  hyperglycaemia  provides  a  possible opportunity 
for dietetic adjustment. Detection of PSH justifies further screening in the 
high risk stroke population to establish the presence of abnormal glucose 
metabolism and the need for further secondary risk prevention. 
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Chapter 7: Insular Cortex 
ischaemia as a predictor of 
hyperglycaemia 
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7.1 Introduction 
 
Various theories have been proposed to explain the aetiology of post stroke 
hyperglycaemia  (PSH).    Unmasking  of  abnormalities  in  glucose 
metabolism,
90  an  epiphenomenon  of  stroke  severity
74  or  a  site  specific 
response  independent  of  severity  have  all  been  suggested.
101  
Understanding of the pathophysiological process underlying hyperglycaemia 
is important in deciding on its management in the acute setting.   
 
Early animal studies have reported a possible relationship between reactive 
hyperglycaemia  and  brain  injury  location.    Original  work  by  the  French 
physician  Claude  Bernard  described  transient  hyperglycaemia  and 
glycosuria, following induction of a lesion in the floor of the fourth ventricle of 
an experimental rabbit as cited in the paper on reactive hyperglycaemia by 
Melamed.
53  In  a  subsequent  experiment  pituitary  injury  in  fasted  rabbits 
resulted  in  an  immediate  and  marked  hyperglycemia.
277  More  recent 
experimental  and  clinical  work  has  suggested  the  insular  cortex  as  an 
anatomical location within the brain that may influence the sympathoadrenal 
response and by extrapolation stimulate PSH.
101;102   
 
The  insular  cortex  has  autonomic  efferent  projections  and  it  has  been 
proposed  that  it  exerts  a  tonic  sympathoinhibitory  tone  on  autonomic 
brainstem centres.  Damage through ischaemia is thought to result in loss of 
the disinhibition, with clinical studies demonstrating increased sympathetic   199 
activity reflected by cardiac arrthymias.
278  In animal studies these effects 
are  lateralised  but  distinct  effects  of  right  and  left  insular  infarction  are 
inconsistently reported in clinical studies.
279 
 
In a recent MRI study of 31 patients within 24 hours of acute stroke, insular 
cortical ischemia was an independent predictor of glucose level (p=0.001), 
with the relationship being independent of pre-existing glycaemic status and 
infarct volume.
101 The results have not been confirmed in larger population 
studies using CT as the imaging modality.
280;281 The poorer sensitivity of CT 
in detecting acute ischaemia has been suggested as a possible explanation 
for the difference in results.   
 
We sought to examine the association between insular cortical ischaemia 
and  post  stroke  hyperglycaemia  in  a  larger  data  set  by  combining  two 
studies that used MR surrogate measures.  The aim of  the study was to test 
the hypothesis that acute ischaemia of the insular cortex is associated with 
the development of post stroke hyperglycaemia.  In addition we sought to 
establish  the  influence  of  lateralisation  on  the  development  of 
hyperglycaemia. 
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7.2 Methods 
 
Studies Selected 
 
Access  was  obtained  to  the  data  set  for  (a)  the  multi-centre  MR  Images 
subset of the IMAGES (Intravenous Magnesium Efficacy in Stroke) trial
33, a 
neuroprotectant  trial  examining  the  effect  of  intravenous  magnesium 
sulphate  on  death  or  disability  at  90  days  and  (b)  the  single  centre 
SELESTIAL  trial  (Spectroscopic  Evaluation  of  Lesion  Evolution  in  Stroke: 
Trial  of  Insulin  for  Acute  Lactic  acidosis  -  a  trial  examining  the  effect  of 
insulin  in  the  form  of  a  GKI  infusion  on  lactate  levels  and  lesion  volume 
progression in acute stroke; see Chapter 5 ). 
 
Both studies were randomised placebo controlled trials.  Time to imaging 
and  study  infusion  differed  with  MR-IMAGES  recruiting  patients  up  to  12 
hours from ictus and SELESTIAL 24 hours.  Repeat imaging was performed 
at 90days for MR-IMAGES and at days three and seven for SELESTIAL.  
Hyperglycaemia,  defined  as  a  capillary  blood  glucose  greater  than  seven 
millimoles per litre, was a necessary inclusion criteria for SELESTIAL.  
 
Clinical data 
 
 
Baseline data recorded included age, gender, stroke severity as measured 
using NIHSS, stroke classification (OCSP),
243 admission blood glucose, risk 
factor profile and documented history of diabetes.  Time to MRI scan from 
ictus was also documented.  The definition of hyperglycaemia for this study   201 
was  a  blood  glucose  of  greater  than  or  equal  to  eight  mmol/l,  to  be 
consistent with the original definition in the study by Allport et al.
101 Timing of 
admission blood glucose in the MR-IMAGES study was recorded as the time 
that coincided with the initial MRI. For the purposes of the study and in the 
absence  of  data  on  glycosylated  Haemoglobin  (HbA1c),  “stress 
hyperglycaemia”  was  defined  as  hyperglycaemia  in  patients  with  no 
documented history of diabetes. 
 
Image analysis 
 
The lesion volumes were interpreted by MMcC. Scans were anonymised and 
interpreted blinded to clinical data .  MRI scans were performed using a 1.5 
or  3.0  Tesla  scanner,  dependent  on  availability  in  respective  centres.   
Anonymised  data  sets  were  transferred  to  a  workstation  and  Diffusion 
Weighted Imaging (DWI) lesion volumes were measured using the cheshire 
software  package  (Perceptive  Informatics,  PAREXEL,  USA).    Following 
delineation of the lesion by the reader, a semi-automated method was used 
to define lesion borders on each slice.  Further manual refinement of each 
slice  produced  the  final  lesion  volume.    The  lesion  volume  was  then 
calculated automatically and expressed in mm
3.  This was then adjusted for 
tabulation  to  cm
3.    Following  lesion  volume  measurements,  scans  were 
reexamined  and  DWI  involvement  of  the  insular  cortex  and  hemisphere 
affected was recorded.  The insular cortex was defined anatomically as the 
region of cortical gray matter at the base of the Sylivian fissure medial to the   202 
frontoparietal and temporal opercula consistent with the definition used by 
Allport et al. Insular cortex involvement was described as present (IC+) or 
absent (IC-). The insular cortex was further subdivided on the basis of the 
flow void in the middle cerebral artery into anterior and posterior portions.  
 
Statistical Analysis  
All statistical analysis was performed using SPSS (version 13.0).  Risk factor 
profile,  hemisphere  involvement  and  insular  cortex  entire,  anterior  or 
posterior involvement were described as percentages and compared across 
groups  using  the  chi-squared  or  Fishers  exact  test  as  appropriate.  
Measures  of  stroke  severity,  blood  glucose  and  lesion  volumes  were 
expressed in medians with interquartile ranges and compared using Kruskal-
Wallis test.  For blood glucose as a continuous variable, univariate general 
linear models were used.  When dichotomised into hyperglycaemia or not 
hyperglycaemia,  biniary  logistic  regression  was  used  with  multivariate 
analysis in a forward regression model.  
 
7.3 Results 
 
Baseline clinical data was available for 98 patients from MR-Images and 40 
patients in the SELESTIAL study.  Two patients in the MR-Images data set 
had no documented admission glucose and a further 22 patients had MR 
scans from the available data set that were not able to be analysed using the 
software.    The  SELESTIAL  data  set  was  complete,  giving  a  total  study   203 
population  of  114  patients.  The  consort  chart  below  demonstrates  the 
breakdown of the combined data set, with further subdivision dependent on 
glycaemic status (figure 7.1) 
 
 
Combined Data Set 
138 Patients 
Study population 
114 Patients 
No admission glucose in 
2 patients 
Unable to measure DWI 
lesion volumes in 22 
patients 
Post Stroke Hyperglycaemia 
39% (45/114) 
Euglycaemia 
61% (69/114) 
Hyperglycaemic 
Diabetics 
21% (24/114) 
Stress 
Hyperglycaemia 
18% (21/114) 
 
Euglycaemic 
Diabetics 
13% (15/114) 
 
Euglycaemic Non-
Diabetics 
47% (54/114) 
 
 
 
Figure 7.1: Consort chart demonstrating breakdown of patients from SELESTIAL and MR-
Images combined into diabetes, stress hyperglycaemia and Euglycaemia. Values expressed 
as percentages with actual numbers in brackets.  
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Post stroke hyperglycaemia (>8mmol/l) was present in 45 of 114 patients 
(39%).    Of  those  patients  with  PSH,  24  had  a  pre-existing  diagnosis  of 
diabetes,  accounting  for  21%  of  the  study  population.    “Stress 
hyperglycaemia”  was  present  in  18%.  Euglycaemic  diabetics  and  non-
diabetics  accounted  for  the  remaining  13%  and  47%  of  the  sample 
respectively.    Hyperglycaemia  was  present  on  admission  in  18/48  (38%) 
patients with left hemisphere strokes and 27/66 (41%) with right hemisphere 
strokes  
 
Insular Cortical Ischaemia 
The median admission blood glucose was similar for patients with insular 
cortex  involvement  (IC+)  (7.1mmol/l)  compared  to  those  without  insular 
involvement  (IC-)  (7.3mmol/l).    Both  median  stroke  severity  (NIHSS)  and 
acute lesion volume measurements were significantly higher in patients IC+ 
compared  to  those  IC-  (Table  7.1).    The  prevalence  of  diabetes  and 
hypertension  were  similar  in  both  groups,  with  atrial  fibrillation  being 
significantly higher in the IC+ group than the IC- group (35% versus 11%).  
 
In those patients with insular involvement the incidence of hyperglycaemia 
was 37% (19/52).  For  patients with “stress hyperglycaemia” proportions for 
IC+(17%)  and  IC-(19%)  were  similar.   When  comparing  hemispheres  the 
proportion  with  hyperglycaemia  were  similar  -  6/18  patients  left  sided 
IC+(32%) and 13/34 patients right sided IC+ (38%) (Table 7.2).    205 
 
  Total 
 
(n=114) 
Insular 
Cortex 
negative 
(n=62) 
Insular 
Cortex 
positive 
(n=52) 
p 
Age 
 
71 (23-98)  71 (41-98)  72 (23-91)  0.873 
Right 
Hemisphere 
58%  52%  65%   
Pre-existing 
Diabetes 
39 (34%)  21 (34%)  18 (35%)  0.545 
Hypertension  81 (72%)  42 (68%)  39 (75%)  0.261 
Atrial Fibrillation  25  (22%)  7 (11%)  18 (35%)  0.003 
Hyperglycaemia  45 (39%)  26 (42%)  19 (37%)  0.347 
Admission 
Blood Glucose 
7.3 (3.4-22.0)  7.1 (3.4-22.0)  7.3 (4.4-19.1)  0.674 
Hyperglycaemia  45 (39%)  26 (42%)  19 (37%) 
Stress 
Hyperglycaemia 
21 (18%)  12 (19%)  9 (17%) 
 
Χ²=0.605 
 
0.605 
NIHSS  11 (2-28)  7 (2-22)  16.5 (4-28)  <0.001 
NIHSS (0-6)  
Mild 
33 (29%)  30 (48%)  3 (6%) 
NIHSS (7-15) 
Moderate 
46 (40%)  25 (40%)  21(40%) 
NIHSS (>15) 
Severe 
35 (31%)  7   (11%)  28 (54%) 
 
 
Χ²=61.11 
 
P<0.001 
 
LACS  33 (29%)  31 (50%)  2 (4%) 
PACS  32 (28%)  17 (27%)  15 (29%) 
POCS  3 (3%)  3 (5%)  0 
TACS  46 (40%)  11 (18%)  35 (67%) 
 
 
Χ²=61.11 
 
 
P<0.001 
DWI Lesion 
Volume 
5.9 (0.03-
349.76) 
1.29 (0.03-
83.27) 
14.7 (1.09-
349.76) 
<0.001 
   
Table 7.1: Patient characteristics, baseline stroke severity, lesion volume 
measurements and stroke classification. Data expressed as total numbers 
(percentages) and median (range). Comparison made between insular 
cortex negative and positive groups. 
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  Right Insular 
Cortex (IC+) (n=34) 
Left Insular Cortex 
(IC+) (n=18) 
p 
Stress 
Hyperglycaemia  7 (21%)  2 (11%)  0.224 
Diabetes 
  11 (32%)  7 (39%)  0.431 
Atrial Fibrillation 
  10 (29%)  8 (44%)  0.218 
Hypertension 
  23 (68%)  16 (89%)  0.086 
Median Age (Range) 
  74 (39-91)  68 (23-83)  0.370 
Median NIHSS 
(Range) 
 
14 (4-24)  18.5 (5-28)  0.049 
Median Blood 
Glucose (Range) 
 
7.4 (4.4-19.1)  7.3 (5.4-11.7)  0.962 
Median DWI lesion 
volume (cm³) 
(Range) 
16.2 (1.1-349.8)  11.8 (1.8-240.6)  0.908 
 
Table 7.2: Comparison of insular cortex involved patients relative to affected hemisphere. 
Values expressed as percentages or medians with ranges. Groups compared using Chi-
square or Mann-Whitney U test.  
 
Insular  Cortex  involvement  was  further  classified  into  entire  involvement, 
posterior involvement or anterior involvement.  Only one patient had solitary 
anterior involvement and was normoglycaemic (blood glucose 6.3) (Figure 
7.1). The proportion with hyperglycaemia for the remaining groups were 37% 
(14/38) in the entire IC+ involvement and 39% (5/13) in the posterior IC+ 
group.  When studying the risk factor breakdown for both the posterior IC+ 
and the entire IC+ groups the proportion with AF (atrial fibrillation) was 38% 
and  34%  respectively,  hypertension  85%  and  71%  respectively  and  for 
diabetes 31% and 37% respectively (Table 7.3).  
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  Entire IC+ 
(n=38) 
Posterior IC+ 
(n=13) 
p 
Stress 
Hyperglycaemia  5 (13%)  4 (31%)  0.118 
Diabetes 
  14 (37%)  4 (31%)  0.483 
Atrial Fibrillation 
  13 (34%)  5 (38%)  0.587 
Hypertension 
  27 (71%)  11 (85%)  0.282 
Median Age  
(Range)  73 (23-91)  69 (55-91)  0.449 
Median NIHSS 
(Range)  18 (5-28)  12 (7-20)  0.01 
Median Blood 
Glucose (Range)  7.4 (4.4-19.1)  7.3 (5.4-10.3)  0.837 
Median DWI lesion 
volume (cm³) 
(Range) 
17.6 (1.1-349.8)  9.3 (1.3-107.6)  0.173 
 
Table 7.3: Comparison of insular cortex involvement dependent on posterior or entire 
involvement. Values expressed as percentages or medians with ranges. Groups compared 
using Chi-square or Mann-Whitney U test. 
 
 
 
 
 
 
Figure 7.2: Diffusion weighted images. (A) Entire Insular cortex involved (B) posterior 
insular cortex involved and (C) preservation of the insular cortex.   
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Stroke severity and Blood Glucose 
There  was  a  correlation  between  admission  NIHSS  and  admission  DWI 
lesion volume (Spearman P =0.530, p<0.001) (Figure 7.3).   
Figure 7.3 Scatterplot of admission lesion volume against NIHSS score 
 
There was also a correlation between NIHSS at presentation and admission 
blood glucose  (Spearman P =0.228, p=0.015) (Figure 7.4).  
 
Figure 7.4 Scatterplot of admission NIHSS score against blood glucose 
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There  was  no  correlation  between  lesion  volume  and  admission  blood 
glucose (Spearman P =0.125, p=0.185) (Figure 7.5).     
 
Figure 7.5 Scatterplot of admission lesion volume against blood glucose 
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Hyperglycaemia Predictors  
 
Binary  logistic  regression  including  insular  cortex  involvement,  entire  or 
posterior  cortex  involvement,  NIHSS,  Age,  history  of  diabetes  and  stroke 
lateralisation were used in a multivariate model to establish   predictors of  
hyperglycaemia  on  admission.  The  only  significant  factor  in  predicting 
hyperglycaemia was an established diagnosis of diabetes (OR4.11. 95% CI 
1.81, 9.33; p=0.001). Neither insular cortex involvement nor more specific 
posterior insular involvement was predictive of admission hyperglycaemia or 
stress hyperglycaemia.  
 
7.4 Discussion 
 
In contrast to the study by Allport et al which had shown that ischaemia of 
the  insular  cortex  may  contribute  to  post  stroke  hyperglycaemia  (PSH), 
independent of DWI infarct volume, pre-existing glycaemic status and clinical 
stroke  severity  we  were  unable  to  demonstrate  similar  results  in  a  larger 
group of patients taken from two randomised placebo controlled trials.
101 
Evidence favouring the role for the insula in mediating a sympatho-adrenal 
response has been derived primarily from animal models. The insular cortex 
has been shown to be an important part of the central autonomic system, 
with  interconnections  to  subcortical  autonomic  centres  including  the 
hypothalamus.    Insular  cortex  stimulation  has  resulted  in  alterations  in 
catecholamine responses and cardiac arrhyhmias
102;282;283 In clinical studies 
involving stroke patients, insular involvement has been associated with ECG   211 
abnormalities and myocardial injury
278. Effect of lateralisation on autonomic 
function  has  been  demonstrated  in  studies  undertaken  in  patients  with 
epilepsy.  Stimulation of the left insula led to bradycardia and hypotension in 
five  patients  with  the  opposite  effect  in  patients  with  right  sided 
stimulation
284.  The effect of lateralisation has not been consistent across 
studies since numbers studied have been relatively small.  One explanation 
for this is that strokes localised to the insular cortex are relatively uncommon 
with only four cases from a registry of 4,800 patients being admitted over a 
10  year  period
285.    The  undoubted  sympathetic  response  that  has  been 
demonstrated  in  both  experimental  and  clinical  studies  is  sufficient  to 
suggest that the exaggerated stress response may result in hyperglycaemia. 
Activation  of  the  hypothalamic-pituitary-adrenal  axis  is  central  to  the 
neuroendocrine  stress  reponse  and  forms  the  basis  of  the  suggested 
hypothesis that PSH is an epiphenomenon of stroke severity.
286 It is also 
plausible although not confirmed in our study that a site specific lesion may 
result in an inflated stress response with an increase in catecholamines and 
cortisol.  Clinical evidence to support an exaggerated response has been 
conflicting.  Serum cortisol has been shown to
74 correlate with stroke severity 
and blood glucose whereas plasma catecholamines were found to have no 
relationship  with  admission  glucose.
68    In  our  study,  we  found  a  weak 
correlation between stroke severity and admission blood glucose. 
Further studies trying to reproduce the findings by Allport et al using CT have 
failed.    In  a  retrospective  review  of  patients  receiving  thrombolysis  within   212 
three hours of stroke ictus registered with the Canadian activase for stroke 
effectiveness  study  (CASES),  pretreatment  hypertension  but  not 
hyperglycaemia  was  predicted  by  insular  ischaemia  in  univariate  linear 
regression.  This predictive effect was lost when additional factors were used 
in multivariate regression.
281 One reason for the discrepancy suggested by 
the authors relates to early blood glucose analysis and imaging.  The data 
from the CASES series was within three hours of ictus, whereas patients in 
the MR study were imaged at a median of 13hours (range 3-23) with blood 
glucose analysis at a median of 7.5 and 13hours for IC+ and IC- patients 
respectively.
101  Blood glucose is known to increase within the first 12 hours 
of stroke onset and that this increase is associated with stroke severity.
74 A 
lack of an association with blood glucose in this study may be explained by 
the  hyperacute  presentation  with  the  admission  blood  glucose 
underestimating a higher blood glucose secondary to a delayed sympathetic 
response. In a study examining the effect of insular cortex involvement on 
ECG  abnormalities,  there  was  found  to  be  no  difference  in  ECG 
abnormalities  on  admission
287,  whereas  earlier  work  had  confirmed  ECG 
changes up to 72hours from ictus
288. Contrary to the theory of a possible 
delay in sympathetic response, a study by our own group which examined 
the highest blood glucose within 72hours of stroke ictus found that insular 
cortex  hypoperfusion  within  3hours  of  ictus  was  not  predictive  of  the 
development of hyperglycaemia.
289 The impact of thrombolysis in altering the 
inflammatory response in our original CT study and the CASES series needs   213 
to be considered. No information was available on the thrombolysis status of 
patients recruited to the MR Images study. As reported earlier (Chapter 5) 
33% (13/40) of patients recruited to the SELESTIAL trial received rt-Pa. As 
numbers are small and the development of peak hyperglycaemia may have 
been affected by randomisation to placebo or GKI infusion further analysis 
was  not  undertaken.  Attenuated  inflammatory  response  has  been 
demonstrated  in  patients  showing  clinical  improvement  after  recombinant 
tissue plasminogen activator treatment.
290   Work by Christensen et al in 179 
patients with blood glucose measurements within six hours of stroke ictus 
undergoing CT imaging found that there was no difference in blood glucose 
between  non-insular  and  insular  involvement  and  again  no  difference 
between right or left sided insular involvement
280. Work by the same group 
found that cortisol levels did not relate to insular damage when examined as 
part of a multivariate analysis which included stroke severity on admission 
and early infarction signs on CT
238.  
 
It has previously been documented that insular lesions are associated with 
ECG  abnormalities  and  a  potential  relationship  to  cerebrogenic  sudden 
death has been cited.
282 Patients with  right sided insular infarcts were found 
to have significantly lower values for heart rate variability and more complex 
arrthymias when compared to controls.  When the same group examined 
this hypothesis in a later study both right sided insular involvement and the 
presence  of  non-sustained  ventricular  tachycardia  were  independent   214 
predictors  of  one  year  mortality.
278;288    Our  understanding  of  the  insular 
cortex  and  its  contribution  to  the  development  of  the  stress  response 
remains poorly understood.  Stimulation of the right insular cortex produces 
changes in blood pressure and heart rate with opposite effects occurring on 
stimulation  of  the  left  insular  cortex.
284  As  previously  documented,  right 
insular  cortex  involvement  is  associated  with  increased  incidence  of 
supraventricular tachycardia.  In our own patient population we found that 
the prevalence of atrial fibrillation was higher in patients with insular cortex 
involvement  when  compared  to  those  patients  without  insular  cortex 
involvement; however we could not find any statistically significant difference 
between respective hemispheres or between posterior versus entire insular 
cortex  involvement.    This  is  contrary  to  previous  studies  which  have 
demonstrated that posterior insular cortex involvement may be associated 
with a higher risk of developing atrial fibrillation after stroke.
291 
 
In comparison to previous studies patients with insular cortex involvement 
had worse stroke severity and also increased lesion volume measurements, 
but consistent with the work by Allport et al when this was controlled for, 
patients with purely posterior insular cortex involvement had similar glucose 
levels to patients with larger lesion volumes and more severe strokes. 
The  retrospective  nature  of  the  study  meant  that  the  timing  of  the  blood 
glucose is unlikely to have coincided exactly  with the MRI..In view of the 
temporal profile of glucose, knowledge of timing relative to stroke onset and   215 
imaging  is  important.  A  further  criticism  relates  to  the  definitions  of 
hyperglycaemia for the two sample populations. Although defined uniformly 
as  a  blood  glucose  ≥8.0mmol/l,  the  different  methods  of  sample  testing 
(capillary versus venous) ensured lack of uniformity in patient selection. It  
has  previously  been  demonstrated  that  magnesium  may  increase  blood 
glucose in experimental models of acute stroke but this is unlikely to have an 
effect  on  results  since  the  blood  glucose  was  taken  as  the  admission 
glucose  level  prior  to  magnesium  administration.
292  Access  to  the  MR-
Images  data  set  did  not  allow  access  to  information  on  infusion  type  for 
respective  study  participants.  Unfortunately  stress  hyperglycaemia  was 
defined on the basis of hyperglycaemia in the absence of an established 
diagnosis  of  diabetes  and  hence  fails  to  exclude  the  population  with 
undiagnosed abnormailities in glucose metabolism. Admission blood glucose 
may fail to detect hyperglycaemia if checked too early as we are now aware 
that blood glucose increases fluctuates within hours of onset.  
 
The association between atrial fibrillation and insular cortex involvement is 
similar to the cause or effect association betwen blood glucose and stroke 
severity and worse stroke outcome.  Does insular cortex involvement purely 
reflect  a  preponderance  of  non-lacunar  strokes,  where  the  mechanism  is 
cardio-embolic or artery-artery embolisation and thus reflects the aetiological 
mechanism as opposed to being the precipitant of the cardiac arrthymia?  
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7.5 Conclusion 
 
Understanding the mechanism underlying hyperglycaemia in acute stroke is 
important.  Damage  to  the  insular  cortex  is  plausible  as  a  site  specific 
hypthesis on the basis of experimental studies .  In contrast to an earlier MRI 
based study demonstrating insular ischaemia as an independent predictor of 
hyperglycaemia, we were unable to confirm the same results using similar 
methodolgy  in  a  larger  population.    Stroke  severity  and  admission  DWI 
lesion  volume  were  significantly  increased  in  patients  with  insular  cortex 
involvement  when  compared  to  those  without.  Atrial  fibrillation  was  more 
common as a risk factor in patients with confirmed insular infarction. The 
only  predictive  factor  for  the  development  of  hyperglycaemia  was  the 
presence of established diabetes.  Isolated localised brain injury is not an 
independent aetiological explanation for post stroke hyperglycaemia.   
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Chapter 8: Stroke unit 
management of hyperglycaemia 
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8.1 Introduction 
 
In  the  absence  of  supportive  trial  evidence,  the  management  of 
hyperglycaemia  in  acute  stroke  remains  uncertain.    Both  American  and 
European  guidelines  advise  management  of  hyperglycaemia,  with  the 
European stroke initiative (EUSI) recommending treatment for blood glucose 
greater  than  10mmol/l
293  and  the  recently  updated  American  guidelines 
lowering the blood glucose threshold for intervention from 16.63mmol/l
142 to 
>11.0mmol/l.
46  The potential benefit if any from tight blood glucose control 
with  insulin  in  acute  stroke  has  been  extrapolated  from  trial  evidence 
obtained in both cardiac and intensive care unit populations.
148;294 The only 
trial specifically examining the effect of insulin in an acute stroke population 
found  no  benefit  for  insulin  in  the  form  of  a  glucose-potassium-insulin 
infusion  administered  within  24hours  of  ictus  over  placebo  on  short-term 
stroke outcome.
156 
 
Despite a lack of evidence for a benefit from blood glucose control, it is well 
established  that  post-stroke  hyperglycaemia  is  associated  with  a  worse 
stroke  outcome.    A  systematic  review  of  thirty-two  studies  examining  the 
effect of hyperglycaemia on mortality and/or functional recovery found that 
the unadjusted relative risk of in-hospital or 30day mortality associated with 
admission glucose level >6 to 8mmol/l was 3.07 (95%CI, 2.50 to 3.79) in 
non-diabetic patients and 1.30 (95%CI, 0.49 to 3.43) in diabetic patients.
236  
A more recent study found a blood glucose level greater than or equal to   219 
7mmol/l within 72hours of stroke onset was an independent predictor of both 
infarct expansion and worse functional outcome.
128 
 
With the recognised uncertainty surrounding treatment of hyperglycaemia, 
management among individual stroke centres differs.  Stroke units reduce 
the risk of death, dependency and institutionalisation.
18 A recent analysis of 
the  stroke  unit  trialists  collaboration  suggests  that  prevention  of 
complications including infections may explain the beneficial effect of stroke 
unit care.
37 Measures to prevent aspiration, oxygen therapy and anti-pyretic 
use were significantly associated with stroke unit care whilst there was found 
to be no significant difference in insulin use between stroke units (8.6%) and 
the control population (6.3%).  
 
The  aim  of  the  study  was  to  establish  whether  or  not  protocols  for 
management  of  hyperglycaemia  were  in  place  at  the  time  of  trial 
development  and  recruitment  for  those  units  involved  in  the  Stroke  Unit 
Trialists’ collaboration. If protocols were available we aimed to determine the 
level of blood glucose for which insulin use should be considered, indications 
for repeat blood glucose monitoring and methods of insulin administration 
used.        
  
8.2 Methods 
 
After  local  development,  a  questionnaire  on  aspects  of  blood  glucose 
management  was  circulated  to  the  individual  lead  authors for  each  study   220 
included  in  the  database  Stroke  Unit  Trialists  Collaboration  systematic 
review.
18 The methodology of the Cochrane systematic review in summary 
involved rigorous searching for clinical trials of organised in-patient (stroke 
unit)  care,  the  formation  of  a  collaborative  group  comprising  the  primary 
trialists, collation of extensive descriptive information and outcome data, and 
the analysis of this data using rigorous meta-analysis methods.
37  
 
For the current analysis we accessed published and un-published trial data.  
The  aim  of  the  study  was  to  document  protocols  for  the  screening  and 
management of blood glucose in the acute phase of stroke (defined as within 
72 hours of ictus).  The time window was chosen on the basis of both clinical 
and imaging studies, which have previously demonstrated hyperglycaemia 
within 72 hours of stroke onset to be associated with increased mortality and 
increased infarct expansion.
60 
 
All studies were reviewed to identify admission criteria and stroke unit type.  
Studies  were  initially  excluded  if  time  to  randomisation  was  greater  than 
seven days and/or the model of stroke care was principally rehabilitation.  
For those units recruiting patients within seven days, studies were included 
in the final analysis if time to randomisation was within 72 hours or there was 
documentation  that  more  than  90%  of  patients  were  admitted  within  this 
acute  time  window.    Data  were  recorded  on  a  standardised  from  that 
included  time  to  admission,  numbers  recruited  to  stroke  unit  care  versus   221 
conventional  care,  year  of  study  and  documentation  of  blood  glucose 
monitoring  and/or  interventions  to  control  blood  glucose.    Where  limited 
information was available, corresponding authors were contacted to provide 
additional details as to whether a protocol for blood glucose screening and 
insulin  use  was  available  at  the  time  of  their  study.    Copies  of  available 
protocols were requested.  Results are presented as a descriptive narrative 
of protocols in place at the time of the trials recruitment.  
 
8.3 Results 
 
The  stroke  unit  trialists’  collaboration  systematic  review  contains  31 
controlled  clinical  trials  involving  6,936  patients.
18  Recruitment  times  to 
randomisation varied from less than 24 hours to 12 months.
18;47 Nine studies 
aimed  at  comparing  co-ordinated  stroke  rehabilitation  to  generic 
rehabilitation  without  targeted  acute  management  were  excluded  from 
analysis.  Of  the  twenty-two  remaining  studies,  three  (14%)  randomised 
patients in a time window of 24 hours.
19;47;295 A further seven studies (32%) 
randomised  within  72hours.
20;38;296-300  Two  studies  (9%)  had  an  inclusion 
time window of five to seven days but recruited the majority of patients within 
24  hours  of  stroke  onset  and  were  therefore  included  in  the  final 
analysis.
301;302  The  remaining  nine  studies  with  recruitment  periods  of 
between seven and eight days were excluded.
18  
Of  the  twelve  studies  included,  there  were  11  published  articles  (three 
abstracts)  and  one  unpublished  dissertation.    Additional  un-published   222 
information relating to the management of blood glucose was obtained from 
nine of the twelve studies, by contacting the corresponding author.  Further 
information was obtained from the authors of an additional four studies that 
were not included in the final analysis.    
  
Studies Included 
Of the twelve studies recruiting patients primarily within 72 hours of ictus, 
there  were  3,229  participants.  Five  studies  compared  a  “comprehensive 
stroke  ward”  (CSW)  to  general  medical  ward  management,
47;295;296;298;302 
where the former was defined as a combined acute and rehabilitation stroke 
unit that accepted patients acutely but also provided rehabilitation for at least 
several  weeks  if  necessary.
18  One  study  compared  a  CSW  to  a  mobile 
stroke team.
297  Three studies compared semi-intensive stroke (SIS) ward 
care to other ward care.
19;38;299 In two studies the SIS ward was compared to 
a  CSW  and  in  the  other  study,  comparison  was  made  to  a  mixed 
rehabilitation  ward.    A  SIS  ward  was  defined  as  “having  continuous 
monitoring, high nurse staffing but no supported ventilation facilities”.
18 One 
study  compared  rehabilitation  within  a  geriatric  medicine  ward  to  general 
medical ward management.
20 The two remaining studies compared a mobile 
stroke  team  to  management  of  stroke  patients  on  a  general  medical 
ward.
300;301 
   223 
Blood glucose monitoring 
Complete  information  on  blood  glucose  monitoring  including  additional 
information  from  respective  authors  was  available  for  nine  of  the  twelve 
studies.  The three remaining studies had no documented information on 
blood  glucose  monitoring  in  the  text  of  the  available  published  or 
unpublished material.
296;300 Only one of the nine studies with complete data 
including  confirmatory  information  from  the  corresponding  author  had  no 
protocol for blood glucose monitoring at the time of study recruitment.
20  In 
the remaining eight studies, there was a difference in both the frequency and 
indications for blood glucose monitoring (Table 8.1). 
Study  Monitoring sequence and indication 
Athens
295  Six  hourly  in  patients  with  Diabetes  and  Hyperglycaemia  (blood 
Glucose >6.7mmol/l) 
Groningen
19  Six hourly in all patients admitted to the SCMU* 
Goteberg-
Sahlgren
298 
Mandatory  glucose  on  admission,  rechecked  in  all  patients  with 
elevated levels. All diabetics had blood glucose checked daily with 
liberal testing of HbA1C. No set program for intervention but would 
intervene if glucose high or low. 
Manchester
301  Monitoring of glucose was part of protocol, frequency not specified. 
Newcastle
20  No Protocol in place 
Orpington
297  Blood glucose monitored four hourly 
Pavia
38  Control of blood glucose at admission and then every two hours for 
two days or until the normalisation of blood glucose.  
Tampere
299  Fasting Blood Glucose on three consecutive days and HbA1c within 
48 hours 
Trondheim
302  Glucose  level  monitored  twice  on  the  day  of  admission  and  then 
once on days 1 and 3 
Table 8.1: Stroke unit monitoring protocols for blood glucose (*SCMU=Stroke Care 
Monitoring Unit, FBG=Fasting Blood Glucose)   224 
 
One  study  simply  stated  that  blood  glucose  monitoring  was  part  of  the 
protocol with no reference to frequency and duration of testing.
301 Two of the 
studies recommended in the protocols that glucose infusions were not to be 
used within the first 48 hours and one week, respectively.
295;302 Two studies 
described the prevalence of hyperglycaemia in their respective populations, 
however only one study documented the defining blood glucose level. (Table 
8.2) 
 
Hyperglycaemia  Study 
Stroke Unit   General Medical Ward 
Orpington 
297 
(Blood 
Glucose>10.0mmol/l) 
27 (18%)  34 (22%) 
Pavia 
38 
(Blood Glucose 
threshold not 
defined)  
8 (6%)  7 (5.2%) 
 
Table 8.2: Documented prevalence of hyperglycaemia in units included in the stroke unit 
trialists’ collaboration. 
 
Intervention with insulin 
Of the twelve studies recruiting patients within 72 hours of ictus, we were 
unable to obtain complete information on two studies, as to whether or not 
an insulin protocol was in place at the time of study recruitment.
296;300 Four 
studies had no documented intervention protocol in place for insulin use at 
the time of trial recruitment.
20;298;299;301  Only six studies had a set protocol for 
the level of blood glucose at which insulin intervention should take place.  
Either  subcutaneous  or  intravenous  routes  were  used  for  insulin   225 
administration in different protocols.  The threshold glucose level by which 
hyperglycaemia was defined and for which intervention with insulin would be 
indicated  differed  from  6.7mmol/l  to  12.0mmol/l  (Table  8.3)    Despite 
recommending intervention with insulin, only two study protocols both within 
a  semi-intensive  stroke  unit  gave  accompanying  literature  on  a 
recommended sliding scale insulin regimen.
19;38  
 
Stroke Unit  Control Group  p   
Study  Blood Glucose level at 
which insulin prescribed  Numbers 
Recruited 
Insulin 
Use 
Numbers 
Recruited 
Insulin Use   
Athens
295 
Glucose >6.7mmol/l  302  Not stated  302  Not stated  _____ 
Akershus
44  Glucose ≥ 12mmol/l  271  6.3%  279  3.3%  _____ 
Groningen
19  Glucose > 10mmol/l  27  3 (11%)  27  3 (11%)  1.00 
Orpington**
297  Glucose > 10mmol/l  152  16 (11%)  152  18 (12%)  0.62 
Pavia
38  Glucose ≥ 11.1mmol/l  134  Not stated  134  Not stated  _____ 
Trondheim***
305  Glucose> 12.0mmol/l  102  12 (12%)  104  8 (8%)  NS 
Table 8.3: Stroke Unit insulin use. Level of blood glucose at which insulin 
intervention would be considered along with the unit names and the number of 
patients recruited to stroke unit care or the control population. (* Routine Stroke Unit 
versus a Stroke Care Monitoring Unit, ** Insulin use in the first 72hours, *** Insulin 
use in the first 24hours). Statistical analysis for demonstrated p scores was as 
described in each respective paper. In the Gronigen study Fishers exact test was 
used. For the Orpington paper logistic regression and in the Trondheim paper Chi-
squared test.    226 
 
 
8.4 Discussion 
 
Guidelines for manipulation of blood glucose in stroke units involved in the 
Cochrane  collaboration  are  consistent  with  previous  published  data  on 
glucose thresholds for intervention in acute stroke populations and reflect the 
uncertainty in the current management of post stroke hyperglycaemia.   For 
those  trials  with  available  threshold  values  above  which  insulin  would  be 
indicated, blood  glucose  varied from  6.7  to  12mmol/l.
295;302  In  an  audit  of 
acute  neurological  stroke  care  across  22  countries  undertaken  by  the 
European Federation of Neurological Societies, the mean threshold blood 
glucose concentration for intervention was 10.6 mmol/l, ranging from 7.4 to 
14.0 mmol/l by country.
145 
 
It is well recognised that post stroke hyperglycaemia is associated with a 
worse  prognosis
236  and  it  has  been  proposed  that  manipulation  of  blood 
glucose  to  prevent  hyperglycaemia  may  influence  stroke  outcome.
303 
Unfortunately trial evidence is lacking with the only published trial to date 
showing no benefit for glucose-potassium-insulin (GKI) infusion over placebo 
on stroke outcome in patients with predominantly moderate hyperglycaemia 
recruited within 24 hours of ictus.
156 The inclusion criteria for trial recruitment 
targeted patients with blood glucose values in the range 6.0-17mmol/l, yet 
the majority recruited had blood glucose in the mild hyperglycaemia range - 
6.8-9.2  mmol/l  in  the  GKI  group  and  6.7-8.8  in  the  placebo  group.    In   227 
addition,  despite  a  strict  protocol  for  adjustment  of  the  GKI  infusion  to 
maintain glucose levels in the range 4.0-7.0mmol/l, the difference in blood 
glucose overall between the two groups was small at 0.57mmol/l.  
 
These  trial  results  indicate  that  there  is  currently  insufficient  evidence  to 
support the use of glucose manipulation using a GKI infusion, in patients 
with mild hyperglycaemia.  The trial failed to provide additional information 
on the management of patients with moderate hyperglycaemia.  Consensus 
opinion continues to recommend the use of blood glucose lowering therapy 
in these circumstances.
46;304    
 
In those units with blood glucose levels for which insulin was indicated, only 
two studies had published blood glucose lowering regimens.
19;38 Regimens 
differed, utilising either a short acting insulin subcutaneous sliding scale or 
an  insulin  infusion.    Neither  study  advocated  the  use  of  a  GKI  infusion 
despite the theoretically reduced risk of hypoglycaemia due to concomitant 
administration  of  glucose.    At  least  in  theory,  sliding  scale  regimens  are 
largely reactive, correcting changes as and when they occur, whereas GKI 
regimens  are  largely  proactive,  predicting  insulin  requirements  and 
maintaining euglycaemia within a therapeutic range.     
 
The finding of different methods for insulin administration is not surprising as 
most studies included in the systematic review predate any of the published   228 
studies  examining  the  feasibility  and  safety  profile  of  maintaining 
euglycaemia in a stroke population.
95;181  
 
Despite protocols for blood glucose management being available, adherence 
to  these  protocols  within  individual  stroke  units  appears  to  vary.    In  the 
Orpington  study,  insulin  was  advocated  in  those  patients  with  a  blood 
glucose  >10mmol/l  managed  in  the  dedicated  stroke  unit  -  yet  only  59% 
(16/27) of patients with confirmed hyperglycaemia received insulin therapy. 
In contrast 53% (18/34) of hyperglycaemic patients managed on the general 
medical  ward  which  had  no  specific  protocol  received  insulin.
297  One 
explanation  for  the  high  percentage  of  patients  receiving  insulin  in  the 
general medical ward is the possible influence of guidelines disseminated 
from the stroke unit being adopted by the treating physicians.  In contrast, 
almost double the percentage of patients (6.3%) managed in the Akershus 
stroke  unit  received  insulin  compared  to  stroke  patients  treated  in  the 
general medical ward (3.3%).
47 The relatively low number of patients treated, 
assuming  100%  concordance,  reflects  the  high  blood  glucose  level 
(12mmol/l) used in the study to define hyperglycaemia.  With the exception 
of the published trial data from Athens which quoted hyperglycaemia as a 
blood glucose >6.7mmol/l
295 all other stroke unit studies with defined values 
have  used  levels  >10.0mmol/l.
19;38;47;297;302  This  reflects  the  lack  of  a 
consensus definition for post stroke hyperglycaemia in patients with acute   229 
stroke and also fails to reflect the poor prognostic outcome in patients with 
blood glucose levels in the range 6.1 to 8.0mmol/l
236.   
 
In  addition  to  the  management  of  hyperglycaemia,  recent  studies  have 
advocated  more  intense  blood  glucose  screening  protocols  to  reflect  the 
temporal profile of blood glucose in the acute stroke period.  Over a 72hour 
period, blood glucose was found to decrease from a peak at eight hours, 
reach its lowest level at 14 -16 hours, plateau and then exhibit a further late 
hyperglycaemic phase at 48-88 hours.
96 Knowledge of the variation in blood 
glucose  with  time  is  important  when  considering  screening  protocols,  as 
certain studies limited repeated testing solely to those patients with diabetes 
or  hyperglycaemia  at  initial  presentation.    In  addition  to  identifying 
hyperglycaemic  surges,  it  is  now  recognised  that  identification  of 
hyperglycaemia  during  the  acute  phase  may  unmask  abnormalities  in 
glucose  metabolism.    Fifty-eight  per  cent  of  patients  screened  at  three 
months following an acute ischemic stroke when admission blood glucose 
was ≥6.1mmol/l had either diabetes or impaired glucose tolerance.
90  
 
The purpose of individual studies within the stroke unit trialists’ collaboration 
was to examine stroke unit care versus management in a control population 
on  functional  and  mortality  outcomes.    Analysis  of  individual  components 
within each stroke unit model to explain the benefit of stroke unit care has 
been  difficult.    In  a  recently  published  analysis,  stroke  unit  care  was   230 
associated  with  a  statistically  significant  increase  in  the  reported  use  of 
oxygen  (OR  2.39;  95%CI:  1.39  to  4.66),  measures  to  prevent  aspiration 
(2.42; 1.36 to 4.36) and paracetamol use (2.80; 1.14 to 4.83). Insulin use 
was similar across groups.
37 
 
The recently published analysis of stroke unit complications was based on 
data from seven trials, of which only four included information specifically on 
insulin use in acute blood glucose management.
19;47;297;302 Our own analysis 
of  the  available  study  data  serves  to  emphasise  the  lack  of  uniformity  in 
blood  glucose  screening  and  management,  which  in  turn  reflects  clinical 
uncertainty in this aspect of stroke unit care.  It is important to acknowledge 
a number of limitations in our own study.  These include the retrospective 
nature of the study, limited information on strict protocols and adherence to 
those protocols at the time of study recruitment and lack of complete data 
availability for all studies.  The management of blood glucose in the pooled 
stroke  analysis  has  to  be  considered  in  the  context  of  published  studies 
involved in the Cochrane review spanning almost a 25 year period, with the 
accompanying improvements in stroke management and co-ordinated care.  
 
8.5 Conclusion 
 
Stroke  units  that provided  data for  the  Stroke  Unit  Trialists’  Collaboration 
employed  varied  protocols  for  blood  glucose  management  in  the  acute 
phase of stroke. Testing for blood glucose concentration was infrequent in 
most.  Of the minority of units that had a protocol in place, the threshold for   231 
intervention  with  insulin  was  >10mmol/l.    Both  future  trials  and  future 
registers of stroke care should give detailed methodology in the maintenance 
of blood glucose. 
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9.1 Overall Conclusion 
 
The management of post stroke hyperglycaemia remains uncertain. It has 
generally  been  accepted  that  hyperglycaemia  is  associated  with  a  poor 
stroke  outcome.  The  thesis  presented  gives  a  review  of  the  literature  on 
hyperglycaemia in acute stroke and evidence for the use of insulin in stroke 
management. Post Stroke Hyperglycaemia is common with prevalence rates 
varying  depending  on  the  population  studied  and  definition  used.  No 
consensus opinion exists as to the most appropriate method and timing of 
blood  glucose  sampling  or  the  glucose  level  defining  hyperglycaemia. 
Clinical studies examining hyperglycaemia in acute stroke tend to include a 
heterogeneous stroke population. Knowledge of stroke mechanism appears 
important in determining the effect of hyperglycaemia on stroke outcome. 
Results from  animal  studies  suggest  a  beneficial  effect of  elevated  blood 
glucose  in  models  of  permanent  occlusion,  with  a  converse  effect  in 
experimental temporary occlusion. 
 
The thesis presented contributes to the current literature in the fields of (1) 
Aetiology, (2) Pathophysiology and (3) Management of PSH.  
 
(1) Aetiology; in our prospective study of the evolution of hyperglycaemia in 
acute stroke we found that stroke severity measured using the NIHSS was 
not  associated  with  hyperglycaemia.    In  a  separate  study  we  found  that 
insular cortex involvement was not a predictor of admission hyperglycaemia.    234 
However,  in  non-diabetic  patients  manifesting  hyperglycaemia  within 
48hours of acute stroke and thus labelled as having “stress hyperglycaemia” 
when prospectively followed and screened there was a high prevalence of 
abnormal glucose metabolism, including diabetes and metabolic syndrome.  
 
(2)  Pathophysiology;  Identification  of  the  underlying  aetiology  for  PSH  is 
fundamental to understanding its mechanistic action and the requirements 
for  intervention.  As  mentioned  above  we  found  a  high  prevalence  of 
abnormal glucose metabolism in non-diabetic patients with PSH.  Our results 
would  suggest  an  unmasking  of  undiagnosed  dysglycaemia  with  the 
associated abnormalities in vasculopathy and haemostasis.  Stroke severity 
did  not  predict  hyperglycaemia  in  patients  based  on  clinical  assessment 
using the NIHSS and thus does not favour the epiphenomenon hypothesis.  
 
(3) Management; Current guidelines advise lowering of blood glucose but 
disagree on the threshold at which to intervene, and make no comment on 
specific insulin treatment regimes, or treatment targets. Analysis of protocols 
from  stroke  units  involved  in  the  Stroke  Unit  Trialists’  Collaboration 
demonstrated that testing for blood glucose concentration was infrequent in 
most. In those units with a protocol, the threshold for intervention with insulin 
was >10mmol/l. In a randomised placebo controlled trial we examined the 
effect of insulin versus placebo on lesion volume progression and cerebral 
lactate  levels  in  acute  ischaemic  stroke  using  novel  magnetic  resonance   235 
imaging  measures.  We  found  no  evidence  to  support  attenuated  infarct 
growth  in  patients  with  mild  to moderate  hyperglycaemia  receiving  a  GKI 
infusion  within  24  hours  of  acute  ischaemic  stroke.  A  trend  towards 
attenuation  of  increased  lactate  concentration  in  the  ischaemic  brain  was 
evident in the GKI treatment arm. The GKI infusion resulted in a modest 
reduction in blood glucose measurements and was associated with lower 
blood pressure, both observations consistent with published trial evidence. 
Asymptomatic  hypoglycaemia  was  common  despite  frequent  monitoring 
within  a  well-established  protocol  and  trained  nursing  staff.  Prevention  of 
hypoglycaemia is important as extrapolation of animal data and case series 
suggest  that  hypoglycaemia  may  increase  final  infarct  size.  A  further 
exploratory analysis raised the possibility that GKI infusion might be harmful 
in patients with persistent arterial occlusion.  
The study demonstrated the feasibility of performing a randomised placebo 
controlled  trial  using  magnetic  resonance  imaging  and  spectroscopy  with 
surrogate outcome measures.  
 
9.2 Implications for current practice and future research 
 
Detection  of  PSH  justifies  further  screening  to  establish  the  presence  of 
abnormal glucose metabolism. A fasting blood glucose sample is insufficient 
and appropriately selected patients should be followed with an oral glucose 
tolerance test. Feeding appears to contribute to hyperglycaemia and early 
dietetic  input  should  be  considered  in  patients  with  post-prandial  surges.   236 
Hypoglycaemia was more common in the hours of midnight to eight am and 
likely justifies pre-emptive reductions in insulin therapy, if being considered 
during  periods  of  prolonged  fasts.  The  potential  detrimental  effect  of 
hypoglycaemia, on infarct progression needs to be considered. 
Intervention  with  insulin  in  the  form  of  GKI  to  treat  mild  to  moderate 
hyperglycaemia  would  not  be  recommended  on  the  basis  of  our  current 
evidence or the evidence from the recently published GIST-UK study. In the 
absence  of  clinical  evidence  stroke  units  should  continue  to  follow 
consensus  guidelines,  advising  intervention  for  patients  with  moderate 
hyperglycaemia  without  aiming  for  aggressive  tight  blood  glucose  control. 
Knowledge of the potential deleterious effects of aggressive blood glucose 
control  has  been  highlighted  in  a  recent  press  release  from  the  North 
American  ACCORD  (Action  to  Control  Cardiovascular  Risk  in  Diabetes) 
trial.
306 Type 2 diabetic patients at high risk of future vascular events when 
randomised  to  intensive  blood  glucose  control  (HbA1c  <6.0%)  had  an 
increased risk of cardiovascular death when compared to patients receiving 
a less intensive treatment protocol (HbA1c 7.0-7.9%). Trial recruitment to the 
intensive blood sugar lowering arm stopped eighteen months early due to 
safety concerns after review of available data. Trial recruitment to the non-
intensive group continues.  
 
Many questions surrounding the role of glucose lowering therapy continue to 
remain unanswered; is intravenous insulin as opposed to the GKI infusion   237 
potentially beneficial to patients with hyperglycaemia? What level of blood 
glucose is felt suitable for intervention? What is the targeted therapeutic time 
window? Is there a role for thrombolysis and glucose lowering treatment? 
Will  identification  of  the  penumbra  with  CT  and  MR  imaging  select 
appropriate  patients  who  may  benefit?  Is  the  effect  of  insulin  infusion 
affected  by  early  recanalisation  of  occluded  vessels?  What  effect  would 
insulin have on outcome if it impedes early mobilisation? How long should 
the insulin infusion last for, with current knowledge of the variation in the 
natural history of blood glucose in stroke demonstrating an early and late 
peak? What impact will feeding have on insulin requirements? What level of 
monitoring  is  required  and  how  feasible  that  is  within  the  confines  of  an 
acute stroke unit and the patient to nurse staffing ratios currently available?  
 
MRI and MRS provide exciting novel ways for patient selection, development 
of potential new drug therapies and the use of surrogate outcome measures. 
A  general  criticism  of  many  previous  stroke  studies  is  the  heterogenous 
population  selected.  Appropriate  screening  could  identify  a  targetted 
population  to  test  a  number  of  different  hypotheses.  The  application  of 
Magnetic  Resonace  Imaging  to  the field  of  PSH  could  assist  in  selecting 
patients  with  lacunar  versus  non-lacunar  infarcts,  MRA  evidence  of 
recanalisation or occlusion and the presence of penumbral tissue (DWI/PWI 
mismatch). As a follow on to the SELESTIAL study, future trials should have 
a  tighter  inclusion  time  window,  knowledge  of  recanalisation  status,   238 
penumbral size and stroke type.  Knowledge of blood glucose through the 
entire  period  of  infusion  would  be  possible  using  subcutaneous  glucose 
monitoring.  Detailed  information  on  duration  of  hyperglycaemia, 
euglycaemia,  hypoglycaemia  and  their  respective  effects  on  infarct 
progression could be obtained.   
 
The  thesis  presented  has  added  to  our  understanding  of  Post  Stroke 
Hyperglycaemia.  Further  hypotheses  have  been  generated  and  future 
research  has  been  suggested.  The  challenges  in  answering  these 
hypotheses  are  considerable,  but  the  potential  impact  upon  our  ability  to 
provide optimal management of stroke patients is greater still.   
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Search Strategy (Chapters 3 & 4) 
 
 
1. stroke.mp. or exp *Cerebrovascular Accident/ 
2. cerebrovascular accident.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
3. exp *cerebrovascular disorders/ or brain ischemia/ or carotid artery diseases/ or 
hypoxia-ischemia, brain/ or intracranial arteriovenous malformations/ or 
"intracranial embolism and thrombosis"/ or intracranial hemorrhages/ or vertebral 
artery dissection/ 
4. brain infarct$.mp. or exp *Brain Infarction/ 
5. cerebral infarct$.mp. or exp *Cerebral Infarction/ 
7. brain hypoxia.mp. or exp *Hypoxia, Brain/ 
8. cerebral hypoxia.mp. or exp *Hypoxia, Brain/ 
9. exp *Ischemic Attack, Transient/ or exp *Brain Ischemia/ or cerebral 
ischaemia.mp. 
10. morbidity.mp. or Morbidity/ 
11. morbidity.mp. or exp *Morbidity/ 
12. mortality.mp. or exp *Hospital Mortality/ or exp *Mortality/ 
13. disability.mp. 
14. exp *"Activities of Daily Living"/ or functional dependence.mp. or exp *"Quality 
of Life"/ or exp *Geriatric Assessment/ 
15. institutional$.mp. 
16. infarct size.mp. 
17. infarct volume.mp. 
18. lesion size.mp. 
19. lesion volume.mp. 
20. rankin score.mp. 
21. barthel score.mp. or exp *Health Status Indicators/ or exp *Disability 
Evaluation/ 
22. exp *"Severity of Illness Index"/ or stroke severity.mp. 
23. NIHSS.mp. 
24. NIH stroke scale.mp. 
25. exp *Tissue Plasminogen Activator/ or tPA.mp. 
26. tissue plasminogen activator.mp. 
27. exp *Fibrinolytic Agents/ or exp *Thrombolytic Therapy/ or thrombolysis.mp. 
28. thromboly$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
29. fibrinoly$.mp. 
30. exp *Neuroprotective Agents/ or neuroprotectant agents.mp. 
31. neuroprotective agent$.mp. 
32. MRI.mp. or exp *Magnetic Resonance Imaging/ 
33. nuclear magnetic resonance.mp. or exp *Magnetic Resonance Spectroscopy/ 
34. exp *Diffusion Magnetic Resonance Imaging/ or DWI.mp. 
35. FLAIR.mp. 
36. exp *Image Enhancement/ or fluid attenuated inversion recovery.mp. or exp 
*Image Processing, Computer-Assisted/ 
37. diffusion weighted imaging.mp. 
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GKI Infusion Protocol (SELESTIAL) [adapted from the GIST-UK study 
protocol]
156 
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Placebo Infusion Protocol (SELESTIAL) [adapted from the GIST-UK 
study protocol]
156  
  SELESTIAL: Normal Saline Infusion Protocol 
 
   Set up a NORMAL SALINE infusion of 1000ml at 100 ml per hour 
The doctor may request the infusion contains potassium depending upon the 
patient’s electrolytes 
Monitor BMs every 4 hours on the BM monitoring chart 
Monitor BP and pulse 4 hourly on the TPR chart 
Blood glucose to be checked at 24 and 72 hours 
U & E’s to be checked at 24 and 72 hours 
If BMs rise above 17, the patient will need GKI (as per GKI protocol) 
or insulin infusion as clinical need dictates 
•  The patient may eat and drink if clinically safe throughout the 24hour infusion. 
•  Patients who are nil by mouth or who continue to require intravenous fluids after 
the infusion period will be prescribed appropriate therapy by the supervising 
Consultant’s team. 
•  If there are problems out of hours with the control infusion then please 
call the on-call SHO.   
This patient has been randomised to receive a normal saline infusion.  The 
infusion will last approximately 72 hours.  It may last longer if there are 
persisting problems with oral intake   243 
 
Structured interview for the modified Rankin scale 
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NIH Stroke Scale 
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Patient Information Sheet (SELESTIAL) 
 
Influence of glycaemic control on brain lactic acidosis in acute stroke 
We are currently approaching patients who have suffered a recent stroke 
and are found to have elevated blood sugars to participate in a study looking 
at the impact of blood sugar control in acute stroke.  
 
Why are we doing this study? 
Blood sugar (glucose) is often high after a stroke, and people with high sugar 
levels  are  less  likely  to  recover  from  the  stroke  than  people  with  normal 
levels. We do not know whether the high blood sugar actually causes the 
outcome  to  be  worse,  but  have  reasons  to  think  that  it  may.  In  animal 
studies, high blood sugar after a stroke causes the brain to produce more of 
a substance called lactic acid. Lactic acid is produced by tissues when they 
have too little oxygen. It is potentially harmful to brain cells, and this may 
therefore be the link between high blood sugar and worse outcome after a 
stroke. 
We have recently confirmed that there is a relationship between blood sugar 
and lactic acid in the brain in humans, based on studies in patients using 
MRI scans. We do not yet know whether lowering blood sugar reduces the 
lactic acid in the brain, and this is what we wish to test. 
 
What is Involved in the Study 
Patients  who  have  high  blood  sugar  will  be  invited  to  take  part.  If  your 
doctors feel that your blood sugar is high enough to need treatment, then 
you will not be asked to take part in the study - treatment will be given to 
lower it. If your doctors aren't sure whether treatment is definitely needed, 
then you will be invited to take part.   255 
If  you  agree  to  participate  in  the  study  you  will  undergo  an  MRI  scan, 
following which you will be randomized to one of three possible treatments: 
(1) Insulin treatment for 24 hours followed by 48 hours with a normal saline 
solution,  (2)  insulin  treatment  for  72  hours  or  (3)  A  dummy  treatment 
(placebo - saline solution). Saline will be administered as an infusion through 
a drip in the arm and is routinely given to stroke patients. Insulin will be given 
in  a  drip  containing  glucose  and  potassium  to  avoid  any  risk  of  lowering 
blood sugar too far. The amount will be adjusted to make sure your blood 
sugar levels are controlled and become neither too high nor too low. This will 
require regular checks with a tiny blood sample taken from a finger. The 
treatment  allocation  is  stored  in  sealed  envelopes  that  will  be  opened 
following  completion  of  the  Baseline  MRI  scan.  All  patients  will  receive 
normal routine treatment for their stroke in addition to the infusions as laid 
down in the ward stroke protocols. 
Everyone in the study will have an MRI scan before treatment starts, at the 
end of the treatment period (around 72 hours), and again 7 days after the 
start. This will show how big the stroke is, whether it becomes bigger over 
time, and what the amount of lactic acid is in the areas around the stroke. 
Checks  on  your  progress  and  clinical  condition  will  be  carried out  by  the 
doctors and nurses on the ward at the same times. 
 
What is involved in the MRI scan? 
MRI scanning is commonly used after a stroke to obtain further information 
about the brain and blood vessels. Because it uses a strong magnetic field, 
patients with pacemakers cannot be scanned and there may be restrictions 
on some other types of implant. Details of any relevant conditions will be 
checked in detail by MRI staff beforehand. In addition to the routine type of 
scan, the study involves a scan to detect lactic acid concentrations in the 
brain. This may take up to 30 minutes. The study asks for three separate 
scans on different days to be performed.   256 
 
Will I benefit from the study? 
You may not benefit individually from the study. We may obtain more useful 
information about your stroke from the MRI scans which could help with your 
treatment. Your blood sugar will be monitored more closely than usual, and 
this  may  identify  the  need  for  future  treatment.  If  you  receive  insulin 
treatment, then it is possible that this may limit some of the damage after the 
stroke. The main benefit will be to provide information that may help with 
stroke treatment or future patients. 
 
Do I have to take part? 
No. 
If  you  are  unhappy  with  taking  part  in  the  study  at  any  time,  you  are 
completely  free  to  withdraw.  You  will  continue  to  receive  all  necessary 
medical treatment. 
 
What if I do take part? 
Information  on  your  medical  history  and  measurements  taken  after  the 
stroke  will  be  recorded for  analysis.  All  data,  including  the  scans,  will  be 
anonymised on all computer records for the study. Results of the MRI scans 
and blood tests from the study will be available to your doctors to use in 
deciding  your  day-to-day  care.  Your  GP  will  be  informed  about  your 
participation by letter.  
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Can I get further information about the study? 
 
If you wish to discuss any other aspect of the study, you can do so with Dr 
Keith  Muir,  or  Dr  Michael  McCormick,  both  contactable  via  the  hospital 
switchboard (0141 201 1100).   258 
Relatives' Information Sheet (SELESTIAL) 
 
Influence of glycaemic control on brain lactic acidosis in acute stroke 
 
We  are  currently  approaching  patients  and  their  relatives  to  consider 
participation  into a  study  looking  at  the effect  of  blood  glucose control  in 
acute stroke.  
Why are we doing this study? 
Blood sugar (glucose) is often high after a stroke, and people with high sugar 
levels  are  less  likely  to  recover  from  the  stroke  than  people  with  normal 
levels. We do not know whether the high blood sugar actually causes the 
outcome  to  be  worse,  but  have  reasons  to  think  that  it  may.  In  animal 
studies, high blood sugar after a stroke causes the brain to produce more of 
a substance called lactic acid. Lactic acid is produced by tissues when they 
have too little oxygen. It is potentially harmful to brain cells, and this may 
therefore be the link between high blood sugar and worse outcome after a 
stroke. 
We have recently confirmed that there is a relationship between blood sugar 
and lactic acid in the brain in humans, based on studies in patients using 
MRI scans. We do not yet know whether lowering blood sugar reduces the 
lactic acid in the brain, and this is what we wish to test. 
 
What is Involved in the Study 
Patients who have high blood sugar will be invited to take part. If the doctors 
feel that your relative's blood sugar is high enough to need treatment, then 
they will not be asked to take part in the study - treatment will be given to 
lower it. If the doctors aren't sure whether treatment is definitely needed, 
then your relative will be invited to take part.   259 
If you agree to your relative’s participation in this study they will undergo an 
MRI scan, following which they will be randomized to one of three possible 
treatments: (1) Insulin treatment for 24 hours followed by 48 hours with a 
normal saline solution, (2) insulin treatment for 72 hours or (3) A dummy 
treatment  (placebo  -  saline  solution).  Saline  will  be  administered  as  an 
infusion through a drip in the arm and is routinely given to stroke patients. 
Insulin will be given in a drip containing glucose and potassium to avoid any 
risk of lowering blood sugar too far. The amount will be adjusted to make 
sure your blood sugar levels are controlled and become neither too high nor 
too low. This will require regular checks with a tiny blood sample taken from 
a finger. The treatment allocation is stored in sealed envelopes that will be 
opened  following  completion  of  the  Baseline  MRI  scan.  All  patients  will 
receive normal routine treatment for their stroke in addition to the infusions 
as laid down in the ward stroke protocols. 
Everyone in the study will have an MRI scan before treatment starts, at the 
end of the treatment period (around 72 hours), and again 7 days after the 
start. This will show how big the stroke is, whether it becomes bigger over 
time, and what the amount of lactic acid is in the areas around the stroke. 
Checks on progress and clinical condition will be carried out by the doctors 
and nurses on the ward at the same times. 
 
What is involved in the MRI scan? 
MRI scanning is commonly used after a stroke to obtain further information 
about the brain and blood vessels. Because it uses a strong magnetic field, 
patients with pacemakers cannot be scanned and there may be restrictions 
on some other types of implant. Details of any relevant conditions will be 
checked in detail by MRI staff beforehand. In addition to the routine type of 
scan, the study involves a scan to detect lactic acid concentrations in the 
brain. This may take up to 30 minutes. The study asks for three separate 
scans on different days to be performed.   260 
Will my relative benefit from the study? 
They may not benefit individually from the study. We may obtain more useful 
information about the stroke from the MRI scans which could help with their 
treatment. Closer monitoring of blood sugar than usual may identify the need 
for future treatment. If they receive insulin treatment, then it is possible that 
this may limit some of the damage after the stroke. The main benefit will be 
to provide information that may help with stroke treatment or future patients. 
 
Do I have to agree to the study? 
No. 
If you are unhappy with you relative's participation in the study at any time, 
you  are  completely  free  to  withdraw  consent.  All  necessary  medical 
treatment will continue to be given. 
 
What if I do agree to the study? 
Information on medical history and measurements taken after the stroke will 
be recorded for analysis. All data, including the scans, will be anonymised on 
all computer records for the study. Results of the MRI scans and blood tests 
from the study will be available to doctors to use in deciding day-to-day care. 
Your relative's GP will be informed about their participation by letter.  
 
Can I get further information about the study? 
 
If you wish to discuss any other aspect of the study, you can do so with Dr 
Keith  Muir  or  Dr  Michael  McCormick,  both  contactable  via  the  hospital 
switchboard (0141 201 1100).   261 
Influence of glycaemic control on brain lactic acidosis in acute stroke 
Consent Form (SELESTIAL) 
 
            
      Please initial box 
 
I  confirm  that  I  have  read  and  understand  the  information  sheet  dated 23
rd  April  2004  
(version 1) for the above study and have had the opportunity to ask questions 
 
   
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
   
I understand that sections of any of my medical notes may be looked at by local researchers 
or  from  regulatory  authorities  where  it  is  relevant  to  my  taking  part  in  research.    I  give 
permission for these individuals to have access to my records. 
 
   
I  give  my  permission  for  the  study  doctor  to  contact  my  GP  to  inform  him/her  of  my 
participation in this study 
 
 
 
   
I agree to take part in the above study.     
 
 
 
 
________________________  ________________        ____________________ 
Name of Patient (Print name)  Date  Signature 
 
 
_________________________  ________________       ____________________ 
Name of Person taking consent  Date       Signature 
(if different from researcher) 
 
 
_________________________  ________________       ____________________ 
Researcher (Print name)  Date  Signature 
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Influence of glycaemic control on brain lactic acidosis in acute stroke 
Form of Assent for Relatives (SELESTIAL) 
 
            
      Please initial box 
 
I  confirm  that  I  have  read  and  understand  the  information  sheet  dated 23
rd  April  2004  
(version 1) for the above study and have had the opportunity to ask questions 
 
   
I understand that my relative’s participation is voluntary and that he/she is free to withdraw at 
any time, without giving any reason, without their medical care or legal rights being affected. 
 
   
I understand that sections of any of my relative’s medical notes may be looked at by local 
researchers or from regulatory authorities where it is relevant to their taking part in research.  
I give permission for these individuals to have access to their records. 
 
   
I give my permission for the study doctor to contact my relatives GP to inform him/her of their 
participation in this study 
 
 
 
   
I agree for my relative to take part in the above study.     
 
 
 
 
I __ __ __ __ __ __ __ __ __ __ __, am the nearest relative/ welfare guardian of 
the patient named below and I can confirm that there is neither a nearer relative or 
welfare guardian to the same said patient.  
 
 
________________________  ____________________ 
Name of Patient (Print name)  Relationship to Patient 
   
________________________  ________________        ____________________ 
Name of Relative (Print name)  Date  Signature 
 
 
_________________________  ________________       ____________________ 
Name of Person taking consent  Date       Signature 
(if different from researcher) 
 
 
_________________________  ________________       ____________________ 
Researcher (Print name)  Date  Signature 
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Influence of glycaemic control on brain lactic acidosis in acute stroke 
 
GP Letter (SELESTIAL) 
 
Dr Keith Muir 
Institute of Neurological Sciences 
Southern General Hospital 
1345 Govan Road 
Glasgow G51 4TF 
 
Date:________________________ 
RE: 
 
 
Dear Doctor 
       
The above named patient has been recruited to SELESTIAL (Spectroscopic 
Evaluation  of  Lesion  Evolution  in  Stroke:  Trial  of  Insulin  for  Acute  Lactic 
acidosis) an acute stroke study examining the influence of glycaemic control 
on brain lactic acidosis and subsequent stroke outcome. Your patient will 
have  received  either  placebo,  24  hour  insulin  infusion  or  72  hour  insulin 
infusion,  on  the  basis  of  a  diagnosis  of  ischaemic  stroke  and  a  capillary 
blood glucose of ≥ 7mmol. Additional MRI scans have been undertaken for 
study purposes and clinical outcome evaluation will be at day 30.  
Patients recruited will be screened for underlying diabetes during the period 
of the study. Results of any investigations will be forwarded to yourself. On 
completion of the study you will be informed of the outcome.  
If you wish to discuss any other aspect of the study, you can do so with Dr 
Keith  Muir  or  Dr  Michael  McCormick,  both  contactable  via  the  hospital 
switchboard (0141 201 1100). 
 
Yours sincerely, 
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Patient Information Sheet (Dysglycaemia) 
 
Prevalence of impaired glucose metabolism following stroke 
(How common are problems with glucose metabolism after Stroke?) 
 
You are being invited to take part in a research study.  Before you decide it 
is important for you to understand why the research is being done and what 
it will involve.  Please take time to read the following information carefully 
and discuss it with others if you wish.  Ask us if there is anything that is not 
clear or if you would like more information.  Take time to decide whether or 
not you wish to take part. 
 
Thank you for reading this. 
 
Why are we doing this study? 
Following a stroke, routine monitoring involves checking blood sugar levels. 
Treating  a  high  blood  sugar  may  improve  the  chances  of  recovery.  High 
blood sugar is common: about 6 people in ten will have high levels in the 
days  after  a  stroke.  Around  one-third  of  these  people  are  diabetic 
(sometimes this is diagnosed for the first time after the stroke), but the other 
two thirds are not diabetic. We do not know  whether this temporary high 
blood sugar level has any long-term importance. Although the high blood 
sugar may be explained by the stress of the stroke, we wish to find out if   265 
patients with “stress hyperglycaemia” have an underlying problem with the 
body’s ability to handle sugar (“glucose metabolism”).  
 
A  proportion  of  patients  will  have  a  condition  called  “Impaired  Glucose 
Tolerance”. Impaired glucose tolerance is not diabetes but does suggest that 
glucose is not being processed normally in the body.  If recognized, impaired 
glucose tolerance can be treated by changes in exercise and diet, so as to 
prevent  the  development  of  diabetes.  Impaired  glucose  tolerance  is 
diagnosed by performing an oral glucose tolerance test: this involves seeing 
how the body deals with sugar after a sugar drink is given. 
 
The purpose of the study is to see whether an elevated glucose at the time 
of  a  stroke  indicates  an  underlying  problem  with  glucose  metabolism.  As 
there is the possibility that stress from the stroke can persist for a period of 
time and may affect the results of the tests we would plan to perform the test 
at a time no sooner than 3 months from the acute stroke.    
 
Why have I been chosen? 
During your recent hospital admission, blood tests showed that your blood 
sugar was slightly high (hyperglycaemia). This is a common finding following 
stroke. We are hoping to recruit about 150 patients whose blood sugar was 
high  immediately  after  a  stroke  to  study  whether  there  is  a  persisting 
tendency to high blood sugar.   266 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form (version 1 11/06/05).  
If  you  decide  to  take  part  you  are  still  free  to  withdraw  at  any  time  and 
without giving a reason.  A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
 
What is an Oral Glucose Tolerance Test (OGTT)? 
Both  diabetes  and  impaired  glucose  tolerance  can  be  diagnosed  by 
performing an oral glucose tolerance test. This involves first taking a blood 
sample for glucose measurement after fasting. You will be asked not to eat 
anything  from  10pm  the  night  before  the  test.  You  will  be  given  an 
appointment card to come to the ward for the following morning to have a 
fasting  blood  glucose  performed.  You  will  then  be  asked  to  take  a  drink 
containing a measured amount of glucose and a second blood test is taken 
two hours later. You will be asked to rest as much as possible for these two 
hours. The blood samples will be taken from a small plastic tube (cannula) 
placed in a vein in your arm. 
 
What else does the study involve? 
A blood sample will also be used to check your cholesterol levels. During 
your  visit  we  will  measure  your  height  and  weight  to  calculate  your  BMI   267 
(Body Mass Index). Your waist and hip circumference will also be measured. 
These measurements give extra information on how your body deals with 
glucose.  
You will also be asked to answer a short questionnaire dealing with your 
current level of function since the stroke.  
A  clinical  examination  will  take  place  to  assess  any  persisting  problems 
since the stroke and your blood pressure will also be measured.   
 
Are there any risks involved in the study? 
None of the study tests involve any risk. Having a cannula placed in a vein is 
uncomfortable, and there may be some bruising afterwards. 
If you have swallowing problems that prevent you drinking safely, then you 
will not be asked to take the glucose drink. We would still like to perform a 
fasting blood sample and complete the rest of the clinical assessment. 
 
Will I benefit from the study? 
Identifying impaired glucose tolerance or diabetes is important as it provides 
an  opportunity  for  medical  management.  If  the  tests  show  that  you  have 
either of these conditions, we will arrange for you to come back to discuss 
how to deal with them, and if necessary refer you to a specialist clinic. Some 
changes in medication may also be advised.  
Will my taking part be kept confidential?   268 
Information  on  your  medical  history  and  measurements  taken  after  the 
stroke will be recorded for analysis. All information will be anonymised on all 
records for the study, so you will not be identifiable.  
 
The results of the blood tests from the study will be available to your doctors. 
Your  GP  will  be  informed  about  your  participation  by  letter,  and  will  be 
informed of all of the results from the study.  
 
What will happen to the results of the research study? 
We plan to publish the results of the study in the medical press and will 
present  our  findings  locally  to  clinical  meetings.    No  participants  will  be 
identifiable in any publication. 
 
Who has reviewed this study? 
The South Glasgow Research Ethics Committee has reviewed and approved 
this study. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation  arrangements.    If  you  are  harmed  due  to  someone’s 
negligence, then you may have grounds for a legal action but you may have 
to  pay  for  it.    Regardless  of  this,  if  you  wish  to  complain,  or  have  any 
concerns about any aspect of the way you have been approached or treated   269 
during the course of this study, please contact the Complaints Department at 
the Southern General Hospital, 0141 201 1100. 
 
Can I get further information about the study? 
If you wish to discuss any other aspect of the study, you can do so with Dr 
Keith  Muir,  or  Dr  Michael  McCormick,  both  contactable  via  the  hospital 
switchboard (0141 201 1100). 
Can I get independent advice about taking part in the study? 
 
Independent advice on taking part in medical research, "Medical Research 
and You", is available from Consumers for Ethics in Research  (CERES) PO 
Box 1365, London N16 0BW 
(www.ceres.org.uk or email info@ceres.org.uk). 
Independent  advice  on  this  specific  study  is  available  from  Dr  Donald 
Grosset, Consultant Neurologist, Institute of Neurological Sciences, Glasgow 
on 0141 201 1100. 
 
Who do I contact if I have a complaint about the study? 
 
Please  contact  the  Complaints  Department  at  the  Southern  General 
Hospital,  
0141 201 1100. 
 
Thank you for taking the time to read this information. 
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Consent Form (Dysglycaemia) 
 
            
      Please initial box 
 
I  confirm  that  I  have  read  and  understand  the  information  sheet  dated 11
th  June 
2005(version 1) for the above study and have had the opportunity to ask questions 
 
   
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
   
I understand that sections of any of my medical notes may be looked at by local researchers 
or  from  regulatory  authorities  where  it  is  relevant  to  my  taking  part  in  research.    I  give 
permission for these individuals to have access to my records. 
 
   
I  give  my  permission  for  the  study  doctor  to  contact  my  GP  to  inform  him/her  of  my 
participation in this study 
 
 
 
   
I agree to my involvement in the study    
 
 
 
 
 
________________________  ________________        ____________________ 
Name of Patient (Print name)  Date  Signature 
 
 
_________________________  ________________       ____________________ 
Name of Person taking consent  Date       Signature 
(if different from researcher) 
 
 
_________________________  ________________       ____________________ 
Researcher (Print name)  Date  Signature 
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